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2 Summary 
The present thesis work faced the challenge to link the development of drug addiction to 
transcriptional changes in the neurons of the central nervous system. Experience and learning are 
known to induce structural modifications in the brain, and these changes are thought to occur 
mainly in the way neurons are interconnected by synapses. More and more evidences point to a 
scenario in which neuronal activity would activate signalization cascades that impinge on 
transcription factors, which, in turn, would activate genes necessary for the reinforcement of 
synapses coding for new informations. 
Given that drug addiction can be considered as an aberrant form of learning and is thought to 
involve synaptic modifications, we try to elucidate some of the transcriptional mechanisms that 
could underlie drug-induced synaptic changes. As a model system, we use primary cultures of 
striatal, cortical and hippocampal neurons dissected from mouse embryos as well as brain slices 
from rats. 
One of the common features of virtually all drugs of abuse is to activate the mesocorticolimbic 
dopaminergic system that results in the release of dopamine onto the neurons of the striatum 
(nucleus accumbens). In this thesis work we show that in striatal cultures, dopamine induces the 
transcription factor C/EBPβ, that in turn drives the expression of the gene coding for substance P. 
This mechanism is likely to be important for the drug-induced tolerance in the brain since it might 
be a part of a feedback acting on dopaminergic neurons. 
Given the suspected importance of C/EBPβ in drug addiction, we also try to elucidate some aspects 
of the basic mechanisms by which the C/EBP family activates transcription. We show that three 
activating members of the C/EBP family recruit the coactivator CBP and trigger its 
phosphorylation. 
Finally, we demonstrate that the newly discovered and cloned transcriptional coactivators, named 
TORCs (transducers of regulated CREB activity) are able to detect the coincidence of a calcium 
and a cAMP signal in the central nervous system. This way, TORCs could contribute to the 
detection of a coincidence between a glutamate and a dopamine signal in striatal neurons – a 
process that is suggested to be important for an association between the rewarding effect of a drug 
and contextual information (such as the environment where the drug had been taken). We 
demonstrate that TORCs are required for hippocampal LTP. 
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3 Résumé 
Le présent travail de thèse a fait face au défi de lier les changements transcriptionnels dans les 
neurones du système nerveux central au développement de l’addiction aux drogues. Il est connu 
que l’apprentissage induit des modifications au niveau de la structure du cerveau,  principalement 
en changeant la manière dont les neurones sont interconnectés par des synapses. De plus en plus 
d’évidences soutiennent un scénario selon lequel l’activité neuronale déclenche des cascades de 
signalisation intracellulaire qui ciblent des facteurs de transcription. Ces derniers peuvent activer 
la transcription de gènes spécifiques qui codent pour des protéines nécessaires au renforcement des 
synapses mémorisant ainsi la nouvelle information. 
Puisque l’addiction peut être considérée comme une forme aberrante d’apprentissage, et que les 
modifications synaptiques sont connues pour être impliquées dans le processus d’addiction, nous 
essayons de décrire des mécanismes transcriptionels étant à la base des changements synaptiques 
induits par les drogues. Comme modèle nous utilisons des cultures primaires des neurones de 
striatum, d’hippocampe et de cortex de souris ainsi que des tranches de cerveau de rat. 
Une des caractéristiques communes de quasiment toutes les substances addictives est de pouvoir 
activer le système mésolimbique dopaminergique provoquant la libération de dopamine sur les 
neurones du striatum (du noyau accumbens). Dans ce travail de thèse nous démontrons que dans 
des cultures du striatum, la dopamine induit le facteur de transcription C/EBPβ qui, à son tour, 
provoque l’expression du gène codant pour la substance P. Ce mécanisme pourrait potentiellement 
contribuer à la tolérance envers les drogues puisqu'il fait partie d’une rétroaction (feed-back) sur 
les cellules produisant la dopamine. 
Etant donné que ces résultats montrent l’importance de C/EBPβ dans la psychopathologie de 
l’addiction, nous avons également décidé d’étudier les mécanismes fondamentaux de l’activation 
de la transcription par C/EBPβ. Nos expériences démontrent que trois isoformes activatrices de la 
famille C/EBP recrutent le coactivateur CBP et provoquent en même temps sa phosphorylation. 
Enfin, nous montrons que les coactivateurs nommés TORC, nouvellement découverts et clonés, 
sont capables de détecter la coïncidence d’un signal cAMP et d’une entrée de calcium dans des 
neurones. Par conséquent les TORCs pourraient contribuer à détecter la coïncidence d’un signal 
glutamate et d’un signal dopamine dans les neurones de striatum, ce qui pourrait être important 
pour associer les effets hédonistes de la drogue à l’information contextuelle (par exemple à 
l’environnement où la drogue a été consommée). Nous sommes les premiers à observer que les 
TORCs sont nécessaires pour la potentiation à long terme dans l’hippocampe. 
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4 Introduction 
4.1 Transcription in biological systems 
4.1.1 Importance of the transcriptional regulation 
The structure and the functioning of a biological organism is determined by the set of proteins it 
comprises. Proteins can have very diverse funtions (immunoglobulins – defense, myosine – 
contraction, etc.), particular interest has to be dedicated to the enzymes that can synthesize or 
modify other molecules present in the organism. Some of the structural elements are themselves 
proteins (keratin, collagen, etc), other structural elements (for example those made of 
hydrocarbones) are produced by enzymes. The flow of information in biological organisms is 
mainly unidirectional: DNA (genes) → messenger RNA (mRNA) → proteins. The genes that give 
rise to mRNA are transcribed and this tightly regulated process (transcription) determines the set of 
proteins that are present in a given cell at a given time point. 
In metazoans every single cell (apart from some minor exceptions) possesses a copy of the whole 
genome in its nucleus although the function of the different (differentiated) cell types are strikingly 
dissimilar. The functional differences between cell types are achieved by transcriptional regulation, 
i.e. the set of transcription factors that are present varies from one cell type to another leading to the 
activation of some specific genes and thereby defining what proteins are synthesized by the cell. 
At the beginning of the cellular differentiation, cues provided for example by the parental organism 
or by the position of the cells in the organism activate a few key transcription factors. These 
transcription factors („master regulators”) activate other ones, thus a branching cascade of 
transcriptional regulation leads to the corresponding branching of the cell fate. 
Besides the long term changes underlying development, transcriptional events can cause temporary 
changes that serve the adaptation of the organism to the alterations of the environment. Several 
hormones induce transcriptional changes in target cells, and what’s more, receptors for some 
hormones (steroids, retinoic acid, tyroxine, etc.) are themselves transcription factors directly 
binding to the DNA in a ligand dependent manner. Transcriptional changes can occur already 30 
minutes after the alteration of the external or internal environment, thus, some of the cellular 
responses to neurotransmitters, to changes in metabolic state or to intruding microorganisms are 
also accomplished at the transcriptional level. 
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4.1.2 Basic mechanisms of transcriptional regulation 
Several regulatory factors (proteins) determine whether a gene is transcribed or not, some of them 
get into physical contact with the DNA, others are part of or regulate protein complexes formed on 
the DNA. On the other hand, the gene comprises regulatory sequences (acting in cis) that serve as a 
binding platform for these complexes. These sequences are called enhancers if they are far away 
from the transcriptional initiation site (Voss et al., 1986). Enhancers can be situated in a 3’ position 
(Trainor et al., 1987) or even in introns (Ge et al., 2003). The 5’ sequence close to the transcription 
initiation site is termed promoter (Dynan, 1986) that can be subdivided into distal promoter 
comprising normally several binding sites for sequence-specific transcription factors and the 
proximal promoter constituted of the TATA box and the initiation site. Silencers are sequences that 
repress transcription by recruiting specific factors, insulators (Bell et al., 1999) can inhibit the 
action of an enhancer on a gene. 
The proteins (acting in trans) that bind to the regulatory sequences of a gene and alter the efficiency 
by which the gene is transcribed are called transcription factors. Some of them are involved in the 
transcription of several genes, these general (basal) transcription factors comprehend TFIIA, 
TFIIB, TFIID, TFIIE, TFIIH and other molecules of less characterized function. These factors form 
a preinitiation complex on proximal promoters in an orchestrated manner (Guarente et al., 1992). 
The first event is the association between the TATA box and TBP (TATA box binding protein), a 
component of the 700 kDa TFIID complex. TBP is a saddle-shaped protein that induces a large 
conformational change in the DNA upon binding. A sharp kink is introduced at both end of the 
TATA-box (Kim et al, 1993). Subsequently, TFIIA is recruited followed by TFIIB that bridges an 
RNA polymerase II molecule to TFIID. After the binding of the polymerase, additional molecules 
are recruited, such as TFIIE and TFIIH (Goodrich et al., 1994) that are required for the promoter 
clearance (i.e. for the release of the RNA polymerase II from the preinitiation complex). It should 
be noted that RNA polymerase I and RNA polymerase III dependent transcription can follow very 
different mechanisms, just like the transcription of the TATA-less genes. 
Other transcription factors bind preferentially to enhancers and are present in a well-defined subset 
of tissues/cell types, or in a restricted time-span (Dynan et al. 1985). These molecules, called 
sequence-specific transcription factors (see chapter 4.1.4) are responsible for the tissue/cell/time 
specific expression of some genes. Their mechanism of action encompasses interaction with 
polymerase II or basal transcription factors such as TFIIB and recruitment of chromatin modifying 
enzymes (for example: acetylases) or ATP-dependent chromatin remodeling factors. I will give an 
overview of sequence-specific transcription factors in chapter 4.1.4. 
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Coactivators (see chapter 4.1.6) are protein molecules that do not contact directly the DNA but can 
alter the rate at which a gene is transcribed. They are typically recruited to the DNA by sequence-
specific transcription factors. One important class of coactivators is that of the ATP-dependent 
chromatin remodeling complexes, such as members of the SWI/SNF, ISWI or the Mi-2/CHD 
subclass (Peterson, 2002). These molecules can disrupt histone-DNA contacts, make nucleosomes 
slide along the DNA, drive the loss of negative supercoils from circular minichromosomes and 
increase accessibility of nucleosomal DNA to transcription factors (Peterson, 2002). A distinct class 
of coactivators comprises histone modifying enzymes. The most characterized activating histone 
modification is the acetylation, the acetyl group can be transferred onto lysine residues (see chapter 
4.1.5) by molecules such as CBP, p300, PCAF or SRC-1. Finally, some coativators do not show 
enzymatic activity, these molecules serve as a bridge between sequence-specific transcription 
factors and the basal transcriptional machinery or the polymerase II. A typical example of this kind 
of coactivator was recently described and named TORC (Conkright et al., 2003) 
 
Figure 1. Overview of the eukaryotic transcriptional machinery. GTF: general transcription factors; TFIID: 
transcription factor IID; Pol II: RNA polymerase II, SRE, GC: examples of binding sites in the distal promoter; NRE: 
example of a binding site in the enhancer.  
4.1.3 Regulating transcription by histone modifications 
The eukaryotic DNA is associated to highly conserved proteins termed histones. All of the four 
histone molecules (H2A, H2B, H3, H4) that build up the core of the nucleosome can be covalently 
modified by acetylation, methylation, phosphorylation and ubiquitinylation (Zhang et al. 2001). 
Among these modifications, acetylation and methylation excels by the impact that they have on 
transcription. 
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Long before the description of the nucleosome structure, Allfrey and collaborators found that acetyl 
and methyl groups could be attached to histones and foresaw that these modifications could enhance 
the rate of mRNA synthesis (Allfrey et al., 1964). This idea gained further confirmation when Allis 
and his colleagues showed that in the transcriptioinally active macronucleus of Tetrahymena 
histones are acetylated, whereas in the transcriptionally inactive micronucleus acetylation is 
undetectable, even after blocking histone deacetylating enzymes (Vavra et al., 1982). 
4.1.3.1 How can histone modifications regulate transcription? 
Different mechanisms seem to underlie the activating effect of histone acetylation on gene 
expression. Histones are rich in positively charged residues (such as arginine and lysine) that are 
postulated to interact with the negatively charged backbone of the DNA. Acetylation and 
methylation neutralize the positive charge of the involved amino acids and thereby loosens the 
histone-DNA contact. The changes in the interaction forces are directly measurable by biophysical 
means such as atomic force microscopy (AFM) (Solis et al., 2004) or optical tweezers. 
The amino-termini of histones are also involved in internucleosomal interactions leading to the 
formation of higher order chromatin structures. The acetylation of H3 and H4 N-terminal tails is 
proposed to disrupt interactions between nucleosomes and consequently break down higher order 
chromatin structures (Marwin et al., 1990, Solis et al., 2004) making DNA more accessible to 
transcription. 
The modification of the histones can create a new binding surface for other molecules. Several 
proteins contain bromo- and chromodomains that specifically interact with acetylated and 
methylated lysines, respectively. One of the most important examples of such kind of interaction is 
the association between HP1 (heterochromatin protein 1) and the methylated K9 residue of H3 
(Lachner et al., 2001). HP1 is an adaptor molecule implicated in both gene silencing and supra-
nucleosomal chromatin structure. Thus the methyaltion of H3 on K9 is thought to help the 
recruitement of HP1 that in turn leads to the formation of heterochromatin. 
4.1.3.2 Crosstalk between different histone modifications 
A given histone modification can exert an effect on another modification, one of the most obvious 
example of this kind of crosstalk is the antagonism between acetylation (leading to activation) and 
methylation (leading to repression) of H3 on K9 (Nicolas et al. 2003). However, crosstalk is still 
possible even if the two interacting modifications are not on the same amino acid residue. For 
instance, another way by which H3-K9 methylation decreases transcriptional activity is the 
inhibition on H3-S10 phosphorylation. The interacting modifications do not even have to be on the 
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same histone molecule. For example, the monoubiquitinylation of H2B facilitates transcription by 
promoting H3-K4 and H3-K27 methylation (Osley, 2004). 
4.1.3.3 Spreading of histone modifications 
Repressing histone modifications are usually associated to clusters of silenced genes. These 
modifications can be preserved through rounds of mitosis thereby contributing to the maintenance 
of the gene expression pattern of differentiated cell lineages. Methylation is a typical repressive 
histone modification that was shown to spread in cis along chromatin and also to outlast mitosis 
(Felsenfeld et al., 2003). During replication, the newly synthesized nucleosomes are deposited 
randomly between the reused, already methylated nucleosomes on both chromatids. HP1 interacts 
with the already methylated K9 residues of H3 and recruits histone methyltransferases thereby 
passing on the methylation signal to newly synthetised histones (Felsenfeld et al, 2003). Activating 
histone modifications such as acetylation were also proven to spread (Zhao et al, 2004), one of the 
likely mechanisms could involve the coactivators CBP and p300 which have a bromodomain and 
also a histone acetyltransferase (HAT) domain. The former is able to bind already acetylated 
histones, thereby teathering the coactivator to the chromatin domain, the latter could acetylate the 
yet unmodified nucleosomes. Similarly to the repressive histone marks, the activating ones like H3-
K4 di- or trimethylation, H3-K79 dimethylation and hyperacetylation were also shown recently to 
outlast mitosis (Kouskouti et al, 2005). 
 
4.1.4 Families of transcription factors 
The notion of transcription factor covers DNA-binding proteins capable of activating transcription 
and consisting of a DNA-binding domain, a trans-activating domain and in some cases a 
dimerization or a multimerization domain. In this chapter only the most important families of 
transcription factors will be reviewed.  
4.1.4.1 Homeodomain proteins 
These proteins participate in the control of development throughout the whole animal kingdom, 
they contribute to the specification of anterior-posterior body axis. Their DNA-binding domain is 
called homeodomain consisting of 60 amino acids arranged in a helix-turn-helix motif. The second 
helix can extend into the major groove of the recognized DNA molecule (Brennan et al., 1989). 
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4.1.4.2 POU domain proteins 
The POU domain comprises a homeodomain and a second, high affinity, POU-specific DNA-
binding domain (Herr et al., 1988). Its name derives from the initials of three transcription factors 
first described as having such a domain: Pit-1 is an important molecule in the pituitary, Oct-1/Oct-
2, an ubiquitous and a B-cell-specific factor respectively, and UNC-86, a molecule that determines 
neuronal fate in Nematodes. 
4.1.4.3 Basic helix-loop-helix transcription factors 
Another important and well-characterized arrangement in DNA binding proteins is the basic helix-
loop-helix (bHLH) motif. These transcription factors contact DNA through a segment of basic 
amino acids located N-terminally form the first alpha-helix. The helices contain hydrophobic amino 
acids that enable two of the molecules to heterodimerize (Jones, 1990). One prominent example of 
bHLH transcription factors is the MyoD family of proteins that orchestrates muscle differentiation 
(Lassar et al., 1991). 
4.1.4.4 Basic leucine zipper (bZIP) transcription factors 
The N-terminal half of the basic leucine zipper (bZIP) domain contains basic amino acids allowing 
for sequence-specific DNA-binding while the C-terminal half mediates dimerization and consists of 
an amphipathic sequence with a leucine in every seventh position (Vinson et al., 2002). The 
transactivation domain of these transcription factors is located N-terminally from the bZIP domain 
(Pathak et al., 1992). One of the possible classification of bZIP transcription factors is based on 
their dimerization properties (Vinson et al. 2002) and distinguishes homodimerizing bZIP molecules 
such as CREB (cAMP responsive element binding protein), CREM or ATF-1, homodimerizing and 
heterodimerizing bZIP molecules such as the C/EBP and the JUN family, and finally 
heterodimerizing bZIP molecules such as the FOS family.  
4.1.4.5 Zinc finger transcription factors 
Numerous transcription factors including steroid receptors have two or more α-helical DNA 
binding motif termed zinc finger. The central amino acids of this motif tend to be basic and the 
structure is stabilized by a centrally located zinc ion that is coordinated by histidine and cysteine 
residues. Several zinc finger transcription factors are involved in development such as WT1 that is 
indispensable for kidney and gonad formation (Kriedberg et al., 1993). Other factors of this family 
mediate the effects of steroids, retinoic acid, thyroxine and vitamine D, these proteins are assembled 
under the name of nuclear hormone receptors. Upon the binding of their cognate hormone, they 
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enter the nucleus and bind specific DNA sequences located in the enhancers of hormone-responsive 
genes (Green et al. 1988). 
4.1.5 Structure, expression pattern and function of C/EBP transcription factors 
So far, six members of the CCAAT/enhancer-binding proteins (C/EBPs) have been cloned and 
described, namely C/EBPα, -β, -γ, -δ, -ε, and -ζ (Lekstrom-Himes et al., 1998). Except for C/EBPζ, 
these molecules bind the same palindromic DNA consensus and are able to homo- and 
heterodimerize within the family (Lekstrom-Himes et al., 1998). To a certain extent C/EBPs can 
tolerate substitutions in the perfect consensus (ATTGCGCAAT) and can, in some cases, bind 
cAMP response elements (CREs) normally recognized by the transcription factor CREB (Park et 
al., 1993). 
4.1.5.1 C/EBPα 
C/EBPα is a 42 kDa protein, the first cloned member of the family (Landschultz et al. 1988), it is 
expressed in liver, adipose, intestine, lung, adrenal gland, peripheral blood mononuclear cells and 
placenta. A shorter 30 kDa form of different transactivation potential is generated by translational 
initation at the third AUG, 351 nucleotides downstream of the first AUG (Schindler et al., 1995). 
Knockout mice lacking C/EBPα die shortly after birth due to the absence of hepatic glycogen and 
resulting hypoglycemia (Wang et al., 1995). 
C/EBPα regulates positively its own transcription by different mechanisms in mouse (Ray et al., 
1994) and in humans (Betts et al. 1993) and this autoregulation results in constitutive expression 
levels in some cell types, for instance in hepatocytes and adipocytes. In addition to its 
antiproliferative effects, C/EBPα is an important regulator of tissue-specific genes in these cell 
types. Examples of C/EBPα-regulated effectors include the AP2 and the SCD1 genes (Christy et al., 
1989) in adipocytes and hepatic cytochrome P450 genes (Jover et al., 1998), acute phase proteins 
(Rabek et al., 1999) and virtually all urea cycle enzymes (Kimura et al., 1998) in hepatocytes. 
In contrast to adipocytes and hepatocytes where C/EBPα is present at the terminally differentiated 
state, in the myelomonocytic lineage its expression precedes that of other C/EBP family members 
(Scott et al., 1992). C/EBPα is required for induction of granulocytic differentiation (Keeshan et al. 
2003) and it is thought to carry an important role in the cell cycle arrest (Nerlov et al., 2004). The 
mechanism by which  C/EBPα  inhibits mitotic activity is still subject  to debate, however, an 
appealing model would be the repression of the E2F complex that is required for cell-cycle 
progression (Porse et al., 2001). Consistently with the inhibitory role on proliferation during 
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granulocyte differentiation, several “loss of function” mutations of C/EBPα were found to be 
associated with acute myeloid leukemia (Nerlov et al., 2004). 
4.1.5.2 C/EBPβ 
C/EBPβ, a 32 kDa protein, has its highest levels of constitutive expression in lung, intestine, liver 
and adipose tissue. It was originally identified and cloned as a mediator of IL-6 signaling that 
promotes the expression of acute phase response genes (Akira et al, 1990). Similarly to C/EBPα, 
the translation of C/EBPβ can give rise to different proteins due to the utilization of alternative start 
codons. A truncated form termed LIP possesses only the DNA-binding and leucine zipper domains 
and can heterodimerize with the full-length protein and consequently acts as a transcriptional 
repressor (Ossipow et al., 1993).  
The mechanism by which the C/EBP family can respond to extracellular signals is best understood 
in the case of C/EBPβ. Initially, it was suggested for NF-M, the chicken homologue of C/EBPβ, 
that a MAPK phosphorylation site situated in an inhibitory domain is responsible for the kinase 
mediated desinhibition of C/EBPβ (Kowentz-Leutz et al., 1994). Phosphorylation at this site was 
shown to disrupt intramolecular interactions within NF-M, and suggested to expose trans-activating 
domains of the molecule (Kowentz-Leutz et al., 1994). A similar mechanism was proposed for the 
mouse homologue of C/EBPβ (Williams et al., 1995). Recently, mouse C/EBPβ was shown to 
acquire DNA-binding activity upon sequential phosphorylation by MAPK and glycogen synthase 
kinase 3β (Tang et al., 2005). 
C/EBPβ is also involved in multiple processes of cellular differentiation. Among cells of the 
myelomonocytic lineage, macrophages show a marked increase in C/EBPβ expression (Natsuka et 
al., 1992) that follows a transient increase in C/EBPα levels and persists in the terminally 
differentiated state (Scott et al., 1992). Furthermore, C/EBPβ was shown to bind the promoter of 
macrophage-specific genes such as IL-1, TNFα or lysozyme (Natsuka et al., 1992). A tightly 
regulated cascade of the C/EBPs orchestrates adipocyte differentiation, C/EBPβ being the first, 
followed by C/EBPδ then C/EBPα (Lane et al., 1999). During this process, C/EBPβ is activated by 
CREB (Zhang et al. 2003) and initiates the expression of C/EBPα that is maintained by 
autoregulation. In the developing liver, C/EBPβ levels first increase then decrease to cede the place 
to C/EBPα (Nagy et al., 1994). The important role of C/EBPβ in triggering hepatocyte 
differentiation is well-illustrated by the fact that pancreatic cells can be transdifferentiated into 
hepatocytes by transfection of C/EBPβ (Shen et al., 2000). 
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A growing body of evidence points to a role of C/EBPβ in the central nervous system. In situ 
hybridization studies have shown that C/EBPβ is widely expressed in the central nervous system of 
adult mouse (Sterneck et al., 1998). In rats, inhibitory avoidance training increases C/EBPβ mRNA 
levels in the hippocampus and this could be blocked by fornix lesions (Taubenfeld, Wiig et al., 
2001). The expression of C/EBPβ in this region is required for the consolidation of inhibitory 
avoidance memories (Taubenfeld, Milekic et al., 2001). Interestingly, for the reconsolidation of the 
same kind of memory, C/EBPβ is necessary in the amygdala but not in the hippocampus (Tronel et 
al., 2005). In mice, contextual memory formation was accompanied with elevated levels of C/EBPβ 
expression (Athos et al. 2002). This effect was abolished by blocking CREB function that also 
interfered with the establishment of contextual memory (Athos et al. 2002). 
4.1.5.3 C/EBPδ 
C/EBPδ has been cloned by its ability to bind the preprotachykinin-A promoter (Kageyama et al., 
1991), it is constitutively expressed in intestines, adipose and lung. High levels of expression are 
detectable in all tissues after stimulation with lipopolysaccharide. 
The transactivating potential of C/EBPδ is comparable with that of the other activating isoforms (α 
and β), however, its DNA binding activity is weaker, presumably due to the presence of 2 proline 
and 4 glycine residues in the DNA-binding region that may interrupt the predicted α-helical 
structure (Hanson, 1998). 
C/EBPδ carries a similar role in adipocyte differentiation as C/EBPβ, and also exhibits a delayed 
DNA-binding activity during this process (Tang and Lane, 1999). In fetal rabbit lung tissue, 
C/EBPδ mRNA is developmentally regulated reaching high levels between 25 and 30 days (Breed 
et al., 1997). The protein follows similar kinetics in fetal rat lung (Rosenberg et al., 2002) and was 
shown to regulate surfactant protein-A expression (Rosenberg et al., 2000; Seppanen et al., 2004). 
C/EBPδ can be considered as a potential tumor suppressor, since in its absence ductal branching is 
increased and mammary epithelial cells exhibit hyperproliferation (Gigliotti et al., 2003). 
Furthermore, immortalized mouse embryonic fibroblasts lacking C/EBPδ show genomic instability 
and several features of transformation, including decreased serum dependence and lack of contact 
inhibition (Huang et al., 2004).  
4.1.5.4 C/EBPγ, -ε, and -ζ 
C/EBPγ is a short, 16.4 kDa isoform that possesses a dimerization domain and a DNA-binding 
domain but lacks a transactivating domain, and therefore acts – in contrast to the activating α, β, 
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and δ isoforms – as a transcriptional repressor (Cooper et al., 1995). C/EBPε has several different 
forms due to differential splicing, use of alternative promoters and internal initiation sites 
(Yamakana et al., 1997). In consequence, its transactivation domain can be truncated to different 
extent. High levels of expression are detected in the myeloid lineage, consistently with the finding 
that C/EBPε seems to be involved in myeloid differentiation (Morosetti et al., 1997). C/EBPζ (also 
known as CHOP or GADD153) is an inhibitory isoform that is induced by DNA damage and can 
heterodimerize with activating C/EBP isoforms. The heterodimers are unable to bind DNA due the 
presence of two proline residues in the DNA binding domain of C/EBPζ (Ron et al., 1992).  
4.1.6 Coactivators 
Transcriptional coactivators are protein molecules that do not contact directly the DNA, but can 
increase the rate of transcription by interacting with enhancer- or promoter-bound sequence-specific 
transcription factors. As discussed above (see chapter 4.1.4), some coactivators can have histone 
acetyltransferase (HAT) or ATPase activity, others are devoid of enzymatic activity and simply 
recruit molecules of the basic transcriptional machinery to the promoters. In this chapter we will 
mainly focus on coactivators investigated during the thesis work, namely CBP, p300 and TORCs. 
4.1.6.1 CBP and p300 
4.1.6.1.1 General description of CBP and p300 
CBP (CREB binding protein), a 265 kDa molecule, was cloned by its ability to specifically bind the 
phosphorylated form of a sequence-specific transcription factor termed CREB (Chrivia et al., 1993). 
By using reporter gene assays, it has been demonstrated that CBP potentiates CREB-dependent 
transcription and its C-terminal portion is able to bind TFIIB, a basal transcription factor (Kwok et 
al., 1994). From these studies a model emerged that ascribed an important role to CBP in cAMP-
mediated gene regulation. According to this model, CBP specifically interacts with CREB 
phosphorylated by PKA and this specificity assures that CRE (cAMP responsive element) 
containing genes are transcribed with an increased rate upon a cAMP signal that is known to 
activate PKA. In subsequent publications, additional mechanisms were described that explained 
why CBP acts as a transcriptional coactivator: its strong N-terminal transcriptional activation 
domain (located between amino acids 272-460) has been described and shown to bind TBP (Swope 
et al., 1996); its histone acetyltransferase activity has been demonstrated (Bannister et al., 1996), 
and RNA helicase A was proposed to bridge RNA  polymerase II to CBP (Nakajima et al., 1997). 
Another large coactivator molecule, termed p300, is considered as a structural and functional 
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homologue of CBP. It has been identified (Harlow et al., 1986) and then cloned (Eckner et al., 
1994) through its ability to interact with the adenovirus protein E1A. 
4.1.6.1.2 Importance of CBP and p300 at the organism level 
Mouse nullizygous for CBP (Tanaka et al., 2000) or p300 (Yao et al., 1998) display embryonic 
lethality, whereas the phenotype of the heterozygous animals is not identical for CBP and p300 
(Tanaka et al., 1998; Yao et al., 1998). Interestingly, mice lacking one copy of CBP and one copy of 
p300 also show embryonic lethality (Yao et al., 1998) illustrating the fact that the two coactivators 
have in part overlapping functions. Mice lacking one copy of CBP or p300 provided important hints 
on the role of these coactivators at the organism level. Among other abnormalities, hematological 
malignancies are observed in their absence (Kung et al., 2000) pointing to a tumor suppressor 
function. In line with these findings, p300 and CBP were found to interact with (Avantaggiati et al., 
1997; Gu, Shi and Roeder, 1997) and acetylate (Gu and Roeder 1997) the tumor suppressor p53. 
Furthermore, mutations impairing CBP/p300 function were isolated from human tumors (Ozdag et 
al., 2002) and chromosomal rearrangements creating fusion molecules called MOZ-CBP (Borrow et 
al., 1996) and MLL-CBP (Taki et al., 1997) were associated with malignous proliferation. 
However, the mechanism by which these fusions promote tumor formation is far from being 
elucidated. 
A developmental disorder called Rubinstein-Taybi syndrome (RTS) was found to be associated 
with mutations of the CBP gene (Petrij et al 1995). RTS is characterized by unusual facial 
appearance, broad thumbs, broad big toes and mental retardation, evidencing that CBP contributes 
to the correct functioning of the central nervous system.  The digital abnormalities observed in RTS 
might result from defective Gli-3 signaling, since Gli-3 mutant mice have similar phenotype (Hui et 
al., 1994) and Gli-3 has been shown to interact with CBP (Dai et al., 1999). For long, RTS has been 
associated with mutations in CBP but not in p300. However, a recent report suggested that 
mutations in p300 could also cause this disorder (Roelfsema et al., 2003) 
4.1.6.1.3 Domain structure of CBP and p300 
Several important domains have been identified in CBP and p300 (figure 2.). An N-terminally 
located LXXLL motif serves as a binding site for nuclear hormone receptors (Heery et al., 1997) 
in accordance with the finding that CBP coactivates nuclear hormone receptor-mediated 
transcription (Kamei et al., 1996). Three zinc finger motifs are present in CBP/p300, the first   is 
located between amino acids 346-432 in CBP and binds numerous important interacting partners. 
C-terminally from this region, a short domain (586-665) has been described that mediates the 
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interaction with the phosphorylated form of CREB. This domain is referred to as KIX, and binds the 
kinase inducible domain (KID) of CREB and other important factors. The three dimensional 
structure of the KIX-KID complex has been resolved by NMR spectroscopy (Radhakrishnan et al., 
1997). In p300, a transcriptional repression domain termed CRD1 lies between amino acids 1017-
1029 diminishing the activity of the N-terminal transcription activation domain. The covalent 
attachment of SUMO (small ubiquitin-like modifier) molecules to two consensus sites between 
1017-1029 is necessary for the inhibition (Girdwood et al., 2003). The consensus sites for 
sumoylation are partially conserved between CBP and p300, and a recent publication reported that 
CBP is repressed by sumoylation in a similar way as p300 (Kuo et al., 2005). 
 
Figure 2. Ribbon diagram of CBP and p300. Interacting proteins are depicted at the top of the figure; functional 
domains are shown below. Many known interactions are not included due to space limitations. Figure taken from ref. 
56. 
The joint presence of a bromodomain (amino acids 1104-1176 in CBP) that binds acetylated lysine 
residues and a histone acetyltransferase (HAT) domain make it reasonable to implicate CBP and 
p300 in the spreading of histone acetylation. A sequence within the HAT domain (1459–1541 in 
CBP) was found to be conserved between numerous acetyltransferases and is supposed to be the 
acetyl-coenzyme-A binding site (Martinez-Balbas et al., 1998). The second zinc finger of CBP lies 
also within the HAT domain. This motif, classified as a PHD-type zinc finger, is necessary for the 
acetyltransferase activity of CBP but not for that of p300 (Bordoli et al., 2001). In some cases the 
expression FAT (factor acetyltransferase) or simply AT (acetyltransferase) activity is preferred over 
HAT activity, since a growing number of molecules other than histones were shown to be 
acetylated by CBP or p300. A prominent example is the acetylation of p53 by p300 that increases 
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the DNA-binding activity of the transcription factor (Gu et al., 1997). The third zinc finger domain 
of CBP and p300 is particularly important for the binding of several interacting partners including 
sequence-specific transcription factors such as C/EBPβ (Mink et al., 1997). Its three dimensional 
structure has been resolved by NMR spectroscopy (De Guzman et al., 2000). The third domain of 
CBP/p300 for which an NMR structure is published (Lin et al., 2001) comprises 46 compactly 
folded residues (2067-2112) and has been named IRF-3 binding domain (IBiD). One of the 
prominent molecules interacting with this region is the steroid receptor coactivator SRC-1 
(Sheppard et al., 2001). 
4.1.6.1.4 Interacting partners of CBP and p300 
CBP and p300 are recruited to promoters and enhancers by sequence-specific transcription factors 
and subsequently facilitate transcription by acetylating histones, or recruiting effector molecules. If 
many sequence-specific transcription factors utilize CBP/p300 in a given cell type/tissue, 
competition can arise due to the limited availability of the coactivator molecules. Interacting 
domains in CBP/p300 have been mapped for a variety of sequence-specific transcription factors 
such as the phosphorylated form of CREB (Chrivia et al., 1993) the phosphorylated form of c-Jun 
(Arias et al., 1994) that specifically bind the KIX domain, c-Fos that binds the third zinc finger 
(Bannister et al., 1995), c-myb that interacts with the KIX domain (Dai et al., 1996), and finally 
C/EBPβ (Mink et al., 1997) and C/EBPα (Schaufele et al., 2001) that associate with the third zinc 
finger. CBP (or p300) is a coactivator for further sequence-specific transcription factors of more 
circumscribed function, it contributes to tumor suppression and cell cycle arrest by interacting with 
p53 (Gu, Shi and Roeder, 1997); to inflammatory processes by binding to NF-kappaB (Gerritsen et 
al., 1997), to erythropoiesis by interacting with GATA-1 (Blobel et al., 1998) and to muscle 
development by binding to Myo-D (Yuan et al., 1996). 
CBP molecules recruited to promoters and enhancers can increase transcription by changing the 
acetylation levels of chromatin and by virtue of interacting with basal transcription factors such as 
TFIIB, TBP or RNA polymerase II (see above) or with other effector molecules such as p300/CBP 
associated factor (P/CAF) (Yang et al., 1996) which itself has histone acetyltransferase activity. 
Another important interacting partner of CBP and p300 is the adenovirus protein E1A (Arany et al., 
1995; Lundblad et al., 1995). Since the immortalizing effects of E1A are blocked by the 
overexpression of CBP or p300, it is reasonable to assume that this interaction contributes to the 
E1A-mediated cellular transformation. E1A has been shown to inhibit CBP/p300 function (Kwok et 
al., 1994), consequently a block by E1A is often considered as a proof of the involvement of 
CBP/p300 in a given specific transcriptional event. 
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4.1.6.1.5 Regulation of CBP by phosphorylation 
For long, attention has been focused on the phosphorylation of CREB but not on that of CBP. This 
phosphorylation can convert short term signals into transcriptional responses, since recruitment of 
CBP is dependent on CREB phosphorylation and sufficient to CREB-mediated gene activation 
(Cardinaux et al., 2000). Subsequently, evidences accumulated substantiating that signals of 
extracellular origin can impinge directly on CBP and thereby modifying transcriptional responses 
without affecting CREB phosphorylation. Numerous kinases have been suggested to be involved in 
such processes. For example, PKA was shown to phosphorylate CBP and increase CBP-dependent 
transcriptional response (Chrivia et al., 1993) and in accordance with this finding, cAMP was 
proposed to increase Pit-1 function through CBP phosphorylation (Xu et al., 1998). The MAPK 
family was also reported to phosphorylate CBP (Janknecht et al., 1996), and phosphorylation by 
this family of kinases was found to increase the HAT activity of CBP (Ait-Si-Ali et al., 1998). In 
PC12 cells, NGF increases the transcriptional activity of CBP in a MAPK-dependent manner (Liu 
et al., 1998). Calcium-dependent pathways can equally trigger CBP phosphorylation, since 
CaMKIV, activated by neuronal NMDA, was shown to phosphorylate CBP and increase its activity 
(Chawla et al., 1998; Hardingham et al., 1999; Impey et al., 2002). In the case of the kinase 
pp90Rsk, only interaction with but not the phosphorylation of CBP has been demonstrated 
(Nakajima et al., 1996). We will provide evidence in this thesis work that the C/EBP family of 
transcription factors can trigger the phosphorylation of CBP in its C-terminal region. 
4.1.6.2 Transducers of regulated CREB activity (TORCs) 
4.1.6.2.1 General description of TORCs 
TORCs are newly described coactivators that were identified and cloned as molecules that can 
increase drastically CREB-dependent transcription (Conkright et al., 2003; Iourgenko et al., 2003). 
Three isoforms have been identified, TORC1, -2 and -3; TORC1 being most abundant in the central 
nervous system (prefrontal cortex, cerebellum) and TORC2 and -3 being most abundant in 
lymphocytes (Conkright et al., 2003). TORCs interact with CREB in a phosphorylation independent 
manner (Conkright et al., 2003). Surprisingly this interaction does not involve the classical 
transactivation domains (Q1 and Q2) of CREB, but rather relies on its basic leucine zipper domain. 
Indeed, substitution of arginine 314 that lies within the leucine zipper abolishes the interaction with 
TORCs (Screaton et al., 2004). Another interesting feature of TORCs is that they can function as 
coincidence detectors sensing simultaneous calcium influx and adenylate-cyclase activation (figure 
3.). Phosphorylated TORCs are retained in the cytoplasm through interaction with 14-3-3 proteins. 
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Calcium activates a calcium-dependent phosphatase, calcineurin, that dephosphorylates TORC, 
meanwhile the cAMP pathway activates PKA that phosphorylates and thereby inhibits SIK, a 
kinase that effectuates TORC phosphorylation. While the separate dephosphorylation or inhibition 
of phosphorylation have little effect, the combination of these two events liberates considerable 
amounts of TORC from the cytoplasm that enters the nucleus and drives the transcription of CREB-
dependent genes (Screaton et al., 2004; Bittinger et al., 2004). 
 
Figure 3. Mechanism of TORC-mediated coincidence detection. CN: calcineurin; SIK2: salt inducible kinase 2; CsA: 
cyclosporin A. Figure taken from ref. 177. 
This mechanism of coincidence detection by TORCs has been described in pancreatic cells where it 
subserves a response to glucose and gut hormones (Screaton et al., 2004). However, TORC1 
expression reaches its highest levels in the central nervous system, furthermore, coincidence 
detection is likely to be an important neuronal function and would allow the organism to translate 
transient coincidences into transcription-dependent long-term neuronal changes such as 
reinforcement of synapses. Therefore in this thesis work we have tried to elucidate whether the 
TORC-dependent coincidence detection operates in neurons of the central nervous system. 
4.1.6.2.2 Domain structure of TORCs 
Several functionally important sequences can be distinguished in TORC molecules. The N-terminal 
coiled-coil domain binds to CREB as a tetramer (Conkright et al., 2003). As few as 44 amino acids 
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of the N-terminal part of TORC2 can be used as a transcriptional repressor since it can compete 
with endogenous TORCs for CREB binding (Bittinger et al., 2004). C-terminally from the CREB-
binding domain, a nuclear localization signal (NLS, Screaton et al., 2004) is located (amino acids 
56-144 in TORC2), allowing for the nuclear import of unphosphorylated TORCs that are not bound 
anymore by cytoplasmic 14-3-3 proteins. Between amino acids 145-320, two nuclear export 
sequences could be identified (Screaton et al., 2004) that promote the CRM1-mediated transport of 
TORCs towards the cytoplasm (Bittinger et al., 2004). In the central region of TORCs (amino acids 
300-500 in TORC2), numerous phosphorylation sites have been identified, among which serine 171 
(TORC2) was shown to be dephosphorylated by cAMP treatment (Screaton et al., 2004). Serine to 
alanine mutation at position 171 strongly diminishes the association between TORC2 and the 
cytoplasmic 14-3-3 proteins. The C-terminal part of TORCs contains a transcriptional activation 
domain (TAD) and interacts with TAFII130 (Conkright et al., 2003; Screaton et al., 2004). 
Recruitment of this basal transcriptional factor to CREB-dependent promoters explains well the 
strong coactivating potential of TORC molecules. 
4.1.6.2.3 Physiological importance of TORCs 
As juged by the so far published results, the physiological importance of TORCs is best established 
in metabolism-related processes. In the pancreas, glucose and gut hormones synergize to maintain 
β-cell viability in a CREB dependent manner. Glucose triggers calcium entry through closure of 
ATP-sensitive K-channels, while gut hormones such as glucagon-like peptide-1 (GLP-1) activate 
the cAMP pathway. These two signals were demonstrated to converge at the level of TORC2 that 
acts as a coincidence detector in this setup (Screaton et al., 2004). In hepatic cells, TORC2 was 
shown to be necessary for gluconeogenesis (Hoi-Koo et al., 2005). Furthermore, in these cells, 
TORC2 translocation was able to discriminate between fasting (glucagon) and feeding (insulin) 
cues, while CREB phosphorylation showed no difference (Hoi-Koo et al., 2005). SIK1 (salt 
inducible kinase-1) and AMPK inhibited efficiently the expression of hepatic gluconeogenic genes 
by promoting TORC2 phosphorylation (Hoi-Koo et al., 2005). From these studies a model emerges 
according to which glucagon activates the PKA pathway that in turn triggers the nuclear 
translocation of TORC2 by blocking SIK1 (TORC2-kinase) activity. This leads to the transcription 
of the CREB-dependent gluconeogenic genes. On the other hand, PKA induces SIK1 at the 
transcriptional level that results in a delayed inhibition on TORC2, restoring the basal expression 
levels of gluconeogenic genes. AMPK is also capable of phosphorylating TORC2 at Ser 171, thus 
in the presence of stressors or low ATP levels gluconeogenesis proceeds at a reduced rate even in 
the presence of cAMP (Hoi-Koo et al., 2005). 
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4.2 Drug abuse as a psychiatric disorder 
4.2.1 Definitions 
Drug abuse is defined as a progressive neglect of alternative sources of reinforcement concomitant 
to the development of compulsive substance taking that persists despite evidence of harmful 
consequences such as disrupted interpersonal relationships and professional failures (Leshner, 1997; 
Leshner et al., 1999; Hyman et al., 2001; Koob et al., 2004). This inability to control substance-
taking is thought to be a complex disease process of the brain, increasingly seen as a 
neuropsychiatric disorder that results from recurring drug intoxication. Indeed, most drug use does 
not necessarily involve addiction or dependence, and the development of cognitive deficits that can 
accompany drug abuse occurs usually after chronic repeated exposure. Several phenomenon have 
been clearly identified with recurring intoxication. 
Tolerance is defined as a decrease in the effect of a drug despite a constant dose, or a need for 
increased dosage to maintain a stable effect. Tolerance often develops to the desired pleasurable 
effects of cocaine, heroin and other abused drugs, leading to dosage increases that can exacerbate 
the molecular changes that lead to addiction.   
Sensitization is an enhancement of some drugs responses, usually after a repeated (i.e. chronic but 
intermittent) administration. On the contrary, tolerance usually occurs with a continuous intake.  
Dependence refers to an adapted state of cells, circuits or organ systems that occurs in response to 
excessive drug stimulation. When unmasked by drug cessation, this adapted state can result in a 
production of exclusively cognitive, emotional symptoms (in the case of psychic dependence) or 
altered physiological state (in the case of physical dependence).  
Addiction is a chronically relapsing disorder that is characterized by a compulsion to seek and take 
drugs (loss of control in limiting intake), and impairment in social and occupational functioning. 
Emergence of a negative emotional state (e.g. dysphoria, anxiety, irritability) when access to drug is 
prevented (defined here as dependence) has been associated with this transition from drug use to 
addiction. 
Addiction usually involves dependence on one or more addictive substances. However, dependence 
can occur without addiction, for example when morphine is used to relieve cancer-related pain or 
when benzodiazepines are used to treat panic disorder (Petursson, 1994; Vgontzas et al., 1995).  
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4.2.2 The brain reward circuit 
The existence of a reward circuit within the brain was first evidenced by Olds and Milner (1954) 
who reported that rats would work vigorously to electrically self-stimulate their own brain – an 
experimental paradigm that was named intracranial self-stimulation (ICSS) (Olds and Milner, 
1954). The natural function of the brain reward circuit is to provide a reward in response to life 
sustaining activities, such as eating or sexual behavior, to encourage repetition of those activities. 
Anatomically, the brain reward circuit is built up of specialized cortical and subcortical structural 
components including notably the prefrontal cortex, amygdala, nucleus accumbens, furthermore 
the subiculum of the hippocampal formation, and the dopamine neurons in the ventral tegmental 
area (Cooper, 2002). 
Microinjections of dopamine receptor antagonists into the neostriatum and the nucleus accumbens 
demonstrated that dopamine is an important mediator of the self-stimulation behavior (Mora et al., 
1975) and, indeed, the most important component of the brain reward circuit seems to be the 
ascending mesolimbic dopaminergic system (figure 4.) that consists of three components: (1) the 
ventral tegmental area, a mesencephalic structure that harbors the cell bodies of dopaminergic 
neurons, (2) dopaminergic fibers originating from the mesencephalon and ascending in the medial 
forebrain bundle, (3) the nucleus accumbens, a forebrain structure that receives dopaminergic 
innervation from the mesencephalon. 
 
Figure 4. The mesolimbic dopaminergic system and its connections with other brain areas. VTA: Ventral tegmental 
area; Nac: Nucleus accumbens; PFC: prefrontal cortex; VP: ventral pallidum. Figure taken from ref. 137. 
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The nucleus accumbens constitutes an interface between limbic structures and the striatum. It 
integrates inputs from numerous brain areas in order to calculate the probability and the magnitude 
of an expected reward and decide whether striatal structures should initiate a movement to obtain it 
(Mongenson et al., 1980). 
The ventral tegmental area (VTA) receives input from several brain structures that can influence 
the activity of its dopaminergic neurons. Information from the hypothalamus arrives to the VTA 
through the medial forebrain bundle (Millhouse, 1969), this arrangement constitutes an ideal 
anatomical substrate for a link between basic biological drive states (such as hunger) sensed by the 
hypothalamus and an increased release of dopamine by VTA cells. The particularly reinforcing 
electrical self-stimulation of the medial forebrain bundle was shown to act on descending fibers 
(hypothalamus → VTA) and not on ascending ones (VTA → nucleus accumbens), suggesting that 
the VTA is firstly activated by hypothalamic input, then dopaminergic cells send back action 
potentials through the medial forebrain bundle to trigger dopamine release in the nucleus 
accumbens (Bielajew et al., 1986). Another important excitatory input to the VTA originates from 
the bed nucleus of the stria terminalis (BNST, part of the extended amygdala), a structure capable 
of sensing interoceptive stressors. Via noradrenaline, stress is suggested to increase the activity of 
GABAergic interneurons of the BNST, that, in turn, inhibits excitatory neurons projecting to the 
VTA (Dumont et al., 2004). Very importantly, the modulation of the VTA through this pathway is 
thought to be critical for opiate withdrawal-induced aversion (Delfs et al., 2000). 
The prefrontal cortex – a cortical area that is involved in decision making – receives dopaminergic 
innervation from the VTA, and sends glutamatergic excitatory projections to the nucleus accumbens 
and back to the VTA. Therefore the medium spiny neurons of the nucleus accumbens are supposed 
to integrate the information coming from the VTA and the prefrontal cortex (see chapter 4.2.4).  
The amygdala sends projections to the nucleus accumbens and to the prefrontal cortex (Cooper, 
2002) and appears to signal the magnitude of the reward and to participate in reward anticipation 
(Pratt et al., 1998). Electrical and chemical stimulation of the amygdala can reinstate extinguished 
cocaine-seeking behavior in rats (Hayes et al., 2003) 
The subiculum – a ventrally situated area of the hippocampal formation – receives information 
from the CA1 area and is ideally situated to relay hippocampally processed contextual cues to 
many regions within the brain reward circuit. Consistently with these anatomical considerations, 
theta burst stimulation of the hippocampus could reinstate cocaine-seeking behavior in rats and this 
effect was dependent on glutamatergic transmission in the VTA (Vorel et al., 2001). This 
experimental result is likely to recapitulate the observation that human addicts tend to relapse when 
they encounter an environment previously associated with drug taking.   
  
25
4.2.3 Dopamine – transmitter of motivation? 
For decades, basic neuropsychopharmacological research in drug addiction has focused largely on 
describing an altered function within neural circuits that would subserve motivational processes 
after repeated exposure to drugs of abuse. This research has led to the identification of neuronal 
circuits and neurotransmitters involved in drug reinforcement. Dopamine (DA) is the 
neurotransmitter that has been classically associated with the reinforcing effects of drugs of abuse 
(Wise, 2004). This notion reflects the fact that the ability of drugs of abuse to increase extracellular 
DA in limbic brain regions (nucleus accumbens, amygdala) is thought to be crucial for their 
reinforcing effects (Nestler, 2001). For the most important substances of abuse we will discuss the 
mechanisms by which dopamine release is enhanced in the striatum (see chapter 4.2.6). 
Although there is general agreement that dopamine release in the nucleus accumbens is linked to 
natural rewards, its precise role is still not completely understood and subject to debate. Primary 
rewarding stimuli (ie. non-conditioned stimuli such as food and liquid rewards) can activate 
midbrain dopaminergic neurons while non-noxious aversive stimuli fail to activate the same 
population of cells (Mirenowicz et al., 1996). Conditioned stimuli (such as a light that indicates the 
availability of a primary reward) are also reported to trigger activity in dopaminergic neurons 
(Ljungberg et al., 1992). 
The firing pattern of dopaminergic neurons undergoes specific, systematic changes during the 
procedure of conditioning. At the beginning, the unconditioned stimulus elicits activity in 
dopaminergic cells. As the learning proceeds, this activity is gradually transferred to the 
conditioned, reward predicting stimulus, and the unconditioned stimulus does not trigger 
dopaminergic cell activity anymore, if it is fully predicted by the preceding, conditioned stimulus 
(Mirenowicz et al., 1994). 
In conditoning experiments (for example in a visual discrimination task) depression occurs in 
dopaminergic cell activity, if a fully predicted reward is not obtained (Hollerman et al. 1998). In 
contrast to the activation by a predicted reward, this depression gets stronger as the learning 
advances (Hollerman et al., 1998). These results lead to the conceptualisation of dopamine release 
as an error signal, that report rewards relative to their prediction. If a reward is completely 
unpredicted or better than predicted, then dopaminergic transmission occurs that could generate 
long lasting changes in neuronal circuits responsible for the perception of reward predicting patterns 
of the environment (Schultz, 2002). 
Dopamine releases as short as 100 ms can be measured by cyclic voltammetry in behaving animals. 
Thanks to this electrochemical technique dopamine changes in the nucleus accumbens could be 
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followed in animals self-administering cocaine. A moderate, transient increase could be detected 
upon the presentation of the drug associated stimulus whereas the infusion of cocaine was 
accompanied by stronger dopamine signal. Furthermore, drug seeking behavior could be triggered 
by electrically evoking dopamine release in animals trained for self-administration (Phillips et al., 
2003). These results taken together with those of Schultz and collaborators indicate that the activity 
of dopaminergic neurons – triggered by environmental cues – is likely to initiate reward/drug 
seeking behavior.  
4.2.4 Inputs from the VTA and the prefrontal cortex converge on striatal 
neurons –implications for drug addiction? 
4.2.4.1 Introduction to striatal signal integration  
Besides other inputs, the striatum (including the nucleus accumbens that is considered as a part of 
the ventral stiatum) receives dopaminergic innervation from the mesencephalon and glutamatergic 
innervation from the prefrontal cortex. In some cases, the two inputs converge on the same dendritic 
spine of a striatal cell, the cortical input targeting the tip of the spine and the mesencephalic input 
targeting rather the neck of the spine (Schultz, 2001). The dopaminergic input is speculated to 
influence synaptic plasticity at the corticostriatal synapses, leading to the reinforcement of those 
that were active at the time of encountering a reward predicting stimuli or a non-predicted reward 
(Schultz, 2001). Similarly, in the case of drug addiction, dopamine signaling may specifically 
reinforce corticostriatal or corticocortical synapses (1) involved in stereotypical behavior, (2) 
storing drug associated information (such as environment), (3) involved in psychic dependence. 
For this reason we will take a brief overview of the evidences that support the striatal integration of 
dopaminergic and glutamatergic signals. 
4.2.4.2 Anatomical background of striatal signal integration 
Electronmicroscopical studies have shown that some of the spines of striatal neurons receive both 
anterogradely labeled cortical and TH-immunorective mesencephalic input. In contrast, 
anterogradely labeled thalamic terminals and boutons showing TH-immunoreactivity were never 
seen to contact the same postsynaptic structure (Smith et al., 1994). On the spines of the striatal 
neurons the terminals of the two converging inputs show specific localization the dopaminergic 
boutons contacting mainly the neck of the spine and the glutamatergic ones mainly its head 
(Robinson et al., 2003). Due to the similar cytoarchitecture of the dorsal striatum and the nucleus 
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accumbens (ventral striatum) these observations can generally serve as an anatomical background 
for striatal signal integration. 
4.2.4.3 Electrophysiological evidences for the plasticity at corticostratal synapses requiring 
simultaneous dopamine and glutamate input to the striatum 
In the corticostriatal pathway both long term potentiation (LTP) and long term depression (LTD) 
have been described (Kerr et al., 2001). In brain slice cultures, LTP could be induced in Mg2+-free 
conditions by high frequency stimulation of cortical afferents (Walsh, 1991) and later was shown to 
be blocked by NMDA-receptor antagonists (Calabresi et al., 1992). In addition to glutamate sensed 
by the NMDA-receptors, dopamine acting on D1-type receptors was also necessary for this LTP 
since potentiation was abolished upon the application of D1 (but not D2) receptor antagonists (Kerr 
et al., 2001). LTP could be induced in the same pathway in the presence of  Mg2+ as well, provided 
that dopamine was applied in pulses timed to coincide with cortical stimulation (Wickens et al., 
1996). Simultaneous electrical stimulation of the cortical and mesencephalic afferents also produced 
LTP in the corticostriatal pathway in urethane-anaesthetized rats, and this phenomenon was not 
observed in dopamine-depleted animals (Reynolds et al., 2000). Finally, the role of dopaminergic 
input in regulating the strengh of corticostriatal synapses was established in a more physiological 
context: in urethane-anaesthetized animals, the activity of striatal neurons in response to cortical 
stimulation was potentiated following an ICSS-like stimulation of dopaminergic cells (Reynolds et 
al., 2001). The term “ICSS-like” refers to stimulations where the activity corticostriatal pathway 
was provided by spontaneous cortical input while dopaminergic cells were stimulated with 
electrodes optimally placed for intracranial self-stimulation behavior that had been extinguished 
(Reynolds et al., 2001).  
4.2.4.4 Role of accumbal glutamate release  in drug-related learning  
Several lines of evidence support the idea that plasticity at corticostriatal synapses underlies drug-
related learning and – as described in chapter 4.2.4.2 – this plasticity requires simultaneous 
dopamine and glutamate inputs to the striatum/nucleus accumbens. The importance of dopamine in 
this context is well-established (see chapters 4.2.3 and 4.2.6), however, some recent publications 
demonstrate that release of glutamate can also be required for drug-related learning as well. For 
instance, blocking of NMDA receptors by an antagonist  injected bilaterally into the nucleus 
accumbens decreased morphine-induced conditioned place preference in rats (Popik et al., 1999). 
Furthermore, in rats, reinstatement of self-administering behavior by a priming cocaine injection 
was shown to be accompanied by accumbal glutamate and dopamine release (McFarland et al., 
  
28
2003). Very interestingly, when naïve rats were given the same priming injection, only dopamine 
release was measurable in the nucleus accumbens (McFarland et al., 2003). These results are 
consistent with the hypothesis that glutamatergic transmission from the prefrontal cortex to the 
striatum vehicles already learnt, drug-associated information. This idea gains further consolidation 
when taking into account the finding that drug-associated cues (such as a light-tone stimulus) failed 
to reinstate cocaine self-administration if the prefrontal cortex was reversibly inactivated with 
tetrodotoxin (McLaughlin et al., 2003)   
4.2.4.5 Perspectives regarding striatal signal integration   
Taken together, these results strongly suggest a model in which an unpredicted or a formerly 
unknown reward (natural or pharmacological reward) triggers dopamine release, and dopamine, in 
turn, reinforces specifically the active corticocortical or corticostriatal synapses thereby enabling 
them to store new, reward-related information. Therefore, in the present thesis work we decided to 
shed light on the molecular mechanisms that enable striatal cells to detect the coincidence of 
glutamatergic and dopaminergic signals. 
4.2.5 Changes in accumbotegmental feedback could explain the reduced 
rewarding effects of chronically taken drugs 
4.2.5.1 Tolerance and adaptations at the molecular level 
All drugs of abuse induce molecular adaptations in the brain that decrease sensitivity to rewarding 
effects (tolerance) and interfere with the normal function of the brain reward circuit towards natural 
rewards. Most of these molecular adaptations are thought to occur in the medium spiny neurons of 
the striatum upon prolonged exposure to dopamine from mesencephalic sources. Drugs are likely to 
bypass mechanisms that rapidly dampen dopamine release upon repeatedly encountering the same 
reward predicting stimuli (see chapter 4.2.3) thereby facilitating abnormal molecular adaptations 
in spiny cells and abnormally strong learning at the corticostriatal synapses.  
4.2.5.2 Anatomical background of the accumbotegmental feedback 
The medium spiny neurons of the striatum can influence the strength of the dopaminergic input that 
they receive from the VTA. The anatomical basis for such a feedback consists of the GABAergic 
fibers of the medium spiny neurons sent back to the VTA, and of the collaterals of these fibers that 
can act directly on striatal terminals of the dopaminergic VTA cells. The retroprojecting spiny cells 
also synthesize neuropeptides, the expression of which can change following chronical drug intake 
  
29
leading to altered accumbotegmental feedback efficiency. The other important target structure of 
the medium spiny neurons is the ventral pallidum. 
Retrograde tracer studies have shown that 60% and 40% of the accumbopallidal neurons are 
immunopositive for preprodynorphin (PPD) and preproenkephalin (PPE), respectively (Zhou et al., 
2003) and 70% of them show immunoreactivity for preprotachykinin-A (PPTA), the precursor 
molecule of substance P. Neurons projecting from the nucleus accumbens to ventral mesencephalic 
regions are all immunopositive for PPD and PPTA but none of them shows immunoreactivity for 
PPE (Zhou et al., 2003).  
4.2.5.3 Dynorphin as a potential mediator of tolerance 
Dopamine from mesencephalic sources is supposed to induce molecular changes in the medium 
spiny neurons of the striatum. Acting on D1 receptors of these cells, it induces the phosphorylation 
of the transcription factor CREB, which, in its active form, drives the prodynorphin gene expression 
(Cole et al., 1995). 
Virus-mediated overexpression of CREB in the nucleus accumbens of rats was shown to decrease 
rewarding effects of cocaine and made low doses of drug aversive, while the dominant negative 
form of CREB had the opposite effect (Carlezon et al., 1998). Altered transcription of the dynorphin 
gene was suggested to account for these changes, since dynorphin expression was higher or lower 
by overexpression of CREB or dominant negative CREB, respectively (Carlezon et al., 1998). 
Moreover, blockade of κ-opioid receptors antagonize the negative effect of CREB overexpression 
on cocaine reward, further confirming the involvement of dynorphin (Carlezon et al., 1998). 
In transgenic mice, overexpression of a dominant-negative form of CREB that colocalizes with 
decreased dynorphin expression in medium spiny neurons, produces an antidepressant-like effect, 
whereas overexpression of CREB results in a phenotype that is reminiscent of depression and might 
recapitulate the anhedonic states observed in humans upon drug deprivation (Newton et al., 2002). 
Hence, emerging evidence suggest that chronic exposure to drugs of abuse upregulates the 
dynorphin-dependent negative feedback between the nucleus accumbens and the VTA, resulting in 
the occurance of anhedonic states and a general decrease of motivation (Nestler, 2004). 
4.2.5.4 Reduced substance P expression might contribute to tolerance 
In addition to the dynorphin-mediated negative feedback from the nucleus accumbens to the VTA, 
positive feedback could also exist in the same pathway. A candidate neuropeptide for mediating this 
effect is substance P produced by the medium spiny neurons of the nucleus accumbens. Substance 
P, acting on terminals or cell bodies of VTA neurons, can increase the concentration of extracellular 
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dopamine in the striatum and its behavioral actions are dependent on dopamine (Elliot et al., 1986; 
Stanius et al., 1978; Kelly et al., 1979; Kombian et al., 2003; Kraft et al., 2001). 
During this thesis work we formulated a hypothesis that dopamine induces substance P expression 
in spiny cells through the cAMP → CREB → C/EBPβ → PPTA (preprotachykinin-A) pathway. 
Acting in this setup, substance P could prolong the dopaminergic transmission in the mesolimbic 
pathway. 
One of the few molecules that have been shown to accumulate in the striatum following chronic 
drug intake is a highly stable member of the Fos family of transcription factors termed ΔFosB 
(Nestler et al., 2001). Moreover, ΔFosB was shown to impede C/EBPβ function (Chen et al., 2004, 
Kveiborg et al., 2004). Thus, according to our hypothesis, accumulating ΔFosB would inhibit 
striatal C/EBPβ and thereby diminish the synthesis of substance P. As a result, in the presence of 
growing amount of ΔFosB, less dopamine would be released upon the intake of a given amount of 
drug, in other words, higher and higher doses of drug would be needed for the same amount of 
dopamine to be released. It should be noted that negative feedback via dynorphin as described by 
Nestler and collaborators and positive feedback via substance P as we hypothesize might coexist in 
the mesolimbic dopaminergic pathway and changes of both might contribute to tolerance and drug-
dependence. 
 
4.2.6 Description of the most frequent types of drug addictions 
4.2.6.1 Introduction 
In this chapter we will briefly review the most frequent classes of substances of abuse. We will 
focus on the role of the mesocorticolimbic dopaminergic system in the molecular adaptations 
induced by chronic intoxication with these different drugs. 
4.2.6.2 Alcohol 
Alcoholism is a chronic disorder (Koob, 2003) that continues to be a major problem in most of the 
countries of the world. Alcohol withdrawal presents a severe withdrawal syndrome consisting of 
tremor, weakness, hyperreflexia and in some cases generalized grand mal seizures termed 
sometimes alcoholic epilepsy or “rum fits” (Lowinson et al., 1997). 
Like many other substances of abuse, ethanol is suggested to exert its reinforcing effects by 
interacting with the mesolimbic dopaminergic system (Gonzales et al., 2004). This idea is 
supported by the finding that in mice, genetic deletion of D1 receptors attenuates ethanol self-
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administering behavior (El-Ghundi et al., 1998). To explain the mechanism by which ethanol 
increases dopamine release in the striatum, GABAergic interneurons in the VTA were proposed as 
target cells the GABAA receptors of which would be activated by ethanol (Pierce et al., 2005). 
Consequently inhibition of dopaminergic cells by GABAergic interneurons in the VTA would be 
raised. Indeed, electrophysiological studies have shown that ethanol increases the firing rate of 
dopaminergic VTA neurons (Brodie et al., 1990). 
4.2.6.3 Nicotine 
The consumption of tobacco products such as cigarettes, cigars, pipes and smokeless tobacco 
continues to be a problem in virtually every country of the world. Cigarette smoke contains about 
4,000 active compounds, but nicotine is considered to play a crucial role in tobacco dependence 
(Kenny et al., 2001). One of the most important factors underlying the addictive properties of 
tobacco is the nicotine-mediated modulation of dopamine transmission in the mesolimbic reward 
circuit (Wise et al., 1989). The mechanism for nicotine-enhanced dopamine release in the striatum is 
established and involves the activation of presynaptic nicotinic acetylcholine receptors (nAChRs) 
situated on dopaminergic terminals (Wonnacott, 1997). Moreover, according to a recent report, 
chronic pre-treatment with nicotine augments nicotine-evoked dopamine release in the striatum 
(Visjani et al., 2005) – a finding that could give further insight into mechanisms of compulsive use 
of tobacco.  
4.2.6.4 Opiates 
Morphine is the main active alkaloid isolated from opium, a narcotic mixture prepared from the 
opium poppy. Heroin derives from morphine by a double acetylation of hydroxyl groups. Other 
synthetic molecules have been designed either to ameliorate to anti-nociceptive properties of 
morphine (fentanyl and derivates) or to fight efficiently against opiate addiction in substitutional 
therapy programs (methadone). 
Morphine and heroin can be smoked, sniffed or snorted, however, in the case of both substances the 
most intense euphoria is experienced upon intravenous injection. Opioids induce strong psychic and 
physical dependence, moreover, tolerance developing to these substances necessitates a continuous 
increase of the dosage in order to obtain the initial effect. Very severe withdrawal syndrome 
develops at cessation of drug intake, consisting of aching muscles and bones, perspiration, 
lacrimation, and other discomforting effects (Lowinson et al., 1997). 
The reinforcing effects of opiates, similarly to other drugs of abuse, are thought to be mediated by 
dopaminergic neurotransmission. Consistent with this idea, chemical lesions of VTA dopamine 
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neurons or dopamine releasing terminals in the nucleus accumbens prevents the acquisition and the 
maintenance of heroin or morphine self-administration (Spyraki et al., 1983; Smith et al., 1985). 
Further, systemic or iontophoretic administration of morphine excites dopaminergic cells in the 
VTA and substantia nigra (Gysling et al., 1983; Matthews et al., 1984). This effect is thought to 
involve μ opioid receptors since injection of μ agonists into the VTA triggers elevations in 
extracellular dopamine (Xi et al., 1998). 
Given the observation that μ opiate receptors in the VTA are mainly located on GABAergic 
interneurons (Dilts et al., 1989), the excitation of dopaminergic cells was supposed to be indirect 
and involve GABAergic interneurons. In line with this assumption, systemic administration of 
morphine inhibits GABA release in the midbrain (Renno et al., 1992), and morphine, when applied 
microiontophoretically into the VTA, decreases the firing rate of GABAergic interneurons and 
augments that of dopaminergic cells (Johnson et al., 1992).  
The causal relationship between the inhibition of GABA release in the VTA by heroin and the 
concomitant increase of striatal dopamine was finally established by directly administrating γ-vinyl-
GABA (GVG) – a compound that blocks the activity of a GABA degrading enzyme – into the 
VTA. In the absence of GABA degradation, intravenously injected heroin do not increase anymore 
accumbal dopamine release (Xi et al., 1998) and heroin self-administering behavior is attenuated 
(Xi et al., 2000) 
Taken together, these results gave rise to a model that explains opiate reinforcement by 
desinhibition, i.e. opiates, acting via μ receptors of VTA interneurons relieve the tonic GABA-
mediated inhibition of dopaminergic VTA cells (Xi et al., 2002). 
4.2.6.5 Cannabinoids 
Although it is illegal in the United States and in most European countries, cannabis became a 
commonplace used regularly by millions and occasionally used by millions more. After continued 
heavy use some physical dependence might develop, although it seems to vary considerably among 
individuals. The rarely reported mild symptoms of withdrawal are anxiety, insomnia, tremors and 
chills (Lowinson et al., 1997). The use of cannabis is widespread in the form of cigarettes made 
from the dried plant Cannabis sativa, or as hashish, the pressed resin of the same plant. 
Δ9-tetrahydrocannabinol (THC), the active compound of marijuana, has been shown to act on 
cannabinoid-specific receptors CB1 and CB2 (Matsuda et al., 1990, Herkenham et al., 1990) 
expressed in several regions of the brain (Breivogel et al., 1998). Furthermore THC has also been 
shown to excite dopaminergic neurons in the VTA and substantia nigra and to increase dopamine 
efflux in the nucleus accumbens and prefrontal cortex (French et al., 1997), an effect that likely 
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account for the reinforcing properties of cannabis. This influence on dopaminergic transmission 
must be indirect, since mesencephalic dopaminergic neurons do not express cannabinoid receptors. 
So far, two pathways have been proposed (Schlicker et al., 2001) to explain the THC-mediated 
increase of dopamine efflux: (1) in the VTA, GABAergic interneurons carrying CB1 receptors keep 
dopaminergic cells under tonic inhibition, and THC, acting on CB1 receptors, can diminish the 
release of GABA; (2) in the nucleus accumbens, glutamatergic terminals – carrying also CB1 
receptors – can excite medium spiny neurons that send GABAergic projections to the VTA. 
Additionally, through CB1 receptors, THC can inhibit glutamate release at accumbal terminals 
thereby relieving striatal inhibition on midbrain dopaminergic cells. 
4.2.6.6 Cocaine 
Cocaine, found in coca bush leaves, is the prototype of a stimulant drug that produces euphoric 
excitation. Cocaine can be ingested by inhalation (snorting), injection or smoking. Crack is a form 
of cocaine base, consumed by smoking and converted from the hydrochloride form (powder 
cocaine) by boiling in a solution of sodium bicarbonate. Because crack contains the non-ionized 
form of cocaine, it reaches the brain extremely rapidly and produces euphoria („high”) very 
efficiently. Tolerance and dependence do develop immediately to cocain use, particularly at higher 
doses (Lowinson et al., 1997). 
The mechanism explaining why cocaine exhibits rewarding properties is rather well-established. In 
physiological conditions, striatally liberated dopamine is cleared from the extracellular space by 
dopamine reuptake transporter (DAT) molecules that are situated on the membrane of 
dopaminergic axon terminals. Cocaine blocks DAT molecules thereby prolonging the effect of 
dopamine on postsynaptic receptors (Ritz et al., 1987). The prolonged availability of extracellular 
dopamine is measurable by in vivo microdialysis studies (Bradberry et al., 1993). For long, 
explanation was missing for the fact cocaine retained its rewarding effects in DAT knockout mice 
(Rocha et al., 1998). Recently it has been shown that mice with deletion of both the DAT and the 
SERT (a molecule similar to DAT, responsible for serotonine reuptake) did not exhibit preference 
for cocaine in a conditioned-place preference paradigm (Hall et al., 2004) leading authors to the 
conclusion that the DAT is not sufficient per se to explain reinforcing properties of cocaine. 
4.2.6.7 Amphetamines 
Amphetamine and its derivatives are used – often recreationally – to produce euphoria, decrease 
hunger and increase alertness, strength, endurance and improve coordination. The psychological 
effects are similar to those produced by cocaine, moderate physical dependence can also occur. For 
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neophytes, use of a daily, intermittent dose of amphetamines results in sensitization while 
prolonged amphetamine intake induces tolerance. Chronic users usually inject doses that would be 
fatal for first-time users (Lowinson et al., 1997). 
Similarly to cocaine, amphetamine interferes with the mesolimbic dopaminergic system at the level 
of DAT (dopamine reuptake transporter) molecules, however the mechanism of action is different. 
Paradoxically, inhibitors of dopamine reuptake – substances that normally increase extracellular 
dopamine in the striatum – prevent the amphetamine mediated increase of dopamine release. This 
observation lead to the concept that amphetamine induces reverse transport through the DAT 
molecules located on the terminals of dopaminergic neurons (Sulzer et al., 1993). Further 
confirmation of this model came from experiments with mice lacking DAT molecules. Striatal 
slices from these animals – unlike those from wild-type animals – do not liberate dopamine in 
response to amphetamine treatment (Jones et al., 1998). Furthermore, microdialysis measurements 
of dopamine from freely moving animals have shown that DAT knockout mice, in contrast to their 
wild-type littermates, fail to increase extracellular dopamine in response to intraperitoneally 
injected amphetamine (Jones et al., 1998). 
4.2.6.8 Hallucinogens 
Hallucinogens evoke a state of excitation of the central nervous system (CNS) and induce changes 
of perception and mood. There is no evidence supporting physical dependence to hallucinogens, 
psychic dependence may vary but usually is not intense. There is no withdrawal syndrome after 
cessation of the chronic administration (Lowinson, 1997). Hallucinogens include LSD (lysergic 
acid diethylamide), substances extracted from fungi such as psilocybin; furthermore some 
substituted amphetamines such as DOM, MMDA. One of the oldest hallucinogens is mescaline, 
extracted from the cactus peyot (Lophophora Williamsii), for long used by northern indian tribes. 
In accordance with the fact that the hallucinogens are usually consumed to attain altered perception 
rather than hedonic states, this family of drugs is thought to act mainly through interfering with 
serotonergic transmission (Aghajanian et al., 1999). However, the most commonly used 
hallucinogen, LSD, is reported to be an agonist of striatal dopamine receptors (Pieri et al., 1974) 
and can stimulate locomotor activity by acting on dopamine receptors provided that endogenous 
dopaminergic transmission is eliminated by chemical leasioning of dopaminergic cells (Kelly et al., 
1975). 
Ecstasy (MDMA) is a synthetic molecule with a chemical structure that resembles both the 
hallucinogen mescaline and the substituted amphetamines. Therefore ecstasy has both 
psychostimulant and  hallucinogen properties (Gold et al., 1989). 
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4.2.6.9 Phencyclidine 
Phencyclidine (PCP) cannot be easily classified and should be considered separately from 
hallucinogens. Most frequently it is sprinkled on smoking material (such as parsley, mint leaves, 
tobacco or marijuana), combusted and inhaled. Lower doses trigger a giddy euphoria often followed 
by anxiety or mood lability. Despite a paucity of controlled studies of tolerance and dependence in 
humans, PCP must be considered, based on primate studies, comparable to classical drugs of abuse 
in this respect (Lowinson et al., 1997). 
PCP is an NMDA receptor antagonist, the molecular mechanisms underlying its rewarding 
properties have not been completely elucidated. However, a number of evidences point to an 
interaction with the mesolimbic dopaminergic system. For instance, in mice, place preference 
induced by PCP can be attenuated by chemical lesioning of dopaminergic neurons or by an 
antagonist specific for D1 dopamine receptors (Noda et al., 1998). Furthermore, tyrosine 
hydroxylase (an enzyme required for dopamine synthesis) heterozygous mice do not show PCP-
induced place preference (Noda et al., 2004). 
5 Summary of results 
5.1 C/EBPβ couples dopamine signaling to substance P precursor 
gene expression in striatal neurons 
We used primary cultures of striatal neurons as a model system of gene expression changes that 
occur in the striatum and the nucleus accumbens upon exposure to dopamine of mesencephalic 
origin. By real-time RT PCR experiments we have shown that dopamine (50 μM) induces C/EBPβ 
at the messenger RNA level and this induction precedes that of the PPTA mRNA, a precursor for 
substance P and neurokinin A. To demonstrate that C/EBPβ is induced at the protein level as well, 
we transfected a 5×C/EBP-LUC reporter plasmid into the neurons and showed that luciferase 
production increased in the cells upon stimulation with dopamine. 
To establish a link between the increases of C/EBPβ and PPTA messenger RNA, we cloned the 
promoter of the PPTA gene into a luciferase and a GFP reporter vector. We demonstrated that the 
cotransfection of expression vectors for C/EBP isoforms increased transcription from the PPTA-
LUC construct. The PPTA-GFP construct allowed us to follow transcriptional activity at the PPTA 
promoter in individual neurons. The cotransfection of dominant negative proteins against CREB 
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and C/EBP decreased the dopamine induced GFP signals as compared to neurons transfected only 
with the PPTA-GFP construct, evidencing that dopamine induces the substance P precursor gene 
through the cAMP → PKA → CREB → C/EBPβ pathway. 
Finally we demonstrated a physical interaction between C/EBPβ and the PPTA promoter by 
DNAse I footprinting and electrophoretic mobility shift assays (EMSA). The only protected region 
of the promoter that we found corresponds to an imperfect C/EBP consensus site. 
5.2 CCAAT/Enhancer-binding protein family members recruit the 
coactivator CREB-binding protein and trigger its 
phosphorylation 
Given that our results suggest that C/EBPβ might carry an important role in drug addiction, we 
decided to investigate general mechanisms by which the C/EBP family activates transcription.  
Using a 5×C/EBP-LUC reporter plasmid, we showed that CBP serves as a coactivator for all three 
activating members of the C/EBP family (C/EBPα, -β, -δ). We used GST pull-down assays to 
demonstrate that bacterially expressed C/EBPβ and C/EBPδ directly interact with CBP without the 
need for additional adaptor proteins. 
While we were studying CBP-C/EBP interaction, we observed that the coexpression of the two 
molecules in HEK 293T cells resulted in a decreased electrophoretic mobility of CBP. In vitro 
dephosphorylation of CBP reestablished its normal electrophoretic mobility demonstrating that the 
covalent modification was a phosphorylation. By expressing different CBP fragments, we 
determined that the phosphorylated residues were situated in the C-terminal region between 
residues 1893 and 2441. 
Since the interaction between CBP and C/EBPδ had not been studied in detail, we mapped regions 
and residues in C/EBPδ that were necessary for CBP binding. We showed that the mutations of 
these regions and residues in C/EBPδ diminished the ability of CBP to coactivate C/EBPδ-
dependent transcription and decreased the phosphorylation of CBP elicited by C/EBPδ 
cotransfection. 
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5.3 TORCs act as neuronal coincidence detectors and play a key role 
in long-term hippocampal plasticity 
The integration of glutamatergic and dopaminergic signals in the nucleus accumbens is likely to be 
an important mechanism for drug addiction. We attempted to elucidate some molecular aspects of 
how the coincidence of these two signals can be detected. 
We showed by quantifying TORC1 and TORC2 messenger RNA that these newly described 
coactivators of CREB are present in the cortex, hippocampus and striatum of the adult mouse brain 
and in primary cultures of mouse cortical, hippocampal and striatal neurons. We demonstrated that 
endogenous TORC1 as well as transfected TORC1-myc and FLAG-TORC2 translocated from the 
cytoplasm into the nucleus upon stimulating the neurons simultaneously with forskolin and KCl, 
whereas only one of the stimuli was inefficient to trigger nuclear accumulation. 
To measure the transcriptional responses, we transfected a CRE-LUC reporter plasmid into mouse 
cortical neurons and showed that only the combination of depolarization and forskolin was 
efficient in increasing luciferase activity, and this effect was abolished by cyclosporin A, a 
compound that blocks TORC translocation. To assure that TORCs are involved in this 
transcriptional response, we forced the degradation of TORC1 and TORC2 messenger RNA by 
specific shRNA molecules and we used a specific dominant negative protein that blocks the 
binding of endogenous TORCs to CREB. 
We provided evidence that the transcription of an endogenous target gene, BDNF can be induced 
by forskolin and KCl in a TORC-dependent manner. 
To demonstrate the physiological importance of the transcriptional responses, we used 
neurotransmitters instead of forskolin and KCl to activate the PKA and Ca2+ pathway. The 
neurotransmitter combinations PACAP/NMDA and DA/glutamate elicited the same responses as 
forskolin and KCl, in hippocampal and striatal neurons, respectively. Therefore, we concluded that 
TORCs are putative mediators of DA/glutamate coincidence-detection, a process thought to be 
important for the establishement of drug-related associations. 
Finally, by transducing rat hippocampal slices with a recombinant dominant negative protein 
interfering with TORC function, we demonstrated that TORCs are required for the late phase of 
hippocampal long term potentiation (LTP), an electrophysiological phenomenon widely accepted 
as a model of how the hippocampus encodes new memories. Moreover, we showed that tetanic (3 × 
100Hz or 4 × 100 Hz) or chemical (forskolin combined with depolarization) stimulations that are 
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capable of triggering LTP, also induce the translocation of endogenous TORC into the nuclear or 
the perinuclear compartment of the CA1 and CA3 cells of the hippocampus. 
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Abstract 
Dopamine-induced changes in striatal gene expression are thought to play an important role in 
drug addiction and compulsive behavior. In this study we report that dopamine induces the 
expression of the transcription factor C/EBPβ in primary cultures of striatal neurons. We 
identify the preprotachykinin-A (PPT-A) gene coding for substance P and neurokinin-A as a 
potential target gene of C/EBPβ. We demonstrate that C/EBPβ physically interacts with an 
element of the PPT-A promoter, thereby facilitating substance P precursor gene transcription. 
The regulation of PPT-A gene by C/EBPβ could subserve many important physiological 
processes involving substance P, such as nociception, neurogenic inflammation, and 
addiction. Given that substance P is known to increase dopamine signaling in the striatum, 
and in turn, dopamine increases substance P expression in medium spiny neurons, our results 
implicate C/EBPβ in a positive feedback loop, the changes of which might contribute to the 
development of drug addiction.  
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Introduction 
In addition to its well established role in nociception in the peripheral nervous system, 
substance P (SP) has been shown to act as a neurotransmitter in the central nervous system. 
Recent reports provided hints that SP could be important for addiction and motivation: in the 
absence of its receptor (neurokinin receptor 1, NK-1), conditioned place preference in 
response to morphine (Murtra et al. 2000), as well as morphine self administration (Ripley et 
al. 2002), are strongly diminished. Furthermore, infusion of a SP analogue into the ventral 
tegmental area induces reinstatement of cocaine-seeking behavior in rats that underwent a 
self-administration training followed by an extinction procedure (Placenza et al. 2004). 
In the vertebrate brain, SP is mainly localized in neurons in the habenula and in striatal 
structures (Medina and Reiner 1995), among which the nucleus accumbens is thought to be at 
the heart of addictive processes. Neurochemical studies provided evidence that SP increases 
the levels of extracellular dopamine (Elliott et al. 1986); moreover, its behavioral and 
chemical actions are dependent on dopamine, since these effects can be blocked by chemical 
lesioning of dopamine releasing nerve terminals (Stinus et al. 1978), as well as by applying 
dopamine receptor antagonists (Kelley et al. 1979). Kombian and coworkers proposed 
recently that SP released by medium spiny neurons acts locally in the striatum on the nerve 
terminals of dopaminergic VTA neurons (Kombian et al. 2003). However, striatal neurons 
projecting to the ventral tegmental area or the substantia nigra can release SP also onto the 
cell bodies of mesencephalic dopaminergic neurons (Kraft et al. 2001). Consistent with this 
idea, it has been shown that following an acute cocaine injection, the amount of SP and its 
mRNA increases in striatal structures, while the peptide is depleted from the substantia nigra 
probably due to a release from the terminals of striatal projection neurons (Kraft et al. 2001). 
Taken together these findings indicate the existence of a positive feedback loop involving the 
striatum and the mesencephalon: in the striatum, dopamine can induce the expression of 
preprotachykinin-A (PPT-A) mRNA coding for SP as has been shown in slice cultures 
(Campbell and Walker 2001); in addition, SP originating from the striatum can stimulate 
midbrain neurons to produce DA, as evidenced by the fact that the administration of a SP 
receptor antagonist can decrease the activity of ventral tegmental area and substantia nigra 
neurons (Minabe et al. 1996). Evidently, modulation of such a positive feedback loop can play 
a very important role in addiction, since dopamine release has been associated with reward 
and reward prediction (Schultz 1998). 
In this study, we attempted to elucidate the transcription factors through which dopamine can 
induce SP expression in primary cultures of striatal neurons. The mechanism of this induction 
is likely to be of great physiological importance since the elevation of SP levels is well 
documented in in vivo systems following administration of ibogaine (Alburges et al. 2000), 
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methylphenidate (Brandon and Steiner 2003; Yano and Steiner 2005), cocaine (Alburges et al. 
2000), ecstasy (Adams et al. 2005), and other drugs of abuse. We provide evidence that 
dopamine treatment of cells results in the up-regulation of the transcription factor C/EBPβ, 
which in turn drives the expression of SP. The C/EBP family (C/EBPα, -β, -δ, -γ, -ε, and -ζ) 
is composed of basic leucine zipper transcription factors that bind to a common cis-regulatory 
DNA element (Ramji and Foka 2002; Schrem et al. 2004). C/EBPs are expressed in many 
tissues, including the developing and adult brain (Sterneck and Johnson 1998; Sterneck et al. 
1998; Nadeau et al. 2005). Furthermore, it has been shown that C/EBPβ and/or C/EBPδ are 
involved in important brain functions, such as neuronal differentiation (Cortes-Canteli et al. 
2002; Menard et al. 2002), glial or neuronal gene regulation (Cardinaux and Magistretti 1996; 
Yukawa et al. 1998; Cardinaux et al. 2000), and synaptic plasticity associated with learning 
and memory processes (Sterneck et al. 1998; Taubenfeld et al. 2001; Chen et al. 2003). 
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Materials and Methods 
Cell Culture and transfection 
Primary cultures of striatal neurons were prepared from 17 day old (E17) Swiss mice embryos 
as previously described (Cardinaux et al. 1997), and plated in Neurobasal medium 
supplemented with B27 (Invitrogen), 30 μM glutamate and 500 μM glutamine. Cells were 
maintained at 37°C in a humidified atmosphere of 95% air/5% CO2 and were transfected after 
7 to 13 days in vitro (DIV). For each well of a 24-well plate, a total of 0.75 μg of plasmid 
DNA was mixed with 2.5 µl of Nupherin-neuron (Biomol) and 125 µl of Neurobasal 
(Invitrogen). After an incubation of 15 min at RT, 1.5 µl TransFectin (BioRad) diluted in 125 
µl Neurobasal was added to the DNA mixture, and incubated 40 min at RT. The conditioned 
neuronal medium was taken off and retained while the cells were overlaid with the 
transfection solution. The plates were centrifuged at 100 × g for 3 min and incubated for 30 
min at 37°C in the cell culture incubator. Finally, the transfection solution was replaced with 
the retained conditioned media, and the neurons were incubated overnight at 37°C. 
Real-time quantitative RT-PCR 
Striatal neurons dissected from E17 mouse embryos were cultured in 35 mm dishes. On 11 
DIV, cells were stimulated with 50 μM dopamine for 15’, 30’, 1h, 2h, 4h, 8h and 24h, then 
washed twice with PBS and lysed. Non-stimulated cells were harvested at 24h. Total RNA 
was then extracted using the RNeasy Mini Kit (Qiagen) according to manufacturer’s 
instructions. RNA was quantified with the RiboGreen reagent (Molecular Probes) and cDNA 
was prepared in a 50 μl reaction by reverse transcription of 200 ng total RNA using TaqMan 
reverse transcription reagents (Applied Biosystems). Controls were performed without reverse 
transcriptase. 2 μl of these reactions along with controls were amplified on 96 well plates 
using either the TaqMan Universal PCR Master Mix for C/EBPβ and –δ, or the 
SYBR®Green PCR kit for PENK and PPTA, and an ABIPRISM 7000 or 7500 Real Time 
PCR System (Applied Biosystems). The following oligonucleotide primers were used: 
C/EBPβ forward: 5’-TCGGGACTTGATGCAATCC-3’ 
C/EBPβ reverse: 5’-AACCCCGCAGGAACATCTTT-3’ 
C/EBPβ TaqMan probe: 5’ FAM-CGTGTAACTGTCTAGCCGGGCCCTG-TAM 3’ 
C/EBPδ forward: 5’-CCGCCTTTGCTATGTCTGAAG-3’ 
C/EBPδ reverse: 5’-CAAGCCTGGAGCGAAATGA-3’ 
C/EBPδ TaqMan probe: 5’ FAM-CCCGACACGCGCAAAGCAGG-TAM 3’ 
proenkephalin (PENK) forward: 5’-TGGTACACGCTCTTCCAGTAACC-3’ 
proenkephalin (PENK) reverse: 5’-AAGGCACGGGCGACTTG-3’ 
preprotachykinin (PPT-A) forward 5’-AAGAGCGCCCAGCAAGTG-3’ 
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preprotachykinin (PPT-A) reverse 5’-CACGAGGATTTTCATGTTCGATT-3’ 
β-actin forward: 5’-GCTTCTTTGCAGCTCCTTCGT-3’ 
β-actin reverse: 5’- ATATCGTCATCCATGGCGAAC -3’ 
β-actin TaqMan probe: 5’ FAM- CCGGTCCACACCCGCCACC -TAM 3’ 
Plasmids 
pGL3-5×C/EBP was previously described (Kovacs et al. 2003). pUB6-HA-C/EBPβ and 
pUB6-HA-C/EBPδ were constructed by subcloning the HA-C/EBP inserts of pcDNA3-HA-
C/EBPβ and pcDNA3-HA-C/EBPδ (Kovacs et al. 2003) into pUB6-V5-His A (Invitrogen). 
pUB6-LacZ (Invitrogen) was used to normalize for transfection efficiency when indicated.  
To construct PPTA-LUC, the (-1000) to (-30) fragment of the PPTA promoter was PCR-
amplified from mouse genomic DNA using the following primers:  
5’-GGGGTACCTTGGTGACAAAGGTAAACATACAGACT-3’ and  
5’-CCGCTCGAGCGGTATTTATCTCAGGCGTGACGAG-3’, and cloned into the XhoI and 
KpnI sites of pGL3 basic vector (Promega). To generate PPTA-GFP, the promoter was taken 
from PPTA-LUC and cloned into a pGL3 based reporter plasmid, in which luciferase was 
replaced by GFP (a kind gift of Dr. I. Monge, Center for Psychiatric Neuroscience, University 
of Lausanne). pRc/CMV-FLAG-A-C/EBP and pRc/CMV-FLAG-A-CREB were kindly 
provided by Dr. C. Vinson (Johns Hopskins University, Baltimore), and are described in (Ahn 
et al. 1998). To generate the bacterial expression vector pET28a-C/EBPβ, a PCR-amplified 
fragment encoding amino acids 22-296 of mouse C/EBPβ was inserted into the NdeI/BamHI 
sites of pET28a (Novagen). All constructs were verified by sequencing. 
Reporter assays 
After cell stimulation, reporter assays were performed at the time indicated in the Figure 
legends. Transfected cells were washed with PBS, lysed in 100 µl 1× Cell Culture Lysis 
Buffer (Promega), and centrifuged in a microcentrifuge for 5 min at 4˚C. To test the samples 
for luciferase activity, 20 µl extract was assayed in a Turner-Designs TD-20/20 luminometer 
using 100 µl of Luciferase Assay Reagent (Promega). Luciferase activity was either 
normalized for total cellular protein (Bio-Rad protein assay), or for β-galactosidase activity 
with the Galacto-Light chemiluminescent assay (Applied Biosystems). All experiments were 
performed in triplicate. 
Transactivation of the PPT-A promoter in individual neurons 
On 13 DIV two rounds of transfection were performed using the nupherin method to obtain 
two population of GFP positive cells, one with, the other one without the dominant-negative 
inhibitor of C/EBP. First, conditioned neuronal medium was taken off and retained while each 
12-mm coverslip (in a 24-well plate) was overlaid with the transfection solution containing 
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0.25 μg PPTA-GFP and 0.5 μg pcDNA3. After 30 minutes the first transfection medium was 
replaced by the second, containing 0.25 μg PPTA-GFP and 0.5 μg pRc/CMV-FLAG-A-
C/EBP. Neurons were incubated further for 30 minutes then the second transfection solution 
was discarded and cells were overlaid with the retained conditioned medium. 14 hours 
following transfection, neurons were stimulated with 50 μM dopamine for 8 hours then 
washed twice in PBS, fixed with 4% paraformaldehyde and proceeded to 
immunocytochemistry to detect the FLAG-tagged dominant-negative proteins.  
All washing steps were performed using 0,1% TX-100 and 0,2% BSA in PBS. Cells were 
permeabilized and epitops blocked using 0,5% TX-100 and 2% normal goat serum, 
respectively. Mouse anti-FLAG M2 (1:600, Sigma) was used as primary, and anti-mouse-
CY3 (1:600, Jackson) as secondary antibody. Coverslips were mounted with a DAPI 
containing mounting medium (Vector) and analyzed with a Zeiss Axioskop 2 mot plus 
microscope. 
Expression and purification of recombinant C/EBPβ 
Escherichia coli (BL21-Codon Plus®, Stratagene) transformed with pET28a-C/EBPβ were 
grown at 37°C to an OD600 of 0.7. Isopropyl-β-D-thiogalactopyranoside was added to a final 
concentration of 0.8 mM, and the culture was further incubated at 37°C for 3 hours. Bacteria 
were harvested by centrifugation, washed with PBS, and resuspended in lysis buffer 
containing 50 mM NaH2PO4/Na2HPO4 pH 7.6, 300 mM NaCl, 5% glycerol, 0.1% Triton X-
100, 2 mM β-mercaptoethanol, 50 mM imidazole. Subsequently, the cells were sonicated, and 
recombinant C/EBPβ was purified from the supernatant over a Ni-NTA agarose column 
(Qiagen). 
DNase I footprinting analysis of the PPT-A promoter 
Footprinting was based on a short technical report that adapted the method to an automated 
capillary sequencer (Yindeeyoungyeon and Schell 2000). FAM-labeled fragments of the PPT-
A promoter were produced by a standard PCR using a FAM-labeled oligonucleotide 
(Microsynth, Balgach, Switzerland) at the 3’end and the PPTA-LUC plasmid as a template, 
purified on agarose gels and extracted from the gel using standard methods (Promega). For 
each condition, 80 ng of DNA fragment was protected for 30 minutes at 30ºC by varying 
concentrations (as indicated in Figure 7.) of recombinant C/EBPβ in 10 mM TrisHCl pH 7.5, 
5 mM KCl, 1 mM EDTA, 2 mM DTT, 8% glycerol. BSA was added to a final protein 
concentration (including C/EBPβ) of 0.4 mg/ml. Protected DNA fragments were digested 
with 2×10–6 units of DNase I for exactly 5 minutes at 26ºC, digestions were stopped by 
adding EDTA (pH 8.0) to a final concentration of 250 mM and cooling the samples rapidly 
down to 4 ºC. Phenol/chloroform extraction was performed, and DNA fragments were further 
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purified on MicroSpin G-50 gel filtration columns (Amersham Biosciences) and then sent to 
Microsynth where ROX-labeled size standards were added and fragments were analyzed on a 
MegaBACE capillary electrophoresis device. 
Electrophoretic mobility shift assays (EMSA) 
A consensus C/EBP-binding site (5’-ACAGATTGCGCAATCTAG-3’) was prepared by 
hybridizing 2 complementary 5’-biotinylated oligonucleotides. Recombinant C/EBPβ (32 
nM) was preincubated at 25°C with 0.5 μg poly(dI-dC) in a final volume of 25 μl binding 
buffer containing 23.8 mM Tris-HCl (pH 8.0), 40 mM KCl, 14 mM NaCl, 8.6% glycerol, 0.8 
mg/ml BSA, 0.04% Nonidet P-40, 0.6 mM EDTA, 2.12 mM DTT. After 10 min, the 
biotinylated probe was added at a final concentration of 200 mM, and the incubation was 
pursued for 30 min at 25°C. For competition experiments, 10- to 100-fold molar excesses of 
unlabeled competitor oligonucleotides were included at the preincubation step. The DNA 
sequences of these competitor oligonucleotides were (only one strand is indicated): PPT-A 
wt: 5’-TCGACTTCCCTAAAATTGCGTCATTTCGAACACAA-3’;  
PPT-A mut: 5’- TCGACTTCCCTAAAGGGTACCCATTTCGAACACAA-3’. At the end of 
the incubation, the samples were subjected to electrophoresis for 90 min at 20 mA in a 6% 
native polyacrylamide gel in 0.5× TBE, 5% glycerol, 0.01% Nonidet P-40. The DNA probe 
was transferred from the gel to a nylon membrane (Hybond N+, Amersham) in a semidry 
blotting system (Bio-Rad) for 30 min at 0.1 A in 0.5× TBE, and UV-crosslinked for 2 min. 
The detection of the biotinylated probe was then performed with the BM Chemiluminescence 
Blotting Kit (Biotin/Streptavidin, Roche) essentially following the manufacturer’s protocol. 
The membrane was blocked overnight at 4°C in 10 mM Tris-HCl, 150 mM NaCl, pH 7.4, and 
0.05% Tween 20 (TBST) containing 1% of blocking reagent, and was subsequently incubated 
for 30 min with Streptavidin-peroxidase diluted 1:30’000 in blocking buffer. After 4 washes 
with TBST, the labeled probe was detected by chemiluminescence. 
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Results 
Dopamine induces C/EBPβ in primary striatal neurons 
C/EBPδ was cloned by its ability to bind to the bovine PPT-A promoter (Kageyama et al. 
1991). However, mechanisms of PPT-A gene regulation are still unclear, and the C/EBPs 
have not been formally involved in this process. As cAMP increases both the expression of 
SP in sensory neurons (Adler and Walker 2000), and the expression of C/EBPβ and C/EBPδ 
in hippocampal neurons (Yukawa et al. 1998), we hypothesized that in striatal neurons, 
members of the C/EBP family could mediate the increase in SP levels in response to 
dopamine. 
 
Figure 1. Dopamine up-regulates C/EBPβ mRNA in primary cultures of striatal 
neurons. 
Neurons were stimulated (or not, in the case of control) with 50 μM dopamine then lysed at 
the indicated time point. C/EBPβ, C/EBPδ and β-actin mRNAs were quantified using the 
real-time RT PCR method. C/EBPβ (open bars) and C/EBPδ (filled bars) levels are 
normalized to β-actin and represented in fold increase relative to control. 
 
We first tested by real-time RT-PCR whether or not dopamine could induce C/EBPβ or 
C/EBPδ mRNA in primary striatal neurons. We found that 2 hours after dopamine treatment, 
C/EBPβ mRNA levels increased approximately threefold whereas C/EBPδ mRNA levels did 
not change (Fig. 1). Next, we intended to show that the increase of C/EBPβ mRNA levels 
resulted in an increase of functional C/EBPβ proteins. Since all the antibodies against 
C/EBPβ that we tested were not sensitive enough to detect it by Western blot (data not 
shown), we transfected striatal neurons with a luciferase reporter plasmid carrying 5 tandem 
C/EBP binding sites. Dopamine-stimulated neurons produced approximately twice as much 
49
  10 
luciferase as non-stimulated cells evidencing the increased amount of functional C/EBPβ 
protein in response to dopamine (Fig. 2). 
 
Figure 2. Dopamine increases C/EBPβ-mediated transcription through D1 receptors. 
Striatal neurons were transfected with a C/EBP-sensitive reporter plasmid (pGL3-5×C/EBP), 
stimulated 5 hours after transfection with 50 μM dopamine (DA), 50 μM of the dopamine D1 
receptor agonist SKF38393 (SKF), or 10 μM of the D2 receptor agonist quinpirole (Quinp) 
for 14 hours and assayed for luciferase activity. The dopamine D1 receptor antagonist 
SCH23390 (SCH) or the D2 receptor antagonist sulpiride (sulp), both at 10 μM, were added 
30 minutes before DA stimulation. Values are normalized for protein levels. Results are 
displayed as the mean ± S.E.M. (n=3) relative luciferase activity. *, P<0.05, ***, P<0.001, 
(Student’s t-test). 
 
The c/ebpβ gene can be regulated by the transcription factor CREB that needs to be 
phosphorylated by PKA to become active (Niehof et al. 1997). Moreover, in striatal cells, D1 
receptors signaling occurs through the cAMP pathway, increasing PKA activity, whereas D2 
receptor signaling has the opposite effect. Consistent with the involvement of D1 receptors in 
dopamine-mediated C/EBPβ increase, we found that the D1 receptor antagonist SCH23390 
significantly reduced the effect of dopamine on luciferase activity, whereas the D2 receptor 
antagonist sulpiride did not. These results were further corroborated by the finding that the D1 
receptor agonist SKF38393 was as effective as dopamine to activate C/EBP-mediated 
transcription, whereas the D2 receptor agonist quinpirole did not significantly change the 
control levels of luciferase activity. 
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Figure 3. Dopamine-mediated preprotachykinin-A increase follows C/EBPβ induction, 
and depends on new protein synthesis. 
(A) Striatal neurons were stimulated (or not in the case of control) with 50 μM dopamine then 
washed and lysed at the indicated time point after stimulation. Preprotachykinin-A (PPT-A), 
proenkephalin (PENK), and β-actin mRNA levels were measured by real-time RT-PCR. PPT-
A (open bars) and PENK (filled bars) levels are normalized to β-actin and represented in fold 
increase relative to control. (B) Striatal neurons were incubated for 30 minutes in the absence 
(Veh.) or not in the presence of 10 μg/ml of the protein synthesis inhibitor cycloheximide 
(CHX) before stimulation with 50 μM dopamine. After 2 or 4 hours, total RNA was extracted, 
and PPT-A and β-actin mRNA levels were measured by real-time RT-PCR. PPT-A levels are 
normalized to β-actin and represented in fold increase relative to the control without 
cycloheximide. 
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The induction of preprotachykinin-A by dopamine follows the induction of C/EBPβ, and 
requires new protein synthesis. 
To gain insight into the kinetics of PPT-A mRNA induction by dopamine in primary cultures 
of striatal neurons, we performed real-time RT-PCR experiments. Striatal medium spiny 
neurons are reported to segregate into a striatopallidal and a striatonigral/striatotegmental 
population (Lu et al. 1998), the first projecting to the pallidum and expressing proenkephalin 
(PENK) and D2 mRNA, the second projecting mainly to the midbrain and expressing 
prodynorphin (PDYN), PPT-A, and D1 mRNA. D2 receptor agonists were reported to 
decrease pENK message in the striatopallidal neurons (Chen et al. 1993), while D1 receptor 
agonists were reported to increase PDYN and PPT-A message in striatonigral/striatotegmental 
neurons (Wang and McGinty 1997). Although we did not test whether such a segregation 
exists in our striatal cultures, we could reproduce a slight decrease and a strong increase in 
PENK and PPT-A mRNA levels, respectively, following dopamine treatment (Fig. 3A). PPT-
A expression peaked at 4h after the application of dopamine, consistent with the idea that 
C/EBPβ, that peaks at 2h, could participate in the regulation of PPT-A mRNA. Furthermore, 
the induction of PPT-A by dopamine was strongly reduced by cycloheximide (Fig. 3B), 
demonstrating that new protein synthesis is required for the induction of this gene. Altogether 
these data suggest that dopamine first activates the c/ebpβ gene, this transcription factor then 
participates in the regulation of the PPT-A gene. 
 
Figure 4. C/EBPβ and -δ transactivate the preprotachykinin-A promoter. 
Striatal neurons were transfected with a PPTA-LUC reporter construct along with an 
expression vector (pUB6) for C/EBPβ, C/EBPδ or an empty expression vector (Control). 
Cells were lysed 18 hours after transfection and assayed for luciferase activity. Values are 
normalized for β-galactosidase activity expressed from equal amounts of pUB6-LacZ 
transfected in each conditions. Results are displayed as the mean ± S.E.M. (n=3) relative 
luciferase activity.  
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C/EBP family members can enhance transcription driven by the preprotachykinin-A 
promoter 
To directly test the hypothesis that C/EBPβ regulates positively the expression of SP, we 
cloned the PPT-A promoter into a luciferase producing reporter vector that we cotransfected 
with an expression vector for C/EBPβ or for C/EBPδ into primary striatal cultures. These two 
isoforms of C/EBP indeed could activate the PPT-A promoter since in the presence of either 
C/EBPβ or C/EBPδ, we measured more than a 5-fold increase in luciferase activity (Fig. 4). 
Given that the transfected amounts of C/EBPβ are likely to be much higher than those of the 
endogenous protein induced by dopamine, we addressed the question of whether the 
transfected PPTA-LUC construct could respond to dopamine treatment. We found that 
dopamine significantly increased luciferase production of the transfected neurons (Fig. 5). 
Furthermore, the activity of the PPTA-LUC reporter activated by dopamine was strongly 
inhibited by A-C/EBP, a specific dominant-negative protein that blocks the activity of C/EBP 
family members (Krylov et al. 1995). Another dominant-negative protein, A-CREB (Ahn et 
al. 1998), had the same effect, in accordance with the idea that dopamine induces C/EBPβ 
through the cAMP → PKA → CREB pathway. 
 
Figure 5. DA activates the preprotachykinin-A promoter in a CREB- and C/EBP-
dependent manner. 
Striatal neurons were transfected with a PPTA-LUC reporter construct along with an 
expression vector for a dominant-negative protein blocking CREB activity (A-CREB), C/EBP 
activity (A-C/EBP) or with an empty vector (conditions Control and DA). 14 hours after 
transfection, cells were stimulated (or not) with 50 μM dopamine (DA) for 8 hours and 
assayed for luciferase activity. Values are normalized for protein levels. Results are displayed 
as the mean ± S.E.M. (n=3) relative luciferase activity. *, P<0.05, ***, P<0.001, (Student’s t-
test). 
53
  14 
To gain ultimate proof that C/EBPβ participates in the regulation of the PPT-A promoter, we 
generated a PPTA-GFP construct that enabled us to visualize PPTA promoter activity by 
measuring fluorescence levels in single cells. We verified that dopamine could enhance GFP 
expression in cells transfected with PPTA-GFP (data not shown). Then we did two rounds of 
transfection of striatal neurons, in the first round we transfected only the reporter PPTA-GFP, 
in the second, we cotransfected the FLAG-A-C/EBP plasmid with PPTA-GFP, thereby 
ensuring that GFP positive cells with and without the dominant-negative protein were equally 
present on the same coverslip. After stimulating the cells with dopamine, we found that 
neurons harboring the dominant-negative A-C/EBP expressed less GFP, confirming that 
C/EBPβ is involved in the regulation of the PPT-A promoter (Fig. 6). 
 
Figure 6. A dominant-negative form of C/EBP (A-C/EBP) inhibits DA-stimulated 
transcription driven by the PPT-A promoter in striatal neurons. 
Striatal neurons were transfected following a protocol (see Materials and Methods) that had 
been optimized to yield two populations of transfected cells, one with FLAG-A-C/EBP and 
PPTA-GFP, the other with PPTA-GFP only. Afterwards, neurons were stimulated with 50 
μM dopamine, fixed, and the dominant-negative protein was detected by 
immunocytochemistry using a mouse anti-FLAG primary and an anti-mouse-CY3 secondary 
antibody. In the presence of A-C/EBP, GFP expression driven by the PPTA promoter is 
strongly reduced. 
 
C/EBPβ binds physically to an activator element of the preprotachykinin-A promoter  
Having shown that C/EBPβ regulates positively the PPT-A gene, we attempted to identify 
C/EBP binding sites by doing footprinting analysis on the (-500) – (-30) fragment of the 
promoter using fluorescently labeled DNA fragments as described by Yindeeyoungyeon and 
Schell (2000). We found that recombinant C/EBPβ could protect a labeled DNA fragment 
produced by PCR at an imperfect C/EBP consensus sequence (Fig. 7) that had already been 
described as an activator element (also known as CRE) of the PPT-A promoter (Morrison et 
al. 1994). Interestingly, based on literature data, this activator element could be strongly 
induced by forskolin, but the majority of the complexes that it bound in HeLa cells did not 
contain Fos, CREB or ATF (Morrison et al. 1994). 
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Figure 7. DNase I Footprinting analysis of the PPT-A promoter using recombinant 
C/EBPβ. 
Fluorescently (FAM)-labeled DNA promoter fragments covering the (-500) to (-30) region 
were produced by PCR using the PPTA-LUC plasmid as template, incubated with varying 
amounts (indicated on the left) of recombinant C/EBPβ, then submitted to DNase I digestion. 
Fragments were analysed using a MegaBace capillary electrophoresis device. The sequence of 
the only protected region that we found is indicated, the imperfect C/EBP consensus is 
highlighted in bold. 
 
Next we turned to electrophoretic mobility shift assays (EMSA) to test the physical 
interaction between C/EBPβ and its putative binding site in the PPT-A promoter. 
Recombinant C/EBPβ bound and shifted a biotinylated oligonucleotide harboring a C/EBP 
consensus (Fig. 7, 1st lane). Binding could be prevented by a 100- or a 10-fold molar excess of 
a DNA fragment encompassing the activator element of the PPT-A promoter that sequestered 
efficiently C/EBPβ (Fig. 8, 2nd and 3rd lane), while the same amounts of a similar 
oligonucleotide with mutated C/EBP binding site could not compete with the biotinylated 
sequence (Fig. 8, 4th and 5th lane) showing the specificity of the interaction between C/EBPβ 
and the activator element. 
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Figure 8. An activator element of the PPT-A promoter interacts in vitro with C/EBPβ. 
A biotinylated oligonucleotide harboring a perfect C/EBP consensus sequence was incubated 
with recombinant C/EBPβ in the presence (2nd- 5th lanes) or in the absence (1st lane) of 
oligonucleotides corresponding to the activator element of the PPT-A promoter. rC/EBPβ 
shifted efficiently the biotinylated consensus (1st lane). Addition of the activator element of 
the PPT-A promoter (PPTA wt) in a 10-fold (10×) or 100-fold (100×) excess abolished the 
shift, whereas a similar oligonucleotide with mutations in the putative C/EBP binding site 
(PPTA mut) in 10-fold (10×) or 100-fold (100×) excess had no such effect.  
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Discussion 
Several transcription factors have been shown to be induced by dopamine or dopamine 
receptor agonists in striatal cultures, including c-fos (Das et al. 1997) and Fra-like proteins 
(Liu et al. 1995). Moreover, both a D1 and a D2 receptor agonist have been reported to drive 
the phosphorylation of CREB (Brami-Cherrier et al. 2002). To our knowledge, we are the first 
to show that the expression of the transcription factor C/EBPβ is induced in striatal neurons 
following dopamine treatment. 
Dopamine is thought to regulate associative learning in the striatum and parkinsonian patients 
have specific defects in “habit” learning (Knowlton et al. 1996). Unraveling a mechanism by 
which dopamine could induce synaptic plasticity in the striatum would be of particular 
interest since virtually all drugs of abuse activate dopaminergic systems (Nestler 2001) and 
long lasting synaptic changes are likely to underlie addiction (Berke and Hyman 2000). Our 
results raise the possibility that some of the genes involved in dopamine-dependent striatal 
synaptic plasticity are regulated by the transcription factor C/EBPβ. 
In developing and mature spinal sensory neurons, cAMP was shown to increase the 
expression of SP (Adler and Walker 2000). However, (Morrison et al. 1994) failed to 
demonstrate by electrophoretic mobility shift assays direct interaction between CREB and the 
CRE of the PPT-A gene. Therefore, our data suggest that CREB could regulate the PPT-A 
promoter in an indirect manner via its ability to enhance C/EBPβ expression (Niehof et al. 
1997). 
An important new idea suggested by the present study is that C/EBPβ could regulate SP 
expression in medium spiny neurons by binding to the PPT-A promoter. Several studies have 
demonstrated that acute (Adams et al. 2001) or chronic (Mathieu-Kia and Besson 1998) 
administration of drugs of abuse results in increased PPT-A mRNA levels. Our results 
indicate that C/EBPβ constitutes the so far missing link between dopamine signaling and 
PPT-A mRNA expression. Given that SP (Elliott et al. 1986) and its N-terminal heptapeptide 
fragment (Hall and Stewart 1992) facilitates dopamine release in the striatum, it is reasonable 
to assume a positive feedback loop involving SP synthesis and dopamine release. 
One of the few transcription factors that have been shown to accumulate in the striatum after 
repeated administration of drugs of abuse is a highly stable member of the Fos family, termed 
FosB (Nestler et al. 2001; McClung et al. 2004). Δ ΔFosB is induced in SP-dynorphin-
containing neurons of the striatum by chronic cocaine treatment (Nye et al. 1995; Moratalla et 
al. 1996). In mice, inducible overexpression of ΔFosB in this neuronal population facilitates 
the acquisition of cocaine self-administration at a low-threshold dose of cocaine (Kelz et al. 
1999; Colby et al. 2003). Interestingly, ΔFosB has been shown to downregulate the 
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expression of C/EBPβ (Chen et al. 2004), and also to inhibit C/EBPβ-dependent transcription 
by directly interacting with C/EBPβ (Kveiborg et al. 2004). 
These data, taken together with our results demonstrating that C/EBPβ regulates the PPT-A 
promoter, lead us to hypothesize that SP-mediated increase of dopamine release plays an 
important role in physiological conditions and that ΔFosB might exert some of its effects on 
drug self-administration partly via C/EBPβ. Gradually accumulating ΔFosB would diminish 
the synthesis of SP and thereby attenuate the positive feedback effect on dopaminergic 
neurons. In these conditions, a higher dose of drug would be needed for the same amount of 
dopamine to be released. This hypothesis is in accordance with a recent report showing that 
activity levels of dopamine neurons code for reward value (Tobler et al. 2005) and also with 
the finding that during naloxone precipitated morphine withdrawal, the N-terminal 
heptapeptide fragment of SP (SP1-7) can alleviate withdrawal signs (Zhou et al. 2003) by 
normalizing dopamine release in the striatum (Zhou and Nyberg 2002). Therefore, the 
possibility that FosB attenuates C/EBPβ-mediated transcription of the PPT-A gene could be 
one of the numerous molecular changes that accompany chronic drug intake and play a role in 
the development of drug addiction. 
Δ
The importance of the regulation of SP synthesis by C/EBPβ is not likely to be confined to the 
striatum. For instance, the proinflammatory cytokine interleukin 1β (IL-1β) appears early 
during intestinal inflammation and increases specifically the SP content and SP 
immunostaining of myenteric nerve fibers (Grider 2003). However, the mechanism by which 
IL-1β augments SP expression is currently unknown. Given that IL-1β has been shown to 
induce C/EBPβ in several cell types including astrocytes (Cardinaux et al. 2000), our study 
raise the possibility that C/EBPβ couples SP synthesis to the IL-1β signal during intestinal 
inflammation. A similar mechanism may subserve the LPS-mediated, IL-1-dependent SP 
induction in sympathetic ganglia (Shadiack et al. 1994) or the LPS-mediated SP induction in 
nodose ganglia, a process thought to carry an important role in bronchial hyperreactivity 
(Huang and Lai 2003). 
The regulation of SP synthesis by C/EBPβ might also occur in the small C-fiber type neurons 
of the dorsal root ganglion (DRG). SP release from these cells has been for long associated 
with the transmission of noxious stimuli from the periphery to the central nervous system 
(Otsuka and Yoshioka 1993; Iversen 1998). Cyclic AMP has been shown to increase SP 
expression in DRG cells (Adler and Walker 2000), thus it would be of particular interest to 
address the question of whether C/EBPβ, as a downstream target of CREB, could be 
responsible for the elevated SP content of DRG neurons following cAMP stimulation. 
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In conclusion, our work suggests that C/EBPβ could be an important factor mediating drug-
dependent synaptic plasticity in the striatum. When taken together with the reported role of 
dopamine and substance P in addiction, the present study contributes to the understanding of 
molecular changes in the brain that characterize the development of drug dependence. 
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CCAAT/enhancer-binding protein (C/EBP) family
members are transcription factors involved in impor-
tant physiological processes, such as cellular prolifera-
tion and differentiation, regulation of energy homeosta-
sis, inflammation, and hematopoiesis. Transcriptional
activation by C/EBP and C/EBP involves the coacti-
vators CREB-binding protein (CBP) and p300, which
promote transcription by acetylating histones and re-
cruiting basal transcription factors. In this study, we
show that C/EBP is also using CBP as a coactivator.
Based on sequence homology with C/EBP and -, we
identify in C/EBP two conserved amino acid segments
that are necessary for the physical interaction with
CBP. Using reporter gene assays, we demonstrate that
mutation of these residues prevents CBP recruitment
and diminishes the transactivating potential of C/EBP.
In addition, our results indicate that C/EBP family mem-
bers not only recruit CBP but specifically induce its
phosphorylation. We provide evidence that CBP phos-
phorylation depends on its interaction with C/EBP and
define point mutations within one of the two conserved
amino acid segments of C/EBP that abolish CBP phos-
phorylation as well as transcriptional activation, sug-
gesting that this new mechanism could be important for
C/EBP-mediated transcription.
The CCAAT/enhancer-binding protein (C/EBP)1 family is
composed of pleiotropic transcription factors involved in tissue-
specific metabolic gene transcription, in signal transduction
activated by several cytokines, and in cell differentiation (for a
review, see Refs. 1–7). Six members of the family have been
described so far: C/EBP, C/EBP, C/EBP, C/EBP, C/EBP,
and C/EBP (8). C/EBP isoforms bind to their cognate DNA
element through a bipartite domain called bZIP. This domain
consists of a basic region, contacting DNA, and a homo- or
heterodimer-forming region called the leucine zipper (9). Be-
cause of the high conservation in the bZIP domain, C/EBP
family members are able to form homo- or heterodimers, and
all, except C/EBP, bind to the same cis-regulatory elements.
C/EBP, C/EBP, and C/EBP are involved in terminal dif-
ferentiation of a variety of cells including adipocytes (10), hepa-
tocytes (11, 12), gut epithelial cells (13), macrophages (14),
myelomonocytes (15), and neurons (16, 17). In the nervous
system, the role of C/EBP family members is not characterized
as well as, for instance, in adipocytes or hepatocytes. However,
a recent study suggests that they are essential for cortical
progenitor cells to become postmitotic neurons (16). Interest-
ingly, certain C/EBP isoforms appear to be involved in learning
and memory processes (18–20), glial or neuronal cell functions
(21–23), and neurotrophic factor expression (24).
Knock-out mice were generated for different C/EBP isoforms
(reviewed in Refs. 7, 8, and 10). These C/EBP-deficient mice
display various phenotypes extending from perinatal lethality
(for C/EBP) to subtle abnormalities. These different pheno-
types suggest that C/EBP family members are not functionally
redundant, which, to a certain extent, was confirmed by studies
in cell cultures (reviewed in Ref. 7). Because the DNA binding
domain of the C/EBP isoforms is highly similar, these func-
tional differences must be mostly due to specific properties of
their transactivation domain.
Relatively little is known about the way C/EBP family mem-
bers activate transcription. C/EBP interacts with TBP and
TFIIB, two major components of the general transcription ma-
chinery (25). Moreover, C/EBP and C/EBP were shown to
recruit the chromatin remodeling complex SWI/SNF (26, 27).
Modification of chromatin is an important step in the activation
of gene transcription. Unlike ATPase/helicase-type remodeling
complexes such as SWI/SNF, other large complexes contain
proteins with histone acetyltransferase (HAT) enzymatic activ-
ity (28). These coactivators acetylate the histone tails of nu-
cleosomes, thus favoring chromatin remodeling and activation
of transcription. CREB-binding protein (CBP) and p300 belong
to this class of coactivators. CBP was first identified through its
ability to bind to the transcription factor CREB (29). Since
then, several other transcription factors were shown to require
CBP for efficient transactivation (for a review, see Refs. 30–
33). CBP functions as an adaptor between the tissue- and
sequence-specific transcription factors and the general tran-
scriptional machinery. Therefore, CBP is believed to activate
gene transcription by recruiting basal transcription factors
(TFIIB, TBP, and RNA polymerase II holoenzyme), by modify-
ing chromatin structure via histone acetylation, and finally, by
recruiting other histone acetyltransferases, such as SRC-1,
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ACTR, or P/CAF. CBP and p300 were shown to participate in
C/EBP- and C/EBP-mediated gene transcription (34–40). A
direct interaction of C/EBP with the E1A-binding domain of
p300 was identified (35), suggesting that these C/EBP isoforms
activate transcription, at least in part, by recruiting CBP/p300.
In this study, we provide evidence that interaction of C/EBP
family members with CBP triggers its phosphorylation. We
show for the first time that C/EBP binds to CBP, and we
identify two amino acid segments in C/EBP that are necessary
for this interaction. Mutations in one of these segments abolish
C/EBP-mediated transactivation as well as CBP phosphoryl-
ation. Together, these results demonstrate that CBP is phos-
phorylated when it interacts with C/EBP family members, sug-
gesting that CBP phosphorylation could play a key role in
C/EBP-mediated gene transcription.
EXPERIMENTAL PROCEDURES
Plasmids—pGL3–5C/EBP was constructed by inserting five copies
of a consensus C/EBP-binding site flanked by BglII and BamHI sites
(5-AGATCTACAGATTGCGCAATCTAGGATCC-3) into the BglII site
of pGL3-Promoter vector (Promega). pcDNA3-HA-C/EBP, pcDNA3-
HA-C/EBP, and pcDNA3-HA-C/EBP were constructed by inserting
an oligonucleotide encoding the HA epitope at the N terminus of the
C/EBP coding regions and ligating the fusion cDNAs into pcDNA3.
pcDNA3-CBP-2FLAG was constructed by inserting two FLAG
epitopes at the C terminus of the CBP coding region. To create pGEX-
C/EBP22–227, pGEX- C/EBP22–193, pGEX-C/EBP22–103, and pGEX-
C/EBP1–196, PCR-generated fragments encoding amino acids 22–227,
22–193, or 22–103 of mouse C/EBP or amino acids 1–196 of mouse
C/EBP were inserted into the NdeI/EcoRI sites of pGEX-4T3
(Amersham Biosciences). To construct pcDNA3-CBP1680–1892-2FLAG,
pcDNA3-CBP1680 –2441-2FLAG, or pcDNA3-CBP1893–2441-2FLAG,
PCR-generated fragments encoding amino acids 1680–1892, 1680–
2441, or 1893–2441 of CBP were inserted into a modified pcDNA3
vector containing sequences encoding a nuclear localization sequence at
the N terminus and two FLAG epitopes at the C terminus. MSVLIP
was described previously (21). pRc/RSV-FLAG-CREB341 was described
by Loriaux et al. (41), and pRc/RSV-ATF-1 was described by Rehfuss et
al. (42). The Gal4-LUC (luciferase) reporter was a kind gift of G. Waeber
(Department of Internal Medicine B, University Hospital, Lausanne,
Switzerland) and was described by Bonny et al. (43). pcDNA3-Gal4
encodes the Gal4 DNA binding domain (amino acids 1–147). pcDNA3-
Gal4-C/EBP1–152 was generated by inserting a BamHI/NotI fragment
from pGEX-C/EBP1–196 into pcDNA3-Gal4. Deletions or alanine mu-
tants of pGEX-C/EBP1–196 and pcDNA3-HA-C/EBP were generated
by site-directed mutagenesis (Stratagene). The corresponding pcDNA3-
Gal4-C/EBP1–152 mutants were constructed from the pGEX-
C/EBP1–196 mutants. All of the constructs were verified by sequencing.
Cell Culture and Transfection Assays—HEK 293T cells were cultured
on gelatin-coated plates in high glucose GLUTAMAX™ Dulbecco’s mod-
ified Eagle’s medium (Invitrogen) containing 10% heat-inactivated new-
born calf serum (Invitrogen), 100 units/ml penicillin G, and 100 g/ml
streptomycin sulfate (Invitrogen). Calcium phosphate transfection as-
says were performed according to an improved protocol described by
Jordan et al. (44). Briefly, 293T cells were seeded at 8 105 cells/60-mm
plate and, 24 h later, were transiently transfected with 8 g of total
DNA. The cell culture medium was changed 8 h later, and 24 h after
transfection, cellular lysates were prepared for luciferase assays or
immunoblot analysis.
Luciferase Assays—Transfected cells were washed with PBS, lysed in
250 l of 1 cell culture lysis buffer (Promega), and centrifuged in a
microcentrifuge for 2 min at 4 °C. To test the samples for luciferase
activity, 20 l of the 250 diluted supernatant was assayed in a
Turner-Designs TD-20/20 luminometer using 100 l of luciferase assay
reagent (Promega). Luciferase activity was normalized to total cellular
protein (Bio-Rad protein assay). All experiments were performed in
triplicate.
Preparation of Cellular Extracts—PC12 cell nuclear extract was pre-
pared according to Dignam et al. (45). To perform experiments with
recombinant proteins expressed in 293T cells, whole cell extracts were
prepared by lysing the cells in 50 mM Hepes, pH 7.6, 250 mM NaCl, 0.2
mM EDTA, 0.5% Nonidet P-40, 10 M NaF, and 10 M Na3VO4 for 30
min at 4 °C. Then the extracts were cleared by centrifugation at
16,000  g for 10 min. To prevent proteolysis, a protease inhibitor
mixture for mammalian tissue (Sigma) and calpain inhibitor were in-
cluded in the lysis buffer.
Immunoblot Analysis—After separation on SDS-polyacrylamide gels
(SDS-PAGE), the proteins were transferred to polyvinylidene difluoride
membranes with a semidry blotting system (Bio-Rad) for 45 min at
20 V as in Cardinaux et al. (46). Blots were blocked overnight at 4 °C in
TBST containing 10 mM Tris-HCl, 150 mM NaCl, pH 7.4, and 0.05%
Tween 20, supplemented with 10% skim milk powder and 1% bovine
serum albumin. Blots were subsequently incubated with a primary
antibody in TBST plus 1% skim milk powder for 2 h at room tempera-
ture. Full-length CBP was detected with an anti-CBP451–682 polyclonal
antibody as in Cardinaux et al. (47), FLAG-tagged CBP fragments were
detected with anti-FLAG M2 monoclonal antibody (Sigma), and HA-
tagged C/EBP isoforms were detected with anti-HA rat monoclonal
antibody (Roche Applied Science). Finally, polyvinylidene difluoride
membranes were incubated with horseradish peroxidase-conjugated
secondary antibodies and developed using chemiluminescence detection
kits (ECL (Amersham Biosciences) or SuperSignal® West Femto
(Pierce)).
GST Pull-down Assays—GST fusion proteins were expressed in
Escherichia coli (BL21-Codon Plus®, Stratagene) and purified over
glutathione-Sepharose beads (Sigma). A 5 M concentration of the ap-
propriate GST-C/EBP fusion proteins were incubated with 10 l of
glutathione-Sepharose beads (Amersham Biosciences) in 150 l of
buffer A (50 mM Hepes, pH 7.6, 1 M NaCl, 0.2% Nonidet P-40, 0.1 mM
EDTA, 1 mM dithiothreitol) for 1 h at 4 °C. The beads were washed
twice with 1 ml of buffer A and twice with 1 ml of HEG100 (20 mM
Hepes, pH 7.6, 10% glycerol, 100 mM KCl, 0.2 mM EDTA, 1 mM dithio-
threitol). The GST-C/EBP bound beads were incubated for 2 h at 4 °C
with 450 g of proteins from PC12 nuclear extract. 100 g of proteins
from transfected 293T whole cell extract, or 20 l of in vitro translated
CBP1680–1892 (using the TNT® T7 coupled reticulocyte lysate system
from Promega) in 300 l of HEG100 supplemented with a protease
inhibitor mixture for mammalian tissue (Sigma). The beads were
washed three times with 1 ml of HEGN300 (20 mM Hepes, pH 7.6, 10%
glycerol, 300 mM KCl, 0.1 mM EDTA, 0.1% Nonidet P-40, 1 mM dithio-
threitol), resuspended in 25 l of SDS-PAGE loading buffer, and heated
to 95 °C for 5 min. For immunoblot analysis, 20 l were electrophoresed
on a 6% SDS-PAGE for full-length CBP or on a 12% SDS-PAGE for
CBP1680–1892, and for Coomassie staining, 5 l were electrophoresed on
a 12% SDS-PAGE.
Dephosphorylation of CBP1680–2441—FLAG-tagged CBP1680–2441 was
immunoprecipitated from whole cell extracts diluted in 50 mM NaCl, 10
mM Tris-HCl, pH 7.8, using 10 l of anti-FLAG M2-agarose beads
(Sigma). For dephosphorylation assays, beads were washed three times
in the same buffer, and for control reactions, the washing buffer was
completed with 10 M NaF and 10 M Na3VO4. CBP fragments were
incubated for 20 min at 37 °C in 50 l containing 50 mM Tris-HCl, pH
8.5, 5 mM MgCl2, and 3 units of shrimp alkaline phosphatase (Pro-
mega). Control reactions were performed at 37 °C in the same buffer
without shrimp alkaline phosphatase, supplemented with 10 M NaF
and 10 M Na3VO4 to inhibit endogenous cellular phosphatases. Reac-
tions were stopped by adding SDS-PAGE loading buffer, and FLAG-
tagged CBP1680–2441 was detected by immunoblot analysis. For each
condition, the input is also shown (i.e. CBP fragments left on ice in 50
mM NaCl, 10 mM Tris-HCl, pH 7.8, and then eluted with SDS-PAGE
loading buffer).
RESULTS
CBP Coactivates C/EBP, C/EBP, and C/EBP-mediated
Transcription—p300 and CBP are transcriptional coactivators
for C/EBP and C/EBP (34–40). To investigate whether
C/EBP is activating transcription through the same mecha-
nisms, we performed a series of reporter gene assays using a
synthetic C/EBP-responsive luciferase reporter gene (pGL3–
5C/EBP), which contained five copies of a consensus C/EBP-
binding site in front of the SV40 promoter and the luciferase
gene. 293T cells were transiently transfected with this reporter
and the same amount of expression vectors encoding HA-
tagged C/EBP, C/EBP, or C/EBP (Fig. 1). C/EBP and
C/EBP increased luciferase gene expression by 2-fold,
whereas C/EBP-mediated transcription was 12-fold higher
than basal luciferase activity. Regardless of these differences in
transcriptional activity, overexpression of CBP increased
C/EBP-mediated transcription by 2–3-fold for each C/EBP fam-
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ily member. The levels of the C/EBP isoforms were not affected
in the presence of CBP (data not shown). Taken together, these
data indicate that CBP is a rate-limiting coactivator involved in
C/EBP-, C/EBP-, and C/EBP-mediated transcription and
suggest that these C/EBP isoforms activate transcription at
least partly by recruiting CBP.
C/EBP and C/EBP Interact with the E1A Binding Domain
of CBP—The amino terminus of C/EBP interacts with the
E1A binding domain of p300 (35). However, interactions of
C/EBP or C/EBP with CBP have not yet been shown. To
bridge this gap, we performed a series of GST pull-down exper-
iments with various purified proteins containing the transac-
tivation domain of C/EBP or C/EBP fused to GST (Fig. 2).
First, we showed that the amino acids 1–196 of C/EBP were
interacting with CBP from a PC12 cells nuclear extract (Fig.
2A), suggesting that C/EBP might recruit CBP in vivo. It was
shown that C/EBP recruits p300 through its E1A binding
domain (35). To test whether C/EBP or C/EBP interact with
the same region of CBP, we then expressed in HEK 293T cells
a FLAG-tagged protein containing CBP amino acids 1680–
1892. A whole cell extract was prepared and incubated with
GST-C/EBP1–196 or various deletions of the C/EBP trans-
activation domain fused to GST (Fig. 2B). A similar interac-
tion with CBP1680–1892 was observed for C/EBP22–227,
C/EBP22–193, and C/EBP1–196, whereas further deleting
C/EBP to amino acid 103 reduced significantly its interaction
with the E1A binding domain of CBP. Together, these experi-
ments strongly suggest that C/EBP as well as C/EBP recruit
the coactivator CBP through its E1A binding domain.
To confirm that C/EBP and C/EBP are able to interact
with the E1A binding domain of CBP directly, without the help
of accessory nuclear factors, CBP1680–1892 was translated in
vitro and labeled with [35S]methionine (Fig. 2C). GST-
C/EBP22–227 and GST-C/EBP1–196 both pulled down the CBP
fragment, thus demonstrating a direct interaction between
C/EBP or C/EBP and the E1A binding domain of CBP.
C/EBP, C/EBP, and C/EBP Modify the Electrophoretic
Mobility of CBP—While we were studying C/EBP-CBP inter-
actions, we noticed that the migration of CBP in a SDS-poly-
acrylamide gel was affected when it was coexpressed with
C/EBP, C/EBP, or C/EBP (Fig. 3). To better characterize
this change in mobility, we next tried to find a CBP fragment
displaying a similar shift in the presence of C/EBP. We first
tested a fragment encoding amino acids 1680–1892 of CBP,
because we had shown in Fig. 2 that it was interacting with
C/EBP. However, no mobility shift was observed with this
CBP fragment (Fig. 4). Then we tested several CBP constructs,
and, interestingly, we found that the electrophoretic mobility of
CBP1680–2441, containing the E1A binding domain and the C
terminus of CBP, was modified when it was coexpressed with
C/EBP, C/EBP, or C/EBP (Fig. 4B). CBP1893–2441 was not
shifted in the presence of C/EBP, demonstrating that amino
acids 1680–1892 were required to induce a mobility shift of
CBP1680–2441. On the whole, these data suggest that by inter-
acting with the E1A binding domain of CBP, C/EBP family
FIG. 1. CBP potentiates C/EBP-mediated transcription. HEK
293T cells were transfected as described under “Experimental Proce-
dures” with 2 g of pGL3–5C/EBP and 0.25 g of
pcDNA3-HA-C/EBP, -, or -, in the absence () or in the presence ()
of 4 g of pcDNA3-CBP-2FLAG. pcDNA3 was used to set the total
amount of DNA to 8 g for each condition. Results are displayed as the
mean  S.E. (n  3) relative luciferase activity. Values are normalized
for protein levels. Note that these results were obtained in the same
experiment but that a different scale was used for C/EBP for presen-
tation purposes.
FIG. 2. CBP interacts with C/EBP and C/EBP through its
E1A binding domain. A, binding of full-length CBP (CBPFL) from
PC12 nuclear extract to GST-C/EBP1–196. The specificity of the in-
teraction was confirmed with a negative control consisting of GST
alone. B, binding of the E1A binding domain of CBP (CBP1680–1892)
expressed in HEK 293T cells to various GST-C/EBP constructs or to
GST-C/EBP1–196. FLAG-tagged CBP1680–1892 was detected by immu-
noblotting using monoclonal anti-FLAG antibody (top). Coomassie Bril-
liant Blue-stained GST proteins are shown in the bottom panel. The
positions of molecular mass markers (in kDa) are shown on the left. C,
GST pull-down experiment with in vitro translated CBP1680–1892 and
the indicated GST proteins.
FIG. 3. C/EBP isoforms alter the electrophoretic mobility of
CBP. HEK 293T cells were cotransfected with 1.5 g of
pcDNA3-CBP-2FLAG and 7.5 g of pcDNA3-HA-C/EBP, -, or - (or
pcDNA3 ()) using the calcium phosphate method. Cellular extracts
were prepared 24 h after transfection, and proteins were analyzed by
SDS-PAGE followed by immunoblotting using monoclonal anti-FLAG
(top) or anti-HA (bottom) antibodies. The position of full-length CBP
(CBPFL) in the absence of any C/EBP isoform is indicated by a black
arrow, whereas the slow migrating form of CBP is marked by an empty
arrow.
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members induce covalent modifications in the C-terminal third
of CBP, which in turn modify its migrating properties.
The Mobility Shift of CBP1680–2441 Is Due to Phosphoryla-
tion—The most common covalent modification of proteins that
induce a mobility shift in SDS-polyacrylamide gel electrophoresis
is phosphorylation. To determine whether the slow migrating
forms of CBP1680–2441 were actually generated by phosphoryla-
tion, we tested whether the mobility shift observed in the pres-
ence of the C/EBP family members was affected by phosphatase
treatment. As shown in Fig. 5, shrimp alkaline phosphatase
totally abolished the slow migrating forms of CBP1680–2441 ob-
served when C/EBP, C/EBP, or C/EBP was coexpressed with
this CBP fragment. This experiment thus demonstrated that the
C/EBP-induced mobility shift is due to CBP phosphorylation.
To exclude a nonspecific effect of protein overexpression, we
then transfected a series of constructs expressing different
proteins together with CBP1680–2441 (Fig. 6). First, we showed
that the truncated form of C/EBP, called LIP (48), which does
not contain a transactivation domain, did not trigger a mobility
shift in CBP1680–2441. Moreover, CREB and ATF-1 that interact
with the CREB-binding domain of CBP did not affect the mo-
bility of the CBP fragment. These data thus confirmed that
CBP phosphorylation was specifically triggered by the coex-
pression of transcriptionally active C/EBP family members.
The transcriptional activation of a protein kinase by the
C/EBP isoforms could explain the appearance of the slow mi-
grating forms of CBP. To test this possibility, we coexpressed
CBP1680–2441 together with a fusion protein consisting of the
Gal4 DNA binding domain and amino acids 1–152 of C/EBP
(Fig. 6, last lane). The bZIP DNA binding domain of C/EBP is
lacking in this deletion mutant; therefore, it cannot activate
any cellular genes. The mobility shift of CBP was still induced
by Gal4-C/EBP1–152, thus excluding a C/EBP-mediated tran-
scriptional activation of a kinase. This last piece of data sug-
gests that CBP phosphorylation is triggered by its interaction
with the transactivation domain of C/EBP even if C/EBP is not
bound to DNA.
Two Conserved Amino Acid Segments of C/EBP Are Critical
for CBP Recruitment—Nerlov and Ziff (25) defined two regions
highly conserved among C/EBP, C/EBP, and C/EBP that
they called box A and box B. Interestingly, deletions or muta-
tions within these regions strongly decrease C/EBP and
C/EBP transcriptional activity (25, 36, 40, 49, 50). Therefore,
we first asked whether these conserved regions, known to be
necessary for C/EBP- and C/EBP-mediated gene transcrip-
tion, were equally important for C/EBP. As shown in Fig. 7A,
in C/EBP, box A extends from amino acid 54 to 67, whereas
box B consists of the amino acids 81–86. We performed a series
of GST pull-down experiments and showed that deletion of box
A or box B almost completely abolished the interaction of
C/EBP with full-length CBP from PC12 cell nuclear extract
and strongly diminished the interaction with CBP1680–1892
(Fig. 7B). Furthermore, deletion of box A or box B markedly
decreased the transcriptional activity of the corresponding
Gal4-C/EBP1–152 mutants (Fig. 7C).
We then introduced some point mutations into C/EBP based
on previously described mutations in C/EBP (25). In this
C/EBP isoform, Tyr67 of box A and Phe77 and Leu78 of box B
were shown to be important for the interaction with TBP and
TFIIB as well as for the activation of transcription. Introducing
corresponding alanine point mutations into C/EBP by chang-
ing Tyr64 (mut 1), Leu81 and Phe82 (mut 2), or all three amino
acids (mut 3) strongly diminished binding of full-length CBP as
well as the interaction with CBP1680–1892 (Fig. 7B). Mutation of
Leu81 and Phe82 in box B (mut 2) was clearly deleterious for the
transcriptional activity of Gal4-C/EBP1–152 in contrast to the
effect of Tyr64 mutation, which is more difficult to understand
(Fig. 7C). Tyr64 mutation on its own did not impair Gal4-
C/EBP1–152 activity, whereas the incorporation of this muta-
tion into mut 2 further reduced its transcriptional activity (mut
3). Therefore, these data highlighted the importance of Leu81
and Phe82 for C/EBP-mediated transcription, showing a role
FIG. 4. C/EBP isoforms induce slow migrating forms of a C-
terminal fragment of CBP. A, schematic representation of CBP and
its most important domains (Zn, zinc finger domain; KIX, kinase-induc-
ible domain-interacting domain; Bromo, bromodomain; HAT, histone
acetyltransferase domain; Q, glutamine-rich region). The CBP frag-
ments used in the experiments shown below are also depicted. B, HEK
293T cells were cotransfected with 1.5 g of the indicated FLAG-tagged
CBP fragments and 7.5 g of the HA-tagged C/EBP isoforms (or
pcDNA3 ()) as in Fig. 3. Cellular extracts were prepared 24 h after
transfection, and proteins were analyzed by SDS-PAGE followed by
immunoblotting using monoclonal anti-FLAG antibody. The position of
CBP1680–2441 in the absence of any C/EBP isoform is indicated by a
black arrow, whereas the slow migrating forms of CBP1680–2441 are
marked by an empty arrow.
FIG. 5. The mobility shift of CBP1680–2441 is due to phospho-
rylation. HEK 293T cells were cotransfected as in Fig. 4. Then
CBP1680–2441 was immunoprecipitated, washed, and incubated for 20
min at 37 °C in the absence () or in the presence () of shrimp
alkaline phosphatase (SAP). Reactions were stopped by adding SDS-
PAGE loading buffer and analyzed by SDS-PAGE followed by immu-
noblotting using the M2 monoclonal anti-FLAG antibody. The position
of CBP1680–2441 in the absence of any C/EBP isoform is indicated by a
black arrow, whereas the slow migrating forms of CBP1680–2441 are
marked by an empty arrow. For each condition, the input i (i.e. CBP
fragments left on ice in washing buffer) is also shown.
FIG. 6. Induction of CBP phosphorylation is specific and de-
pendent on C/EBP transactivation domain. HEK 293T cells were
cotransfected with 1.5 g of FLAG-tagged CBP1680–2441 and 7.5 g of
the indicated transcription factor as in Fig. 4. Gal-C/EBP, amino acids
1–152 of C/EBP fused to yeast Gal4 DNA binding domain. The position
of CBP1680–2441 in the absence of any C/EBP isoform is indicated by a
black arrow, whereas the slow migrating forms of CBP1680–2441 are
marked by an empty arrow.
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for Tyr64 only in combination with mutations of these two
amino acids. Mutating Tyr64 to alanine strongly reduced CBP
binding (Fig. 7B, mut 1), whereas this mutation had no effect
on the transcriptional level (Fig. 7C). This apparent discrep-
ancy may be due to the intrinsic properties of the GST pull-
down and luciferase assays. In the transfected cells, the inter-
action of C/EBP and CBP occurred in a context that is difficult
to mimic in vitro. In other words, Tyr64 mutation might only
marginally affect CBP recruitment in vivo, despite its effect in
the GST pull-down experiments. Taken as a whole, these re-
sults indicate that the interaction of C/EBP with CBP depends
on two conserved regions that are critical for the transcrip-
tional activity of C/EBP.
C/EBP Box B Is Required for CBP Phosphorylation—Hav-
ing defined deletion and alanine mutations that affect CBP
recruitment and transcriptional activity, we next tested the
effect of these mutations on the ability of C/EBP to induce
CBP phosphorylation. Surprisingly, deletion of box A (54–
67), which strongly reduced the interaction with CBP in the
GST pull-down experiments, did not abolish the mobility shift
of CBP1680–2441 (Fig. 8A). In contrast, deletion of box B (81–
86) or both box A and box B resulted in a strong inhibition of
CBP phosphorylation. These results therefore suggest that
CBP phosphorylation mostly rely on the integrity of box B. This
was confirmed by testing the effect of Gal4-C/EBP1–152 ala-
nine point mutations that were coexpressed with CBP1680–2441
in HEK 293T cells. As shown in Fig. 8B, replacement of Leu81
and Phe82 with alanine strongly reduced the mobility shift of
the CBP fragment, whereas Tyr64 mutation had no effect.
Taken together, our data thus suggest that C/EBP is trigger-
ing CBP phosphorylation mostly through box B.
DISCUSSION
Numerous studies have highlighted the presence of C/EBP
binding sites in the promoter of genes involved in a variety of
cellular processes (reviewed in Ref. 7). However, many ques-
tions remain about how C/EBP family members activate tran-
scription. In this paper, we provide evidence that C/EBP-me-
diated transcription involves the recruitment of the coactivator
CBP. We show that the interaction of C/EBP with the E1A
binding domain of CBP relies on two amino acid segments
called box A and box B that are conserved between the activat-
ing members of the C/EBP family. Interestingly, C/EBP,
C/EBP, and C/EBP induce slow migrating forms of full-
length CBP, as well as of a C-terminal fragment of CBP, when
they are coexpressed in HEK 293T cells. This mobility shift is
due to CBP phosphorylation, because slow migrating forms
disappear after phosphatase treatment. Finally, we show that
deletion of box B or mutation of Leu81 and Phe82, which alters
CBP recruitment and transcriptional activity, almost com-
pletely abolishes CBP mobility shift as well, suggesting a link
between CBP phosphorylation and C/EBP-mediated gene acti-
FIG. 7. Mutations of C/EBP that affect CBP binding and
transcriptional activity. A, conserved amino acids of C/EBP cor-
responding to box A and box B as defined by Nerlov and Ziff (25). The
numbers above the sequence refer to amino acid positions in C/EBP.
Alanine point mutations that were used in B and C are indicated. B,
binding of full-length CBP (CBPFL) from PC12 nuclear extract (top) or
CBP1680–1892 expressed in HEK 293T cells (middle) to wild type (wt) or
mutant GST-C/EBP1–196. 54–67, deletion of box A; 81–86, deletion
of box B. Full-length CBP or FLAG-tagged CBP1680–1892 were detected
by immunoblotting as in Fig. 2. Coomassie Brilliant Blue-stained GST
proteins are shown in the bottom panel. The positions of molecular mass
markers (in kDa) are indicated. C, effect of box A and box B mutations
on the transactivation potential of C/EBP. HEK 293T cells were trans-
fected as described under “Experimental Procedures” with 1 g of Gal4-
LUC and 0.1 g of pcDNA3-Gal4 (Gal) or pcDNA3-Gal4-C/EBP1–152
wild type (wt) or with the various mutations of Box A and Box B.
pcDNA3 was used to set the total amount of DNA to 8 g for each
condition. Results are displayed as the mean  S.E. (n  3) relative
luciferase activity. Values are normalized for protein levels.
FIG. 8. Mutant forms of C/EBP with reduced transactivation
potential and CBP binding activity fail to induce CBP phospho-
rylation. A, HEK 293T cells were cotransfected with 1.5 g of FLAG-
tagged CBP1680–2441 and 7.5 g of pcDNA3 (), HA-tagged wild type
C/EBP (wt), or the indicated HA-tagged C/EBP mutants. Transfection
conditions and CBP detection were as in Fig. 4. 54–67, deletion of box
A; 81–86, deletion of box B; 54–67  81–86, deletion of both box A
and box B (see Fig. 7). B, HEK 293T cells were cotransfected with 1.5 g
of FLAG-tagged CBP1680–2441 and 7.5 g of yeast Gal4 DNA binding
domain alone (Gal), Gal-C/EBP1–152 (wt), or the indicated Gal-C/
EBP1–152 mutants described in Fig. 7A. Transfection conditions and
CBP detection were as in Fig. 4. The position of CBP1680–2441 in the
absence of any C/EBP isoform is indicated by a black arrow, whereas
the slow migrating forms of CBP1680–2441 are marked by an empty
arrow.
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vation. The effects of mutations that affect C/EBP box A are
more difficult to interpret. Deletion of box A (54–67) strongly
reduces transcriptional activity and interaction with CBP but
does not alter CBP phosphorylation. Moreover, mutation of
Tyr64 within box A markedly decreases CBP binding but nei-
ther affects transcriptional activity nor CBP phosphorylation.
As mentioned earlier, this apparent lack of data correlation
might be due to the properties of the assays used to monitor
CBP binding, C/EBP-mediated transcriptional activity, and
CBP phosphorylation. A mutation that reduces the interaction
with CBP in vitro might not significantly alter CBP phospho-
rylation in vivo, because the nuclear environment could favor
weak and transient interactions that would not be visible in the
GST pull-down assays. Alternatively, CBP could be phospho-
rylated very rapidly even if the C/EBPCBP complex is not
stable. Altogether, C/EBP mutations affect similarly CBP
phosphorylation and transcriptional activity, except for the box
A deletion mutant that strongly reduces transcriptional activ-
ity but not CBP phosphorylation. Other factors might interact
with box A and participate in C/EBP-mediated transcriptional
activation. Deletion of box A would thus impair recruitment of
these factors, whereas Tyr64 mutation would not. These factors
could be, for instance, TBP or TFIIB, because they were shown
to interact with this region in C/EBP (25). However, the
involvement of other coactivators is also possible.
We show that CBP phosphorylation relies both on the E1A
binding domain, with which C/EBP isoforms interact, and the
C-terminal glutamine-rich domain. This suggests that the in-
teraction of C/EBP with CBP somehow recruits a protein ki-
nase that phosphorylates one or several sites between amino
acids 1893 and 2441. Recruitment of this yet uncharacterized
kinase could occur in different ways. For instance, this kinase
could be steadily associated with the C/EBP isoforms and could
phosphorylate CBP when the C/EBPCBP complex is built up.
Alternatively, C/EBP binding may regulate the availability of a
phosphorylation site by inducing a conformational change in
CBP, or instead, the complex formed by C/EBP and CBP could
be recognized by the kinase. Solving this issue will require
identification of the protein kinase phosphorylating CBP in the
presence of C/EBP. We tried to diminish CBP phosphorylation
using many protein kinase inhibitors but were unable to deter-
mine which protein kinase is involved in this process.
A rather different interpretation of our data would be that
C/EBP activates the transcription of a kinase gene whose prod-
uct would then phosphorylate CBP. However, the following
pieces of evidence argue against this possibility. First, our data
suggest that CBP phosphorylation site(s) should be located
between amino acids 1893 and 2441; nevertheless, CBP phos-
phorylation occurs only if the domain with which C/EBP inter-
acts is present. If the role of C/EBP were solely to activate the
transcription of a CBP kinase, then this domain would proba-
bly not be required. Second, deletion of box A (54–67) dras-
tically reduced C/EBP transcriptional activity. Accordingly,
this C/EBP mutant should not activate the kinase gene as
efficiently as wild-type C/EBP, and thus CBP phosphorylation
should be greatly reduced. However, CBP phosphorylation still
occurred with this C/EBP mutant, suggesting that the tran-
scriptional activation of a kinase is not involved. Finally, the
best evidence so far comes from the data obtained with the
Gal4-C/EBP1–152 construct. The bZIP DNA binding domain of
C/EBP is lacking in this deletion mutant, and hence, it cannot
bind to DNA or heterodimerize with endogenous C/EBP family
members. Therefore, it is very unlikely that it could activate
the gene of a CBP kinase. Nevertheless, CBP phosphorylation
was induced by Gal4-C/EBP1–152, suggesting that CBP phos-
phorylation is triggered by its interaction with the transacti-
vation domain of C/EBP rather than by the transcriptional
activation of a protein kinase.
During the preparation of this manuscript, Schwartz et al.
(51) showed that C/EBP family members also trigger the phos-
phorylation of p300 C-terminal part. Conserved posttransla-
tional modifications of CBP and p300 suggest that they are
important for gene regulation mediated by C/EBP and poten-
tially other transcription factors as well. Identifying which
serines or threonines are phosphorylated in CBP1680–2441 is an
important issue to determine the functional role of this phos-
phorylation. In this CBP fragment, two putative phosphoryla-
tion sites were previously identified: first, a protein kinase A
phosphorylation site on serine 1772 (52) that might increase
Pit-1 function in the presence of cAMP (53), although this issue
remains controversial (54); second, a protein kinase B phospho-
rylation site (threonine 1872 in mouse CBP) that modulates the
interaction of C/EBP with p300/CBP and mediates the effect
of insulin on gene expression (38). We mutated Ser1772 or
Thr1872 to alanine, but this had no effect on CBP phosphoryl-
ation induced by C/EBP (data not shown).
What could be the role of CBP phosphorylation in C/EBP-
mediated gene transcription? It has been long known that CBP
and p300 are phosphoproteins (reviewed in Refs. 31 and 33).
For instance, cell cycle-dependent phosphorylation of p300 was
first observed by Yaciuk and Moran (55). Likewise, retinoic
acid and E1A induce phosphorylation of p300 during the dif-
ferentiation of F9 cells (56). However, the huge size of p300 and
CBP hindered the identification of phosphorylation sites within
these coactivators. Consequently, only a few studies could cor-
relate p300/CBP phosphorylation with a functional effect. For
example, Ser301 of CBP was identified as a major target of
CaMKIV phosphorylation in hippocampal neurons (57). Muta-
tion of Ser301 impaired N-methyl-D-aspartate- and CaMKIV-
stimulated transcription, demonstrating that CaMKIV signal-
ing contributes to CREB/CBP-dependent transcription by
phosphorylating CBP at Ser301. In addition, Ser89 of p300 was
shown to be phosphorylated in vivo, most probably by protein
kinase C (58). Another report identified this site as a target of
AMP-activated protein kinase (59). In both cases, Ser89 phos-
phorylation is inhibitory, since it either diminishes the p300
intrinsic HAT activity (60) or blocks the interaction of p300
with nuclear receptors (59). Several other studies reported
regulation of p300 or CBP by protein kinases such as CaMKIV
(61–63), MAPK (64–68), or cyclin E-Cdk2 (69–71), but none of
them identified the amino acids targeted by these kinases.
Interestingly, however, many of these studies showed that CBP
or p300 were more important targets of protein kinases than
the transcription factors themselves. For instance, MAPK ap-
pears to stimulate Elk-1-mediated gene expression by phospho-
rylating the C-terminal part of CBP rather than Elk-1 itself
(64). Similarly, the activation of c-Jun by calcium does not
require c-Jun phosphorylation but rather activation of CBP by
calcium/calmodulin-dependent kinases (63). Pit-1-mediated
regulation of the growth hormone and the prolactin genes
involves the cAMP-protein kinase A pathway. However, mu-
tating all the protein kinase A consensus sites in Pit-1 has no
effect on the transcription of the growth hormone gene, sug-
gesting that protein kinase A-mediated phosphorylation of
CBP is responsible for cAMP activation (72). The prolactin gene
is also inducible by cAMP without involving Pit-1 phosphoryl-
ation (68). In this case, cAMP was suggested to induce the
MAPK family, which in turn phosphorylates CBP/p300 to stim-
ulate transcription.
Stimulation of HAT activity was shown to be a way of in-
creasing the coactivator function of CBP in a phosphorylation-
dependent manner. A remarkable increase in histone acetyla-
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tion was detected when the C-terminal region of CBP was
phosphorylated in vitro by the p44 MAPK/extracellular signal-
regulated kinase 1 (67). Similarly, the cyclin ECdk2 (to be
consistent with C/EBPCBP complex, which may target the
same sites as MAPK, phosphorylates CBP in a cell cycle-de-
pendent manner, thus enhancing its HAT activity (71). With
this in mind, we measured the HAT activity of CBP coex-
pressed with C/EBP, C/EBP, or C/EBP but found no signif-
icant difference with the activity of CBP expressed alone (data
not shown).
In conclusion, one can speculate that C/EBP-mediated phos-
phorylation of CBP might have many diverse effects. For in-
stance, it could induce a conformational change in CBP that
might favor its interaction with components of the basal tran-
scription machinery (e.g. TBP or TFIIB). On the other hand,
phosphorylation of CBP could trigger the recruitment of other
chromatin remodeling complexes. Sorting out this issue will
require identification of which protein kinase as well as which
phosphorylation sites are involved in this process. However,
regardless of what will result from these studies, one can al-
ready anticipate that CBP phosphorylation is an important
modulatory mechanism in C/EBP-mediated gene transcription.
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One of the prominent functions of the brain is to link different input signals by 
association and to preserve this coupling at the level of synaptic connections. In this 
study, we report that TORCs, recently cloned CREB coactivators, contribute to this 
process by sensing the coincidence of two input signals at the neuronal level and by 
converting it into a transcriptional response that leads to the synthesis of factors 
required for enhanced synaptic transmission. We provide evidence that TORCs are 
necessary for the late phase of long-term potentiation (L-LTP) in the hippocampus. 
TORCs are newly discovered CREB coactivators drastically increasing transcription 
independently of CREB Ser133 phosphorylation (1, 2). Recently it has been shown that 
TORC2 functions as a coincidence detector in pancreatic cells: glucose acting through L-type 
calcium channels and gut hormones acting through the cAMP pathway promote 
synergistically the dephosphorylation and the concomitant nuclear translocation of TORC2 
(3). Given the well-established role of CREB in synaptic plasticity, learning and memory (4-
6), we addressed the possibility that TORCs could function as calcium- and cAMP-sensitive 
coincidence detectors in the central nervous system and could contribute to L-LTP in the 
Schaffer collateral-CA1 pathway that is considered as a model of how the hippocampus 
encodes memory traces (7). 
First, we tested the presence of TORC1 and TORC2 mRNA by real-time RT-PCR in adult 
mouse brain and in primary cultures of neurons dissected from E17 mouse embryos. We 
found that both TORCs are present in the cortex, hippocampus and striatum, although TORC1 
is approximately 20 times more abundant (Fig 1A). Next we verified that transfected and 
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endogenous TORCs translocate to the nucleus of cortical neurons upon stimulation with 
forskolin (FSK) and KCl, as it would be required for transcriptional activation. FSK is 
supposed to decrease TORC phosphorylation via cAMP inhibition of salt-inducible kinases 
(SIKs) activity, while KCl promotes calcium entry and thereby triggers TORC 
dephosphorylation via the calcium-activated phosphatase calcineurin/PP2B (3, 8). Indeed, 
nuclear translocation of TORC1 and TORC2 occurred upon activation of the cAMP and 
calcium pathways (Fig 1B, C, D), while FSK or KCl alone had little effect (Supporting Fig.1). 
Inhibition of calcineurin by cyclosporine A (CsA) abolished the nuclear entry of TORCs 
(Supporting Fig. 1 and data not shown), demonstrating the importance of TORCs 
dephosphorylation for their nuclear localization. TORC2 translocated more readily, since 
inhibition of nuclear export by leptomycin B was necessary to see the nuclear accumulation of 
transfected as well as endogenous TORC1. 
 
 
Fig. 1. Calcium and cAMP pathways promote nuclear translocation of TORC1 and TORC2 in mouse cortical 
neurons. (A) Real-time RT-PCR measurements of mouse TORC1 and TORC2 mRNA levels in mouse neuronal 
cultures and adult brain (Cx=cortex; Hipp.=hippocampus; Str.=striatum). (B) Nuclear translocation of 
endogenous TORCs in non-transfected neurons treated as in (A). Microtubule-associated protein 2 (MAP-2) 
stains neuronal processes. (C) Immunofluorescence of neurons transfected with mouse TORC1-myc showing its 
nuclear translocation in the presence of FSK, KCl, and leptomycin-B. DAPI staining is shown to localize nuclei. 
(D) Immunofluorescence of neurons transfected with mouse Flag-TORC2 showing its nuclear translocation in 
the presence of FSK and KCl. 
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Having shown the presence and the nuclear translocation of TORCs in neurons, we assessed 
their role in CREB-mediated transcription. We measured the expression of a CRE-reporter 
gene transfected into mouse cortical neurons after exposure to FSK and KCl, either separately 
or in combination. Interestingly, only the pairing of both stimuli efficiently activated CREB-
dependent transcription (Fig. 2A). Consistent with the involvement of TORCs, this synergistic 
activation was abolished by the immunophillin binding calcineurin inhibitors CsA and 
FK506, but not by rapamycin, an immunophillin binding compound that does not inhibit 
calcineurin (Fig. 2A and Supporting Fig. 2). In a parallel experiment, we controlled the 
phosphorylation status of CREB (Fig 2B), and showed that the transcriptional inhibition by 
CsA is clearly not accompanied by altered levels of Ser133 phosphorylation. Moreover, the 
slight increase in CREB phosphorylation that we observe upon combined FSK and KCl 
exposure is not likely to explain the synergistic activation of CREB-mediated transcription. 
In former studies the phosphorylation status of CREB was suggested to be a coincidence 
detector. CaMKIV and PKA can both phosphorylate Ser133 (4-6), consequently, cAMP and 
Ca2+ signals were proposed to be integrated at the level of CREB phosphorylation. Our results 
suggest that the simultaneous increase in cAMP and Ca2+ levels is detected rather by TORCs, 
and, indeed, based on theoretical considerations, TORCs are much better situated to detect 
such a coincidence: two simultaneously active kinases targeting the same Ser133 
phosphorylation site have at best additive effects, however, coincidence detection by TORCs 
relies on the simultaneous activation of a phosphatase and inhibition of a kinase that allows 
for a strong synergism between cAMP and Ca2+ signals. Nonetheless, CREB phosphorylation 
by neuronal activity is likely to play an important role at promoters of condensed structure 
that require histone acetylation by CBP (5, 6, 9). 
The characterization of CREB-TORC interaction has shown that TORCs bind to the CREB 
bZIP DNA-binding domain in an arginine 314-dependent manner (1, 3). We transfected 
cortical neurons with a GAL4-CREB construct lacking the bZIP domain or with an 
Arg314Ala mutant CREB, and compared their activity to the wild-type CREB constructs (Fig. 
2C, D). These mutant forms of CREB, although having a phosphorylable Ser133 residue, did 
not support cAMP/Ca2+ coincidence detection, providing additional evidences for the role of 
TORCs in this process. 
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Fig. 2. TORCs mediate synergistic effects of calcium and cAMP signals on CREB activation and BDNF gene 
expression. (A) Luciferase assay of mouse cortical neurons transfected with a CRE-luciferase reporter gene, 
exposed to FSK and/or KCl, in the absence (Veh.) or in the presence of CsA.(B) Western blot of phospho 
(Ser133) CREB levels in cortical neurons treated as in (A). (C) Luciferase assay of mouse cortical neurons 
transfected with full-length GAL4-CREB (wt) or truncated GAL4-CREB ΔbZIP (aa 4-283) plus 5x GAL4-
binding site luciferase reporter. (D) Effect of FSK and KCl on mouse cortical neurons transfected with a CRE-
luciferase reporter in combination with either wild-type (wt) CREB or a mutant CREB defective in TORC 
binding (R314A). (E) Effect of FSK and KCl on mouse cortical neurons transfected with a CRE-luciferase 
reporter in combination with either GFP or a dominant-negative consisting of TORC1 147 first aminoacids fused 
to GFP (DN T1-147). (F) Luciferase assay of cortical neurons exposed to FSK and/or KCl, transfected with a 
CRE-luciferase reporter gene and shRNA producing plasmids against TORC1 (T1) and TORC2 (T2) or GFP. 
(G) Luciferase assay of mouse striatal neurons transfected with a CRE-luciferase reporter gene, exposed to 
dopamine (DA) and/or glutamate (Glut), in the absence (Veh.) or in the presence of CsA. (I) Real-time RT-PCR 
measurements of BDNF mRNA levels in mouse cortical neurons exposed to FSK and/or KCl, in the absence 
(Veh.) or in the presence of CsA. 
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To further support the idea that calcium and cAMP coincidence detection in neurons relies on 
TORCs, we designed a specific dominant-negative protein consisting of the first 147 amino 
acids of TORC1 fused to GFP. This part of the TORC1 sequence harbors a nuclear 
localization signal in addition to the CREB-binding domain (3). In preliminary experiments, 
we showed that it efficiently blocks TORC1- and TORC2-dependent transcription in HEK 
293T cells (data not shown). The expression of this dominant-negative protein drastically 
decreased the cAMP- and Ca2+-mediated enhancement of CREB-dependent transcription, 
while GFP expression had no effect (Fig. 2E). 
To definitely prove the involvement of TORCs, we used RNA interference to preclude the 
expression of endogenous TORC1 and TORC2. The transfection of shRNA producing 
plasmids along with the CRE-reporter gene completely abolished the synergism triggered by 
calcium and cAMP pathways (Fig. 2F). Taken together, these data constitute a compelling 
body of evidence that in neurons Ca2+ and cAMP synergistically activate CREB-mediated 
transcription by recruiting TORCs to the nucleus. 
In neurons, calcium and cAMP signaling pathways are activated by a plethora of 
neurotransmitters and neuropeptides, therefore, we addressed the question of whether the 
coincidence of physiologically relevant neurotransmitter combinations can be detected by 
TORCs. In the striatum, for instance, medium spiny neurons receive glutamatergic input from 
the neocortex/hippocampus and dopaminergic input from the midbrain. The coincidence of 
these two signals may have implications for addiction-related learning (10, 11). In the 
hippocampus, NMDA receptor activation is an important signal for CA1 cells, and, 
interestingly, pituitary adenylate cyclase-activating peptide (PACAP) can modulate the 
activity of these neurons (12). These observations prompted us to repeat our reporter gene 
assays using glatamate/dopamine on striatal neurons (Fig. 2G) and NMDA/PACAP on 
hippocampal neurons (Fig. 2H). Again, we found that CREB-dependent transcription was 
facilitated significantly only in the presence of both neurotransmitters, and CsA abolished this 
effect (Fig 2G, H). These results strongly suggest that TORCs can detect the coincidence of 
several physiologically important neurotransmitter combinations. 
The coincidence of two external or internal stimuli permits the establishment of an association 
which is thought to be stored in the synapses of the central nervous system. Therefore, it is 
reasonable to assume that at a cellular level, the short-lived coincidences result in the 
synthesis of synaptic proteins or neurotrophic factors. BDNF is a bona fide CREB target gene 
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(13) and in addition to its neurotrophic effects it has been shown to produce a long-lasting 
enhancement of synaptic transmission in the hippocampus (14). These findings prompted us 
to test whether TORCs are involved in the regulation of BDNF gene expression. As shown by 
real-time RT-PCR, Ca2+ and cAMP synergistically increased the levels of BDNF mRNA, and 
CsA treatment strongly reduced this effect (Fig. 2I). These results support the idea that 
endogenous neuronal CREB target genes are regulated by TORCs in the same way as the 
transiently transfected CRE-reporter construct used in our previous experiments. 
CREB has been shown to be involved in synaptic plasticity and LTP (15-22) and its 
phosphorylation status has been reported to reflect neuronal activity (9, 23). However, CREB-
mediated gene transcription does not correlate with Ser133 phosphorylation in every case. For 
instance, monocular deprivation induces LacZ expression in the visual cortex of CRE-LacZ 
transgenic mice (24), while phosphorylation of CREB at Ser133 does not change (25). 
Similarly contradiction remains concerning the exact way of how CREB is activated during 
LTP in the Schaffer collateral-CA1 pathway. Tethering a strong transcriptional activation 
domain (VP16) to CREB facilitates hippocampal LTP (18), however, transgenic mice with a 
mutant CREB unphosphorylable at 133 show normal hippocampal potentiation (26). 
Furthermore CRE-mediated gene expression correlates better with the expression of 
hippocampal LTP than CREB phosphorylation: 3 trains of tetanic stimulation, sufficient to 
establish late-phase LTP, results in strong CRE-mediated gene expression and very little 
CREB phosphorylation, while only one train of stimulation, that is not sufficient for L-LTP, 
induces weak CRE-mediated gene expression but stronger CREB phosphorylation than three 
trains of stimulation (27). Taken together, these contradictory results raise the possibility that 
in some cases of synaptic plasticity, neuronal activity regulates CREB through the recruitment 
of TORCs. 
Long-term potentiation in the Schaffer collateral-CA1 pathway is known to require 
postsynaptic NMDA receptor activation and subsequent Ca2+ influx (28) and several studies 
reported the involvement of the cAMP pathway, although this issue remains somewhat 
controversial (29). Intracellular infusion of a protein kinase A inhibitor into CA1 pyramidal 
cells interferes with the early-phase of LTP (30), while targeting the same inhibitor to the 
nucleus restricts the effect to the late-phase (31). 
BDNF-deficient transgenic mice show a reduced LTP in the Schaffer collateral-CA1 pathway 
(32, 33). Importantly, increased BDNF expression has been shown to contribute to the 
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facilitated LTP in the CREB-VP16 transgenic mice (20), leading to the idea that BDNF is one 
of the molecules that is transcribed, translated and is cell-widely distributed following LTP 
induction allowing for synaptic capture (heterosynaptic LTP). Indeed, mice heterozygous for 
BDNF do not show heterosynaptic LTP in the hippocampus (20). 
 
Fig. 3. LTP-inducing stimulations trigger TORCs perinuclear and nuclear translocation in hippocampal slices. 
Slices were pretreated with 10 ng/ml leptomycin-B, submitted to tetanic stimulation of the Schaffer-collaterals (3 
or 4 trains at 100 Hz separated by 5 min intervals) or to LTP-inducing chemical stimulation. Subsequently, slices 
were fixed, recut to 35 μm thickness and TORCs were localized by immunofluorescence. (A) Endogenous 
TORCs accumulate in the perinuclear compartment of CA1 neurons following chemical or electrical stimulation. 
Arrows indicate the position of the nucleus of representative neurons. (B) Endogenous TORCs accumulate in the 
nuclear and perinuclear compartment of CA3 neurons following LTP-inducing chemical stimulation. 
Requirement of Ca2+, cAMP, CREB, and BDNF, in Schaffer collateral-CA1 LTP, taken 
together with our results that TORCs are activated by Ca2+, cAMP and drive the expression of 
BDNF, raises the possibility that TORCs are involved in hippocampal synaptic plasticity. To 
address this question, we first immunolocalized the endogenous TORCs in rat hippocampal 
slices before or after tetanic stimulations that induce L-LTP in the Schaffer collateral-CA1 
pathway. We stimulated brain slices with three or four tetanic trains (1s, 100 Hz, 5 minutes 
between trains) in the presence of leptomycin-B, verified the establishment of LTP by 
electrophysiological recording, and detected the TORCs by immunofluorescence. We could 
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show an important accumulation of TORCs in the cell bodies and in the proximal part of the 
apical dendrites of CA1 pyramidal cells after tetanization (Fig. 3A). The lack of robust 
nuclear accumulation in these conditions is likely to be due to restricted nuclear import of 
TORCs. To see whether we could trigger stronger nuclear entry of TORCs, we submitted the 
slices to a chemical stimulation that has been reported to potentiate synaptic transmission in 
the Schaffer collateral-CA1 pathway (34).While in CA1 pyramidal cells TORCs retained their 
predominant perinuclear localization (Fig. 3A), in CA3 pyramidal cells we could detect strong 
nuclear accumulation of TORCs (Fig. 3B). This relocation of TORCs after tetanic or chemical 
stimulations that induce LTP in the Schaffer collateral-CA1 pathway suggested that these 
CREB coactivators could play a role in the induction of L-LTP in the hippocampus. 
To directly test this hypothesis, we used an approach based on a protein transduction domain, 
consisting of 11 arginines, that has been shown to efficiently deliver proteins into neurons, but 
not into astrocytes, in hippocampal slices (31). We added the 11 arginine transduction domain 
to the TORC dominant-negative used in Fig. 2E, and transduced hippocampal slices with this 
purified recombinant protein (TORC-DN-EGFP-11R). As a control protein, we used EGFP 
fused to a nuclear localization signal and the 11 arginines (NLS-GFP-11R, Fig. 4A). Three 
trains of tetanic stimulation (1s, 100 Hz, 5 minutes between trains) resulted in a strong 
potentiation of the fEPSP slopes in transduced slices. TORC-DN-EGFP-11R provoked a 
decay of this potentiation that was statistically significant already 50 min after the tetanic 
stimulation, and at 3 hours fEPSP slopes approximated the baseline level (Fig. 4B). On the 
contrary, in the presence of NLS-EGFP-11R, the enhanced synaptic transmission persisted up 
to three hours after HFS. These results constitute a strong evidence that TORCs are necessary 
for hippocampal synaptic plasticity. 
We provide evidence that TORCs are required for hippocampal L-LTP in the Schaffer 
collateral-CA1 pathway. In physiological conditions the coincidence of Ca2+ and cAMP in 
this pathway may be indicative of repeated arrival of input signals. Calcium-stimulated 
adenylate cyclases have been shown to convert Ca2+ entry into cAMP signals, therefore 
subsequent inputs exciting the same CA1 cell might result in Ca2+ entry that is coincident with 
PKA activity triggered by the preceding stimulus. Indeed, the combined deletion of calcium-
stimulated adenylate cyclases AC1 and AC8 prevents the late phase of LTP in the Schaffer 
collateral-CA1 pathway (35). 
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Fig. 4. TORCs are required for L-LTP in the Schaffer-collateral-CA1 pathway. (A) To check for the transduction 
efficiency, hippocampal slices were transduced with 0.5 μM of the recombinant TORC dominant-negative 
protein (TORC-DN-EGFP-11R) or the control recombinant protein (NLS-EGFP-11R) for 1 hour, washed for 30 
minutes, fixed and mounted with DAPI. Cells in the stratum pyramidale of the CA1 region are shown. Many 
cells contain recombinant protein in the nucleus as evidenced by the colocalization of EGFP and DAPI staining. 
(B) Hippocampal slices were transduced with 0.37 μM of TORC-DN-EGFP-11R or NLS-EGFP-11R, then 
transferred into a recording chamber. Extracellular field potentials (fEPSPs) evoked in the CA1 region by 
electrical stimulation of the Schaffer collaterals were recorded. Stimulus intensity was adjusted to evoke 40% of 
the maximal fEPSPs. Paired-pulse facilitation was assessed with a pair of stimuli separated by a 50-ms interval. 
LTP was induced by three trains of 100-Hz pulses (1 s duration) separated by 5 min intervals (HFS), then 
fEPSPs were monitored for 180 min using a baseline stimulation. Starting 50 min after the end of HFS, LTP was 
significantly smaller in slices (n = 6, 6 rats) treated with TORC-DN-EGFP-11R than in control slices (n = 5, 5 
rats) treated with NLS-EGFP-11R (t-test, p<0.05; i.e. at 180 min post HFS, p=0.015). An arrow indicates a 
stimulation of 1-s train at 100 Hz. (C) Examples of postsynaptic responses before (pre HFS, black traces) and 
180 minutes after (180 min post HFS, red traces) the tetanic stimulation. Scales for these traces: 1 mV (vertical), 
10 ms (horizontal). (D) Transduction of the dominant-negative protein against TORC does not interfere with the 
presynaptic function as evidenced by unchanged paired-pulse facilitation. 
In conclusion, we have shown that in neurons, calcium and cAMP pathways do not synergize 
at the level of CREB Ser133 phosphorylation, but rather by favoring the nuclear translocation 
of TORCs. CREB has been shown to be involved in long-term hippocampal synaptic 
plasticity, and our finding that TORCs are required for hippocampal L-LTP strongly suggest 
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that these coactivators play a pivotal role in the regulation of CREB activity in the central 
nervous system. Our results reveal a critical mechanism that might have broad implications 
given the importance of CREB-mediated transcription in memory consolidation, addiction, 
neuronal survival, circadian rhythmicity and developmental plasticity. 
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Material and methods 
Cell Culture and plasmid transfection 
Primary cultures of cortical or striatal neurons were prepared from 17 day old Swiss mice 
embryos as previously described (1), and plated in Neurobasal medium supplemented with 
B27 (Invitrogen), 30 μM glutamate and 500 μM glutamine. Cells were maintained at 37°C in 
a humidified atmosphere of 95% air/5% CO2 and were transfected after 6 days in vitro (DIV). 
For each well of a 24-well plate, a total of 0.75 μg of plasmid DNA was mixed with 2.5 µl of 
Nupherin-neuron (Biomol) and 125 µl of Neurobasal (Invitrogen). After an incubation of 15 
min at RT, 1.5 µl TransFectin (BioRad) diluted in 125 µl Neurobasal was added to the DNA 
mixture, and incubated 40 min at RT. The conditioned neuronal medium was taken off and 
retained while the cells were overlaid with the transfection solution. The plates were 
centrifuged at 100 x g for 3 min and incubated for 30 min at 37°C in the cell culture 
incubator. Finally, the transfection solution was replaced with the retained conditioned media, 
and the neurons were incubated overnight at 37°C. 
Mouse TORC1 cDNA was cloned by RT-PCR from brain total RNA using the following 
primers: 5’-GGCGAGAAGATGGCGACTTCGAACAATCC-3’ and 5’-
CTCACAGGCGGTCCATTCGGAAGGTGTCC-3’. pcDNA3-mTORC1-myc was then 
constructed by subcloning the TORC1 cDNA into a pcDNA3-myc vector. pcDNA3-FLAG-
mTORC2 (2) was provided by M. Montminy (Salk Institute, La Jolla). CRE-luciferase and 
pUB6-LacZ (Invitrogen) have been described previously (3). The TORC dominant-negative 
pcDNA3-TORC11-147-EGFP was constructed by fusing the first 147 amino acids of mouse 
TORC1 to EGFP. R314A mutation was introduced into pRc/RSV-FLAG-CREB (4) via site-
directed mutagenesis (Stratagene). pcDNA3-GAL-CREB ΔbZIP was derived from pRc/RSV-
GAL-CREB(4-283) (4), and pcDNA3-GAL-CREB(4-341) was constructed by replacing in 
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pcDNA3-GAL-CREB ΔbZIP the truncated C-terminal end of CREB with the full-length C-
terminal part taken from pRc/RSV-FLAG-CREB. The Gal4-Luc reporter gene has been 
previously described (5). Details on the construction and purification of plasmids will be 
provided on request. 
Pharmacology and cell stimulation 
Neuronal stimulation was usually performed 20 hr post-transfection. To reduce endogenous 
synaptic activity and prevent calcium entry through NMDA receptors, cortical neurons were 
pretreated for 30 min with 1 µM tetrodotoxin (Alexis), 100 μM APV (Sigma), and 40 μM 
CNQX (Sigma). To increase the specificity of the stimulations, neurons not depolarized with 
KCl were exposed to 10 μM nifedipine (Sigma) and neurons not stimulated with FSK were 
treated with 20 μM H-89 (Calbiochem). The effect of these inhibitors on CREB-mediated 
transcription is shown in Supporting Figure 3. When indicated, neurons were exposed 30 min 
before stimulation to 5 μM cyclosporine A (Calbiochem), FK506 (LC Laboratories) or 
rapamycin (Calbiochem). 30 min after the addition of the inhibitors, cells were stimulated 
with 10 μM FSK (Calbiochem) and/or 30 mM KCl. For the stimulation of striatal neurons, 50 
μM dopamine (RBI) was used instead of FSK, and 20 μM glutamate instead of KCl. 
Glutamate stimulation was performed in the presence of 10 μM nifedipine instead of AP-5 
and CNQX. For the stimulation of hippocampal neurons, 10 nM PACAP-27 (Bachem) was 
used instead of FSK, and 20 μM NMDA (Sigma) instead of KCl. NMDA stimulation was 
performed in the presence of 10 μM nifedipine instead of AP-5 and CNQX. 
Immunocytochemistry 
Mouse cortical neurons were cultured on 12 mm glass coverslips. For the detection of 
endogenous TORC1 and mTORC1-myc, 10 ng/ml leptomycin-B (Sigma) was added to block 
nuclear export. 30 minutes after the addition of the inhibitors, cells were stimulated with 10 
μM FSK and 50 mM KCl. Two hours later, cells were washed twice in PBS and fixed with 
4% paraformaldehyde: All washing steps thereafter were performed using 0,1% Triton X-100 
and 0,2% BSA in PBS. Cells were permeabilized and blocked using 0,5% Triton X-100 and 
2% normal goat serum. The following primary antibodies were used: rabbit pan-TORC (aa 1-
42 of human TORC1) antiserum (2, 6) (1:1500) for endogenous TORCs, mouse anti-MAP2 
(1:8), mouse anti-myc (1:1000, Cell Signaling) for TORC1-myc and mouse anti-FLAG M2 
(1:600, Sigma) for FLAG-mTORC2. Secondary antibodies were anti-mouse-Cy3 (1:600, 
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Jackson) and anti-rabbit-Alexa 488 (1:200, Molecular probes). Coverslips were mounted with 
a DAPI containing mounting medium (Vector) and analyzed with a Zeiss Axioskop 2 mot 
plus microscope or a Zeiss LSM 510 Meta confocal microscope. 
To perform immonohistochemistry following electrical or chemical stimulation, fixed 350 
μm-thick slices were recut to 35 μm thickness using a freezing microtome. Briefly, slices 
were submerged in a 0.1 M phosphate buffer containing 30% sucrose for 10 minutes, placed 
onto a flat platform of frozen sucrose solution, recut, than immediately transferred into the 
immunofluorescence (IF) solution (0.2% BSA, 0.1 % Triton X-100 in PBS). Non-specific 
epitopes were blocked in 0.5 % Triton X-100 and 2.5 % normal goat serum for 30 minutes, 
then slices were washed three times in IF solution. Rabbit pan-TORC antiserum (1: 1000) and 
secondary anti-rabbit-Alexa 488 antibodies (1: 600, Molecular Probes) were applied in IF 
solution, for 24 and 16 hr respectively. Slices were thoroughly washed in IF solution, 
mounted in DAPI containing mouting medium (Vector) and analyzed with a Zeiss Axioskop 2 
mot plus microscope or a Zeiss LSM 510 Meta confocal microscope. 
Reporter Assays. 
Reporter assays were performed 4 hr after cell stimulation. Transfected cells were washed 
with PBS, lysed in 100 µl 1x Cell Culture Lysis Buffer (Promega), and centrifuged in a 
microcentrifuge for 5 min at 4˚C. To test the samples for luciferase activity, 20 µl extract was 
assayed in a Turner-Designs TD-20/20 luminometer using 100 µl of Luciferase Assay 
Reagent (Promega). Luciferase activity was normalized for transfection efficiency by 
measuring β-galactosidase activity with the Galacto-Light chemiluminescent assay (Applied 
Biosystems). All experiments were performed in triplicate. Results are displayed as the mean 
± SEM (n=3) relative luciferase activity. 
Western blotting 
One hour after stimulation, cortical neurons were lysed in 50 µl boiling 3x SDS-PAGE buffer, 
and boiled for 10 min. The samples were briefly sonicated, clarified by centrifugation, and 
subjected to SDS-PAGE electrophoresis. After transfer to a nitrocellulose membrane, 
phospho-CREB was detected using the PhosphoPlus® CREB (Ser133) antibody kit (Cell 
Signaling) following the manufacturer’s instructions. 
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RNA interference 
Mouse cortical neurons were transfected at 5DIV with 0.2 μg CRE-luciferase, 0.15 μg pUB6-
LacZ, and either 0.4 μg pSUPER-GFP, or 0.2 μg of pSUPER-TORC1 and 0.2 μg of 
pBS/U65-TORC2 (2). Two days later, they were stimulated as described above, and reporter 
assays were performed 4 hr later. The shRNA producing plasmids were directed against the 
following target sequences: GFP: 5’- GAACGGCATCAAGGTGAAC-3’; TORC1: 5’-
CGAACAATCCGCGGAAATTTA-3’;and TORC2: 5’-TCTCTGCCCAATGTTAACCA-3’. 
The efficiency of these silencing plasmids was checked by their ability to inhibit the 
overexpression of their target protein in HEK293T cells. 
Real-time quantitative RT-PCR 
Cortical, hippocampal, and striatal neurons dissected from E17 mouse embryos were cultured 
in 35 mm dishes. Samples of cortex, hippocampus, and striatum were taken from adult mouse 
brain by the micropunches technique. For the quantitation of BDNF mRNA, cortical neurons 
were stimulated for 90 min as described above with 10 μM FSK and 30 mM KCl. Total RNA 
from primary neurons or brain samples was then extracted using the RNeasy Mini Kit 
(Qiagen) according to manufacturer’s instructions. RNA was quantified with the RiboGreen 
reagent (Molecular Probes) and cDNA was prepared in a 50 μl reaction by reverse 
transcription of 200 ng total RNA using TaqMan reverse transcription reagents (Applied 
Biosystems). Controls were performed without reverse transcriptase. 2 μl of these reactions 
along with controls were amplified on 96 well plates using the SYBR®Green PCR kit and an 
ABIPRISM 7000 or 7500 Real Time PCR System (Applied Biosystems). The following 
oligonucleotide primers were used: TORC1 forward: 5’-
AGACAGACAAGACCCTTTCTAAGCA-3’, TORC1 reverse: 5’-
CAGGACTTGGGCCTGGAA-3’, TORC2 forward: 5’-GGCCTTCGAGGAGGTGATG-3’, 
TORC2 reverse: 5’-TATAAGCCAGTCGCAGTTTTTGG-3’, BDNF forward: 5’-
AAAACCATAAGGACGCGGACTT-3’, BDNF reverse: 5’-
GAGGCTCCAAAGGCACTTGA-3’, β-actin forward: 5’-
ATATCGTCATCCATGGCGAAC-3’, β-actin reverse: 5’-CCGGTCCACACCCGCCACC-
3’. 
84
  15 
For the quantitation of TORC1 and TORC2, an absolute standard curve method was used. 
Briefly, standard curves were determined for β-actin, TORC1 and TORC2 using increasing 
cDNA copy numbers. The copy number of TORC1 and TORC2 mRNA was then determined 
in each sample and divided by the amounts of β-actin mRNA to give copy number per unit β-
actin mRNA. For the quantitation of BDNF, a comparative ΔΔCT method was used. 
Expression and purification of recombinant proteins 
To construct pEXP5-TORC-DN-EGFP-11R and pEXP5-NLS-EGFP-11R, inserts were 
amplified from pcDNA3-TORC11-147-EGFP by PCR, and cloned into pEXP5 (Invitrogen) by 
TOPO cloning. The sequence coding for the 11R protein transduction domain was included in 
the PCR primers. A double-stranded oligonucleotide coding for the nuclear localization signal 
(NLS=MDPKKKRKGR) was introduced into pEXP5-EGFP-11R using the NcoI and EcoRI 
sites. All constructs were verified by sequencing. 
Expression of recombinant proteins in Escherichia coli BL21-AI™ (Invitrogen) was induced 
with 0.2% L-(+)-arabinose (Sigma) for 3h30. Bacteria were lysed in 50 mM phosphate buffer 
(pH=7.6), 0.3 M NaCl, 5% glycerol, 0.1% Triton X-100. Just before use, the lysis buffer was 
completed with PMSF, β-mercaptoethanol and imidazole to a final concentration of 0.4 mM, 
2 mM and 20 mM, respectively. Recombinant proteins were purified on an Ni-NTA agarose 
affinity column (Qiagen), washed twice with 20 mM, and eluted with 100 mM imidazole in 
lysis buffer. The integrity of the proteins was checked by SDS-polyacrylamide gel 
electrophoresis.  
Hippocampal slices. 
Male rats (R/WISTAR HAN from Charles River, L’Arbresle, France) of 4-6 weeks old were 
decapitated. Brains were dissected out and 350 µm-thick horizontal hippocampal slices were 
made in oxygenated ice-cold artificial cerebrospinal fluid (ACF) with high Mg2+, low Ca2+, 
and K+ (in mM: 118 NaCl, 2 KCl, 4 MgCl2, 0.5 CaCl2, 1.2 NaH2PO4, 25 NaHCO3, 10 
glucose). Slices were submerged in oxygenated ACF (in mM: 124 NaCl, 3.5 KCl, 1.3 MgSO4, 
2.5 CaCl2, 1 NaH2PO4, 26 NaHCO3, 10 glucose) at RT. After an hour, slices were superfused 
with oxygenated ACF containing either TORC-DN-EGFP-11R (0.37 µM) or NLS-EGFP-11R 
(0.37µM) for 1 hr, washed out with oxygenated ACF for 5 min, transferred in an interface 
recording chamber, and superfused with oxygenated ACF at 28°C. Electrophysiological 
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recordings started after 30 min. Transduction of TORC-DN-EGFP-11R and NLS-EGFP-11R 
into cells and nuclei were checked 30 min and approximately 5 hr (end of experiments) after 
washout in slices that were transduced at the same time. 
Electrophysiology.  
Extracellular field potentials evoked in the CA1 region by electrical stimulation of the 
Schaffer collaterals were recorded with a glass electrode filled with ACF and positioned in the 
stratum radiatum. Signals were collected, stored and analyzed using conventional 
electrophysiological techniques. The stimulation electrode consisted of two twisted teflon-
coated platinum/iridium wires. Stimulation consisted of 100-µs current pulses. Experiments 
were initiated when stability of response evoked by a 0.016 Hz baseline stimulation was 
maintained for ~15 min. A dose-response curve was first established using stimuli ranging 
from 10 to 300 µA. The stimulus intensity was then adjusted to evoke ~40% of maximal 
fEPSPs. Paired-pulse facilitation was assessed with a pair of stimuli separated by a 50-ms 
interval. LTP was induced by three trains of 100-Hz pulses (1 s duration) separated by 5 min 
intervals (HFS) after a stable response to a 0.016 Hz baseline stimulation was obtained for 15 
min. The effect of HFS on the response magnitude was then monitored for 180 min using a 
0.016 Hz baseline stimulation. Typically, HFS was applied approximately 1 hr 30 min after 
the end of superfusion with either TORC-DN-EGFP-11R or NLS-EGFP-11R.  
Nuclear translocation of endogenous TORCs upon LTP-inducing protocols. 
Hippocampal slices were prepared as above, transferred in an interface recording chamber, 
and superfused with oxygenated ACF at 28°C. After at least 1 hr 30 min, slices were 
superfused with oxygenated ACF containing 10 ng/ml leptomycin B. After approximately 45 
min, LTP-inducing electrical or chemical protocols were applied. LTP-inducing electrical 
protocols consisted of either three or four 1-s trains of 100-Hz pulses separated by 5 min 
intervals which were applied on the Schaffer collaterals at an intensity of 100 µA. LTP-
inducing chemical protocol was as described by Thompson et al. (2004) (7). In brief, slices 
were superfused for 15 min with 50 µM FSK followed by 5 min superfusion in high-K+ /Ca2+ 
oxygenated ACF (30 mM KCl, 0 mM MgSO4, and 10 mM CaCl2). Slices were finally fixed in 
4% paraformaldehyde approximately 45 min after the LTP-inducing protocol. Control slices 
were maintained in oxygenated ACF containing 10 ng/ml leptomycin B for the same time 
periods as slices submitted to LTP-inducing protocols prior to fixation.  
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Supporting On-line Figures 
 
Supporting Fig. 1. (A) Activation of cAMP or calcium pathway alone do not promote nuclear translocation of 
TORC1 in mouse cortical neurons. Immunofluorescence assay of neurons transfected with mouse TORC1-myc 
showing its localization in the presence of FSK or KCl, and leptomycin-B. (B) Inhibition of calcineurin by CsA 
blocks the nuclear accumulation of TORC2 in mouse cortical neurons. Immunofluorescence analysis of neurons 
transfected with mouse Flag-TORC2 showing its cytoplasmic localization in the presence of CsA, even when 
cells were stimulated with FSK and KCl. DAPI staining is shown to localize nuclei. 
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Supporting Fig. 2. Comparative effect of CsA, FK506, and rapamycin on CREB-mediated transcription. 
Luciferase assay of mouse cortical neurons transfected with a CRE-LUC reporter gene, exposed to FSK and 
KCl, in the absence (-) or in the presence of 5 μM of the immunophillin-binding calcineurin inhibitors CsA and 
FK506, or in the presence of 5 μM rapamycin, an immunophillin-binding compound that does not inhibit 
calcineurin. 
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Supporting Fig. 3. Effect of the combination of various inhibitors on CREB-mediated transcription. Luciferase 
assay of mouse cortical neurons transfected with a CRE-LUC reporter gene, exposed to FSK and/or KCl, in the 
absence (-) or in the presence (+) of tetrodotoxin (TTX), APV, CNQX, nifedipine, and H-89 used to reduce the 
basal levels of calcium and PKA activity. 
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7 Discussion of results 
7.1 C/EBPβ couples dopamine signaling to substance P precursor 
gene expression in striatal neurons 
Striatal synaptic plasticity is thought to be one of the cellular changes that accompany the 
development of drug addiction. According to the currently accepted view, neuronal activity can 
trigger transcription that leads to the expression of genes required for synaptic plasticity. A 
prominent transcription factor involved in this process is CREB that can promote the expression of 
several neuronal genes (Nestler, 2004). 
We show that dopamine, through D1 receptors, increases the expression of C/EBPβ in striatal 
medium spiny neurons. Being a transcription factor of the bZIP family, C/EBPβ can drive the 
transcription of several neuronal genes among which those necessary for synaptic plasticity. 
Dopamine has been shown to be necessary for the LTP at corticospinal synapses. High frequency 
stimulation of the cortex leads to LTD at these synapses, however, in the presence of dopamine 
LTD can be reverted to LTP (Wickens et al., 1996, Reynolds et al., 2001) It would be particularly 
interesting to address the question of whether C/EBPβ is involved in this process, since the 
reinforcement of the corticostriatal synapses is speculated to contribute to compulsive behavior at a 
later stage of addiction. 
We identify the preprotachykinin-A gene coding for substance P and neurkinin-A as a target of 
C/EBPβ in striatal medium spiny neurons.  Substance P produced by these cells can act on the cell 
bodies of VTA neurons or on the striatal terminals of VTA neurons to promote dopaminergic 
transmission. Consequently substance P can participate in a positive feedback loop: its expression is 
induced by dopamine in striatal cells and it further enhances dopamine release (see chapter 4.2.5.4 
for details). 
Interestingly, ΔFosB, a highly stable member of the Fos family that has been shown to gradually 
accumulate in the nucleus accumbens after repeated drug administration, was reported to inhibit 
C/EBPβ at the protein level and also to decrease the transcription of the C/EBPβ gene (Chen et al., 
2004; Kveiborg et al., 2004). On the basis of these observations we formulated a hypothesis that 
during addiction, increasing amounts of ΔFosB could gradually repress the transcription of the 
PPTA gene and thereby attenuates the positive feedback effect of substance P on VTA 
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dopaminergic neurons. As a consequence, with increasing amounts of ΔFosB, a higher and higher 
dose of drug would be needed for the same amount of dopamine to be released.  
To explain decreasing hedonic effects of drugs of abuse upon repetitive usage and anhedonic states 
upon discontinuing the drug, a dynorphin-mediated negative feedback loop has been porposed by 
Nestler and coworkers. Dynorphin was reported to be induced through the dopamine → D1 → 
cAMP → PKA → CREB pathway in the medium spiny neurons and can act on VTA cells to 
dampen dopamine release (Nestler et al., 2004). The mechanism that we are proposing could 
coexist with the dynorphin-mediated inhibition of dopaminergic neurons and might be involved in 
gradual changes that accompany the development of drug addiction by establishing a link between 
ΔFosB and dopamine release. 
By reporter gene assays we show that C/EBPβ can transactivate the gene coding for substance P 
and by electrophoretic mobility shift assays (EMSA) and footprinting experiments we demonstrate 
a physical interaction between the promoter of this gene and C/EBPβ. The importance of these 
results is not likely to be confined to the striatum. For instance the proinflammatory cytokine IL-1β 
has been shown to induce substance P in myenteric nerve fibers (Grider, 2003; Hurst et al., 1993), 
however, the signaling pathway has not been elucidated. Our results raise the possibility that 
C/EBPβ, that is induced by IL-1β in astrocytes (Cardinaux et al., 2000), could be a mediator of this 
effect. Similarly, C/EBPβ may be involved in the LPS-dependent induction of substance P in 
sympathetic ganglia (Shadiack et al., 1994) and in nodose ganglia (Huang et al., 2003). These 
observations open up the way for further studies addressing the question of whether the regulation 
of the PPTA promoter by C/EBPβ is involved in neurogenic inflammation.  
Transmission of noxious stimuli to the central nervous system relies on the small C-fiber type 
neurons of the dorsal root ganglion. Substance P release from these cells has been for long 
considered as a “pain signal” (Otsuka et al., 1993). Interestingly, cyclic AMP has been shown to 
increase the substance P content of these cells, however, the molecular pathways of this induction 
have not been elucidated. Thus, in this physiological process again, the regulation of the PPTA by 
C/EBPβ might play an important role. 
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7.2 CCAAT/Enhancer-binding protein family members recruit the 
coactivator CREB-binding protein and trigger its 
phosphorylation 
Given that our results have shown that C/EBPβ is induced in striatal cultures by dopamine and 
thereby might contribute to the molecular changes that accompany the development of drug 
addiction, we decided to study the fundamental mechanisms of C/EBP-mediated gene 
transcription. Therefore, the results of this study can be generalized and applied in every cell type 
that use C/EBP family members as transcription factors. 
Phosphorylation of proteins occurs widely in biological systems and allows cells to react relatively 
rapidly to changes that eventuate in the extracellular space or in the cell itself. Phosphorylation is 
known to influence transcription as well, consequently short term changes in cellular function can 
be converted into long-term ones. For instance, the transcription factor CREB is activated by 
protein kinase A and its phosphorylated form interacts with the coactivator CBP (Chrivia et al., 
1993). Consequently a short lasting signaling event that activates protein kinase A can alter gene 
expression and thereby induce long-lasting changes. 
CBP is a large protein molecule used by several sequence-specific transcription factors as a 
coactivator. CBP activates transcription by its intrinsic histone-acetyltransferase acitivity and by its 
ability to recruit general transcription factors (Goodman and Smolik, 2000). 
In this study, using reporter assays we show that all three activating members of the C/EBP family 
(α, β and δ) uses CBP as a coactivator in 293T cells. We are the first to demonstrate direct 
physical association between C/EBPδ and CBP and, upon sequence homology with C/EBPα, we 
define two conserved amino acid sequence in C/EBPδ that are required for this interaction. We 
refer to these two sequences as Box A and Box B. Although the transcriptional activation domains 
(TAD) of C/EBPα and C/EBPδ are substantially different, this result support the idea that some 
common activating functions of the C/EBP isoforms are accomplished by sequences that are 
conserved across the family. 
We report that the cotransfection of activating C/EBP isoforms results in the appearance of a slower 
migrating form of CBP. By in vitro phosphatase treatment, we demonstrate that this reduced 
electrophoretic mobility of CBP is due to phosphorylation. The minimal CBP fragment that 
showed the mobility shift was 1680-2441, neither the 1680-1892 nor the 1893-2441 fragment was 
affected by the cotransfection of CBP. From these data we conclude that the E1A binding domain 
(1680-1892) is necessary for the CBP-C/EBP association while the phosphorylation occurs in the 
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C-terminal portion (1893-2441) of the protein. The mobility change of the 1680-2441 fragment 
corresponds to more than 10 kDa, thus we suspect that the covalent modification induces profound 
conformational changes in the molecule.  
To confirm that this is not an unspecific effect of protein cotransfection, we showed that LIP (liver 
inhibitory protein), ATF-1 (activating transcription factor-1) and CREB, in contrast to C/EBP 
isoforms, do not alter the migrating properties of CBP1680-2441. To exclude that the phosphorylation 
is due to the C/EBP-mediated induction of a kinase rather than being triggered by a direct C/EBP-
CBP interaction, we generated C/EBP constructs lacking the bZIP domain that are not capable of 
activating transcription. These constructs still triggered the phosphorylation of CBP favoring the 
idea of an interaction-mediated phosphorylation. 
Finally we find some correlation between C/EBPδ-mediated transcriptional activation, C/EBPδ-
CBP interaction and C/EBPδ-triggered phosphorylation of CBP by introducing mutations (or 
deletions) into the Box A and Box B of C/EBPδ. Of particular interest is the triple point mutant 
Y64A, L81A, F82A of C/EBPδ that fails to activate transcription in reporter assays, does not induce 
CBP phosphorylation and shows reduced interaction with CBP.  
Taken together these data suggest that the recruitment and phosphorylation of CBP can be 
necessary for C/EBP-mediated transcription. For long phosphorylation events impinging on the 
transcriptional machinery were thought to affect rather sequence-specific transcription factors than 
coactivators – an idea fostered by the initial finding that the activation of CREB requires its 
phosphorylation at serine 133 and the coactivator CBP interacts specifically wih this 
phosphorylated from. Our results not only demonstrate that C/EBP family members (as lots of other 
sequence-specific transcription factors) use CBP as a coactivator, but constitute a novel example 
substantiating the fact that transcriptionally relevant phosphorylation can also occur at the 
coactivator level. 
Further studies will be necessary to identify the kinase implicated in C/EBP-triggered CBP 
phosphoryaltion, to elucidate by which mechanism this process leads to transcriptional activation 
and finally to identify the phosphoacceptor amino acids in the C-terminal portion of CBP. 
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 7.3 TORCs act as neuronal coincidence detectors and play a key role 
in hippocampal synaptic plasticity 
One of the prominent functions of the central nervous system is to detect the coincidence of two 
input signals and to preserve this coupling at the level of synaptic connections. This function 
constitutes a neuronal substrate for operant conditioning and heteroassociative learning. However, 
the molecular mechanisms of neuronal coincidence detection are far from being elucidated. 
The coincidence of glutamatergic and dopaminergic signals in the striatum (nucleus accumbens) is 
of particular importance for the drug addiction field, as it has been discussed in chapter 4.2.4 The 
dopaminergic input is suggested to signal an incentive state to the nucleus accumbens whereas 
glutamatergic input may transmit environmental cues (hippocampal glutamatergic input) or 
planned motor activity (prefrontal cortex glutamatergic input) to the same brain region. In the 
medium spiny neurons of the striatum, dopamine can signal through cAMP (PKA) while glutamate 
can elicit a calcium influx. This lead us to focus our attention on the TORC family of coactivators 
since TORC2 has been shown to detect the coincidence of Ca2+ and cAMP (PKA) in pancreatic 
cells (Screaton et al., 2004). Given that the coincidence of these two pathways is likely to be 
important in other types of neurons, we speculate that our results can be generalized to the whole 
brain and uncover a universal mechanism underlying learning and memory. This hypothesis is 
further corroborated by the finding that CREB, the transcription factor that TORCs coactivate, has 
been found to carry crucial role in learning, memory and synaptic plasticity. 
To investigate TORC function in the central nervous system we have first checked that TORC1 and 
TORC2 are present in primary neuronal cultures and in the adult brain using real-time RT-PCR. We 
found that both isoforms are present, TORC1 being more abundant. 
We verified that the combination of depolarization (KCl) and forskolin triggered the nuclear 
translocation of endogenous and transfected TORCs in neurons. We found that KCl or forskoline 
alone had little effect on the localization of TORCs, however, in combination they induced strong 
translocation that could be inhibited by cyclosporin A (CsA), a calcineurin inhibitor. TORC2 
translocated more readily, to visualize the nuclear accumulation of TORC1 the cells had to be 
treated with leptomycin-B, an inhibitor of nuclear export. 
These results show that the mechanism of TORC translocation that has been first described in the 
pancreas operates in neurons as well: only dephosphorylated TORC can enter the nucleus, the 
phosphorylated form is retained in the cytoplasm by the anchoring protein 14-3-3. Ca2+ activates 
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calcineurin that dephosphorylates TORC whereas PKA desactivates SIK, a kinase that 
phosphorylates TORC. 
We speculate that the difference between the readiness of translocation of the two isoform could 
have a functional importance and may contribute to the filtering of stimuli captured by the nervous 
system. TORC2 might detect a coincidence of signals that are slightly different from the baseline 
level, however, massive activation of TORC-dependent gene transcription may only be possible in 
consequence of strong signals that are capable of relocalizing the more abundant TORC1 into the 
nucleus. Thus the resistance of TORC1 to translocate might avoid the aspecific strengthening of 
synapses by fluctuations of neuronal activity. 
Next, we measured the transcriptional response that accompanies TORC translocation by 
transfecting a CRE-LUC reporter plasmid into the neurons. We showed that KCl and forskolin 
synergistically activated the transcription of the reporter gene, high above the levels of the 
individual stimuli. The effect was TORC-dependent since it could be blocked by (1) CsA that 
inhibits TORC translocation; (2) a dominant negative protein (TORC11-147-EGFP) that occupies 
binding sites for endogenous TORCs on CREB molecules; (3) small interfering RNA molecules 
that trigger the destruction of endogenous TORC1 and TORC2 messenger RNA. The 
phosphorylation status of CREB, that we assayed with a phosphospecific antibody, did not reflect 
the transcriptional activation: forskolin or KCl, when applied alone, triggered a strong CREB 
phosphorylation that could not be substantially elevated by combining the stimuli. Furthermore, 
CsA, that drastically blocked reporter activity, did not affect CREB phosphorylation. 
From these data, we conclude that the pivotal substrate for Ca2+/cAMP coincidence detection is 
rather TORC than CREB itself. However, the phosphorylation of CREB and the concomitant 
recruitment of CBP could still be crucial to acetylate histones and thereby activate promoters with 
closed chomatin structure. 
In former studies the phosphorylation state of CREB itself was suggested to be a Ca2+/cAMP 
coincidence detector. Although we cannot completely exclude that CREB functions in this way, we 
would like to emphasize that TORCs are far better situated to detect such a coincidence. Two 
simultaneously active kinases targeting the same S133 phosphorylation site on CREB at best (i.e. if 
there is no saturation) have additive effect. However, coincidence detection by TORCs relies on the 
simultaneous activation of a phosphatase and inhibition of a kinase that, based upon theoretical 
considerations, allows for a synergism between Ca2+/cAMP signals. 
We have strong evidence coming from our reporter assays that a Ca2+/cAMP coincidence indeed 
has synergistic effect on target gene transcription, and, on the other hand, it is reasonable to assume 
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that biological systems rely on similar synergisms rather than on additive effects given the better 
signal to noise ratio that it provides. 
To activate Ca2+ and cAMP pathways in more physiological conditions, we applied NMDA and 
PACAP on hippocampal neurons, or glutamate and dopamine on striatal neurons. We found a 
synergistic effect of these neurotransmitter combinations on the transfected CRE-LUC reporter 
plasmid. Pairing of NMDA-receptor activation and PACAP signaling can be physiologically 
relevant in the CA1 cells of the hippocampus (DiMauro et al., 2003), while the coincidence of 
dopamine and glutamate signals in striatal medium spiny neurons is likely to have vast implications 
for drug addiction. 
To extend our results to endogenous CREB target genes we measured changes in BDNF mRNA 
levels that occur upon combined stimulation with KCl and forskolin. We found that depolarization 
and adenylate-cyclase activation synergistically augmented BDNF message and this was 
abolished by CsA suggesting that TORCs are implicated in this process. 
Finally we tested the involvement of TORCs in the protein synthesis dependent late-phase long 
term potentiation (LTP) in the Schaffer collateral-CA1 pathway that is widely accepted as a model 
of how the hippocampus encodes new memory traces. We transduced rat hippocampal slices with 
the TORC11-147-EGFP dominant negative protein coupled to the 11R transduction domain 
(Matsushita et al., 2001) that targets the molecule specifically into neurons but not into astrocytes. 
We have shown, that the dominant negative protein reduced the late-phase (but not the early-
phase) of LTP while the control protein (NLS-EGFP-11R) had no such effect. 
We also demonstrated that stimuli capable of inducing LTP also changed the localization of 
endogenous TORC in rat hippocampal slices. Tetanic electrical stimulation (3×100Hz or 4×100 
Hz) resulted in mainly perinuclear accumulation and a moderate nuclear entry of TORC in the CA1 
and CA3 cells of the cornu ammonis. Chemical stimulation with KCl and forskolin, that induced a 
so called chemical LTP that we could detect with electrophysiological measurements, provoked 
strong nuclear entry of TORC in CA1 and CA3 cells. 
These results are in complete accordance with the finding that CREB-dependent transcription is 
necessary for the induction of LTP, and the activation of CRE-dependent genes by the artificial, 
constitutively active CREB-VP16 molecule apparently bypasses the need for a signaling from the 
synapse to the nucleus that is otherwise indispensable for LTP (Barco et al., 2002). Recently it has 
been showed that the facilitation of LTP by the CREB-VP16 fusion molecule is most likely due to 
the enhanced production of BDNF (Barco et al., 2005). 
In physiological conditions, the coincidence of intracellular Ca2+ and cAMP elevations in CA1 cells 
may be indicative of repeated arrival of input signals. Calcium-stimulated adenylate cyclases have 
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been shown to convert Ca2+ entry into cAMP signals (Cooper, 2003), and this might allow TORCs 
to sense the repeated activation of specific CA3-CA1 synapses. To unfold the mechanism of such a 
detection of repeated stimuli, let’s consider two input signals from the same set of presynaptic CA3 
cells. The first input triggers Ca2+ influx in the postsynaptic CA1 cells that can be converted into a 
cAMP signal by calcium stimulated adenylate cyclases. Obviously, the second input also elicites 
Ca2+ influx in the postsynaptic cells that can be coincident with the cAMP signal ensuing from the 
first input. Indeed, the combined deletion of calcium-stimulated adenylate cyclases AC1 and AC8 
prevents the late phase of LTP in the Schaffer collateral-CA1 pathway (Scott et al., 1999). 
In future studies it would be interesting to address the question of whether TORCs can participate in 
the signaling from the synapse to the nucleus. More precise localization studies are needed to 
determine whether TORCs are expressed in dendritic spines or not. In medium spiny neurons, 
dopaminergic and glutamatergic inputs target the neck and the tip of the dendritic spine, 
respectively. Local detection of the coincidence of these two signals by TORC that could 
translocate in the nucleus would be an appealing mechanism that has strong implications for 
addiction research. 
The new concept of TORC-mediated neuronal coincidence detection might have broad implications 
given the importance of CREB-mediated transcription in memory consolidation, addiction, 
neuronal survival, circadian rhythmicity, and developmental plasticity (Lonze et al., 2002). 
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